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ABSTRACT 
Introduction 
The epidemiology of polymyalgia rheumatica (PMR) and giant cell arteritis 
(GCA) is poorly characterised, with little known about the aetiological 
factors involved in disease onset and progression. This project aimed to 
determine the incidence and prevalence of PMR and GCA, including their 
related morbidity, and to investigate aetiological hypotheses for disease 
onset and progression using community-based populations and 
contemporary classification criteria. 
Methods 
Three large phenotypically informative datasets were constructed: 
GCANS (n = 4,728), EPIC-Norfolk (n = 25,660) and DCVAS (n = 712) to 
establish the descriptive epidemiology and investigate aetiological 
hypotheses centred on cardiovascular risk factors in cross-sectional and 
longitudinal study designs. The EPIC cohort included unique data from 
retinal photographs, allowing the application of vasculometric analysis. 
Results 
The prevalence ranged from 0.91% to 1.62% for PMR and 0.25% to 
0.47% for GCA. Age and traditional cardiovascular risk factors were 
important for both disease onset with associations between hypertension 
and LDL with PMR. Visual impairment developed in 8% of GCA cases with 
six months of onset; risk factors for blindness in GCA included peripheral 
vascular disease. Inflammatory arthritis developed in 10% of PMR cases 
at 10 years with greatest risk in smokers. Analysis of retinal photographs 
showed an association between venular width and PMR, but no other 
characteristic morphological features were identified. 
Conclusions 
These are the first estimates of PMR and GCA incidence and prevalence 
for the UK to apply current classification criteria. This is the first study to 
use a prospective design to show traditional cardiovascular risk factors to 
be important for disease onset and progression; their presence may point 
towards a need for more careful monitoring. The novel vasculometric 
data from retinal photographs provides insight into aetiological 
hypotheses of disease, particularly those with underlying vascular 
dysregulation mechanisms, and may be of potential value in screening.  
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GLOSSARY 
Definitions of any term specific to the thesis, including abbreviations are 
given below. 
CIF Cumulative incidence function is the probability 
that the outcome or event is observed before a 
specified time point. 
Competing risk When individuals are at risk of multiple 
outcomes. 
Cox Regression Cox proportional hazard model a form of 
‘survival’ model or ‘time-to-event’ model in 
which time is divided into infinitesimal bands or 
clicks. It models the hazard ratio as a function 
of covariates and although the individual and 
baseline hazards may change with time they 
are assumed to be proportional between groups 
to one another at all times. 
 
Enrolment period The length of time that recruitment to a cohort 
study is open to new participants. 
xxviii 
 
HR The hazard ratio is the ratio of the hazard 
function evaluated at two values of an 
explanatory variable.  
Incidence Rate of new disease development during a 
defined period of time. Usually expressed as 
either an incidence rate i.e. number of new 
cases per unit of time or as cumulative 
incidence, also referred as the incidence 
proportion, number of new cases occurring over 
a defined period and is a risk rather than rate 
of disease.  
Incidence density  A measure of incidence rate, also referred to as 
person-time incidence rate, where number of 
new cases are defined by the person years at 
risk (i.e. the total time contributed to follow-up 
by people who are at risk of disease) and takes 
account of death and differences in follow-up 
time particularly useful if there is a long 
enrolment period.  
Kaplan Meier An estimate of the survival function which is 
the product of conditional survival to each time 
at which an event occurs. 
xxix 
 
Left censoring When the precise date of the event of interest 
(disease onset or outcome) is unknown and 
may predate the start of follow-up. 
Lexis expansion Used in survival function estimation. Periods of 
time are split so that each record contains the 
follow-up on one subject through one time 
band (each observation is expanded into 
several observations based on the interval of 
follow-up time). Time can be defined by 
calendar time in order to create age bands. 
Logistic regression A statistical model used to assess the 
dependence of a binary outcome (e.g. disease 
present or absent) on a number of explanatory 
factors. The probability (p) of one of the 
outcome states is expressed in the form of 
logit, loge (p / (1-p)), which is assumed to be 
predicted by the linear combination (weighted 
sum) of the explanatory factors.  
OR The odds ratio is the ratio of two odds, where 
odds are the  chances in favour of the event. 
The odds is defined as p / 1 - p, where p is the 
probability, e.g. with a probability of 20% the 
odds are ¼. 
xxx 
 
Prevalence The proportion of individuals with a given 
disease from a defined population. Usually 
expressed as either point prevalence 
(frequency of disease at a given point in time) 
or period prevalence (frequency of disease at 
the end of a time period even if time of disease 
onset was prior to the start of the observation 
period). 
Right censoring When the outcome of an individual is unknown 
due to loss of follow-up or alternatively if a 
participants survives to the end of follow-up 
their time of death is right censored due to 
administrative censoring. 
Regression A model for predicting one variable from the 
value of a set of other variables.  
RR The risk ratio, or relative risk is the probability 
of the outcome associated with a one unit 
increase in the risk factor relative to that 
calculated without such an increase. 
SHR Sub-hazard ratio or more formally the hazard 
of the subdistribution: a hazard ratio 
accounting for a competing risk of the outcome 
of interest. The subhazard ratio is the ratio of 
xxxi 
 
the subhazard function evaluated at two 
different values of the covariates. 
Stratified model A survival model which constrains the 
regression coefficients to be equal across 
stratum bands of the stratified variable but 
allows other covariates to vary across the 
strata. 
Wald test The Wald test is a parametric statistical test 
used, for example, in logistic regression to 
determine whether the predictor variable is 
significantly associated with the outcome 
against the null. The Wald statistic follows an 
approximate chi-squared distribution. 
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CHAPTER 1   INTRODUCTION 
1.0 SUMMARY 
This thesis considers the epidemiology of two overlapping conditions that 
affect older people – Polymyalgia rheumatica (PMR) and Giant Cell 
Arteritis (GCA), the descriptive epidemiology and aetiology for disease 
onset and progression are investigated. This chapter gives a brief 
introduction to PMR and GCA and the importance of these two conditions 
in which the treatment approaches have changed little since the 1960s, 
the context for the present work is outlined. 
1.1.0 PMR and GCA: overlapping diseases with 
significant morbidity 
Polymyalgia rheumatica (PMR) is an inflammatory condition of unknown 
aetiology, causing shoulder and hip girdle pain and stiffness (1) while 
Giant cell arteritis (GCA) is a form of vasculitis predominantly affecting 
medium and large arteries and has substantial morbidity (2). PMR and 
GCA are often considered to be part of same disease spectrum (3-5). 
PMR and GCA often coexist, with 40-60% of patients with GCA having 
symptoms of PMR. Following temporal artery biopsy, up to 21% of 
patients with isolated PMR have been reported to show findings 
consistent with GCA (6). In addition, patients with PMR have been seen 
to have increased uptake within the subclavian vessels indicative of 
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undetected large vessel vasculitis, as assessed by 18F-
fluorodeoxyglucose positron emission tomography (18F-FDG-PET) (7, 8).  
Difficulty in characterisation of these diseases is not limited to 
distinguishing between them but also extends to recognising their 
relationship with other diagnoses. They are difficult to diagnose not least 
due to the lack of a single specific diagnostic test. In the United States it 
is estimated that accuracy of a family physician diagnosis of PMR is 24% 
(9) with 40% of cases managed exclusively in the community (10). In 
the UK PMR is most often diagnosed and treated in primary care without 
referral to hospital (11), with glucocorticoids (steroids) the mainstay of 
treatment (12, 13). Response to steroids is considered a key feature of 
PMR with it being a core criteria in several classification sets (14-16). 
This can lead to later unmasking of diagnoses once steroids are 
withdrawn, or alternatively, diagnoses may subsequently develop or 
evolve, for example, PMR transitioning to inflammatory polyarthritis (17). 
Morbidity is not restricted exclusively to PMR, with GCA a medical 
emergency as due to ischaemia of the eye resulting in permanent visual 
loss in up to 35% of patients (18, 19). Visual loss and deterioration can 
be prevented by rapid initiation of high dose steroids (20). Steroid 
treatment regimens are not standardised in either condition and no 
steroid-sparing agents have been found to be effective as yet (21), 
although the results of the GiACTA trial (trial of tocilizumab in patients 
with GCA) are awaited at the time of writing this thesis. Prolonged 
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courses of glucocorticoid treatment are often undertaken, possibly 
because of clinicians’ overriding concern to prevent blindness, increasing 
the risk of toxicity including cataract and glaucoma and other well-
documented problems. In the UK, 62% of patients with PMR/GCA are 
prescribed steroids long-term with a median duration in excess of 1.2 
years, with a one to three interquartile range of between 0.6 and 2.5 
years (22). This trend has been increasing and due to the changing 
demographic of the UK population towards an older median age, more 
people are likely to be diagnosed with PMR and GCA, making reversal of 
this trend unlikely.  
During 1990 – 2001, PMR incidence in the UK was estimated to be 84 per 
100,000 person years (23), although comprised community treated 
patients, this study failed to apply classification criteria making 
comparison to other studies difficult. 
Giant Cell Arteritis (GCA), is the commonest systemic vasculitis in the 
western world (24), although the incidence of GCA varies across 
countries: the highest rates are reported in Nordic countries, the UK and 
the US (23, 25-27). Its incidence estimate in the UK from 1990 - 2001 
was 22 per 100,000 person years (23), but again without applying the 
current classification set for the disease. The incidence of PMR, taken 
together with GCA in patients aged >60yrs, is higher than that of 
rheumatoid arthritis, a difference increasing to more than tenfold in 
people aged >70yrs. Due to the problems of either population selection 
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or inability to apply classification criteria, data on the occurrence of 
disease outcomes is difficult to interpret particularly if studies have 
included different methods of case selection and definition. This extends 
to ocular complications in GCA, where recruitment of exclusively treated 
hospital patients leads to wide variation in the reported risk of blindness 
(with further detail given in 2.3.1). 
1.1.1 Ocular complications 
Approximately one in twelve patients with GCA will suffer monocular 
blindness. From hospital case series analysis, the commonest ocular 
complication is anterior ischemic optic neuropathy (AION). Other ocular 
ischaemic changes include central arterial or branch retinal arterial 
occlusion (CRAO or BRAO), choroidal ischaemia and posterior optic 
neuropathy (PION) (28).  A prospective case series of 170 patients from 
the USA with biopsy-proven GCA showed 69 had AION (40%), 12 had 
CRAO (7%) and six had PION (3%). Fluorescein angiography was carried 
out in 55 of these 170 patients with 12 having detectable cilioretinal 
artery occlusion (21%).  Nearly all patients had evidence of posterior 
ciliary artery occlusion on fluorescein angiography (28). In another 
retrospective study of 47 patients from Switzerland with GCA who had 
undergone fluorescein angiography, 22 had AION (47%), 17 had 
choroidal ischaemia (36%) and 7 had CRAO (15%) (29).  
Magnetic Resonance Imaging (MRI) is helping to document further 
ischaemic changes affecting the ocular circulation. A study using high 
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resolution MR imaging of 43 patients with GCA demonstrated that 20 
(46%) patients had mural enhancement of the ophthalmic artery 
suggesting inflammation (30). 
Despite the significance of these diseases to patients and practising 
physicians in primary and secondary care, current data about risk factors 
are inconsistent and limited through retrospective study design or small 
sample size.  The aetiology of PMR and GCA has hitherto been studied 
using case-control designs with the inherent risks of recall bias and 
finding representative control groups. As a result the epidemiology of 
PMR and GCA and risk factors for disease onset and progression need 
revisiting. In particular, patients with these conditions need to be 
recruited from community-based populations, but importantly, current 
classification sets need to be applied in order that results can be 
comparable to other future studies.  
The development of large cohort studies now affords the opportunity to 
study in detail the descriptive epidemiology of both PMR and GCA and 
examine risk factors for disease development and progression. 
Prospective cohorts are of great value since information on risk factors is 
collected prior to disease onset negating problems of recall bias and since 
disease status is unknown at the start of observation, controls should be 
representative to subsequent cases.  
The aim of this thesis is to describe the epidemiology of both conditions 
from community-based cohorts and a large international collaborative 
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study using longitudinal time-to-event analysis to investigate both factors 
associated with disease development and progression, with a particular 
focus on eye disease. 
CHAPTER 2   BACKGROUND 
2.0 SUMMARY 
This chapter describes the clinicopathological features of PMR and GCA, 
their treatment, the arterial blood supply to the eye; to summarise the 
epidemiology of PMR and GCA and the published risk estimates for eye 
morbidity associated with GCA. A discussion with a particular emphasis 
on the risk factors for disease development and progression is presented. 
The differences between diagnosis and classification criteria is discussed. 
The major themes to be addressed in this thesis are outlined, namely: 
the need to provide community-based estimates of incidence and 
prevalence that are able to apply classification criteria; to study 
aetiological factors in prospective cohort studies; and to describe retinal 
changes and ocular outcomes from large adequately powered studies. A 
description of the datasets to be used and their value in being able to 
address these aims is presented.  
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2.1.0 Clinicopathological features of PMR and GCA 
This section outlines the main the clinical and pathologic features of PMR 
and GCA, the tests used in current practice to establish their diagnosis, 
and the common pharmacological approaches to treatment. 
2.1.1 Clinical features of PMR 
Barber first used the term Polymyalgia rheumatica (PMR) in 1957, to 
describe a sudden onset inflammatory condition typified by stiffness and 
pain of the shoulder and pelvic girdles associated with constitutional 
effects (31). The condition previously carried numerous other names, 
with Bruce in 1888 describing cases of senile rheumatic gout (1). In this 
paper he notes “There is, perhaps, no disease as to which professional 
opinion differs more than as to rheumatic gout. This diversity of views is 
unfortunate, as it affects the kind of treatment and mode of life of the 
patient, and it disturbs the lay mind and gives occasion for remarks as to 
the uncertainties of medicine.” 
This uncertainty continues to the current day as in common with many 
rheumatic diseases, they are defined by common patterns of symptoms 
and physical signs. There are no specific diagnostic tests for PMR, a 
clinical diagnosis is made based on history, examination findings, often 
raised inflammatory markers and exclusion of other diagnoses. Typically, 
onset of disease is rapid, within a fortnight, with pain and stiffness 
affecting the shoulder and hip girdles, which may be accompanied by 
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general malaise, peripheral joint synovitis, weight loss and depression. 
Patients with PMR often have raised C-reactive protein (CRP) and or 
erythrocyte sedimentation rate (ESR). As a result, there is some 
uncertainty as to whether all cases classified as having PMR in studies 
actually have PMR or another diagnosis and may result in patients being 
treated with long-term steroids unnecessarily (32-34). The most recent 
classification set highlights the importance of excluding alternative 
diagnoses when making a diagnosis of PMR (35). Further discussion on 
the difference between diagnosis and classification is given below in 
Section 2.2.0. In the research setting, use of ultrasound, 18F-FDG-PET and 
MR imaging are providing further evidence of additional clinical features 
(36-38). Due to increased cost, workforce planning and agreed standards 
for diagnostic validation, currently these imaging modalities have limited 
and variable clinical utility in routine everyday practice.  
2.1.2 Treatment of PMR 
The usual rapid response to treatment with glucocorticoids has been used 
in classification sets for the disease (14, 16, 39). Prior to the 1960s, 
treatment with glucocorticoids was reserved for more severe cases, with 
salicylates suggested as the first line agent (40). Since then 
glucocorticoids have become the standard treatment for polymyalgia 
rheumatica (41, 42).  
As with many conditions, no ideal glucocorticoid regimen has been 
formally tested using a placebo controlled, double-blind randomised trial. 
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Despite this, national guidance suggests an initial starting dose of 
between 12.5 mg to 25 mg daily of prednisolone, continued for two to 
four weeks, with an aim of reaching 10 mg once daily after four to eight 
weeks (43, 44). Once the dose of 10 mg once daily is reached, a 
reduction by one mg per month is generally recommended (43). This 
slow withdrawal phase was perhaps first suggested by Hart in 1969 (45), 
and is supported by more recent observational data (46), and in a 
systematic review (47). The national guidance regimens would seem to 
suggest the earliest steroids can be stopped would be 44 to 50 weeks 
after commencing prednisolone (43, 44).  
However, many patients with PMR are unable to stop their steroids within 
this time-frame: observational data from the US from the 1980s showed 
40% of patients with PMR were only able to stop their glucocorticoids in a 
mean time of 95 weeks, with 40% estimated to have a glucocorticoid 
regimen of longer than four years (48).  UK data similarly reveals a year-
on-year trend for increasing median duration of steroid therapy: data 
from the Health Improvement Network (THIN) for UK adult patients 
registered with contributing general practices between January 1989 and 
December 2008 (22) show that in 1991 the median duration of steroid 
therapy for men with PMR/GCA was men was 53 weeks (CI 95% 28.4, 
126.1) and 58 weeks (CI 95% 28.4, 122.9) for women; by 2005 it had 
reached 56.7 weeks in men (CI 95% 33.6, 101) and 63.7 weeks (CI 95% 
32.3, 128.3) in women (22). 
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These data seem to demonstrate a reluctance to discontinue steroids in 
patients with PMR. This is of particular concern in view of the increasing 
awareness of the risks associated with long-term steroid use even at 
what might previously have been regarded as safe ‘physiological’ doses.  
Well-recognised adverse effects of cumulative steroid exposure include: 
eye related morbidity (cataracts, glaucoma), cardiovascular risk factors 
(hypertension, diabetes), increased risk for infections and fragility 
fractures (49). A Task Force endorsed by the European League Against 
Rheumatism (EULAR) produced recommendations for steroid therapy in 
rheumatic diseases. Following a systematic review of 18 studies, the 
following adverse event rate per 100 patient years of follow-up was 
reported: eye morbidity (cataracts, glaucoma) 4/100, cardiovascular 
morbidity (dyslipidaemia, oedema and electrolyte imbalance, renal and 
heart dysfunction, hypertension) 15/100, endocrine morbidity (glucose 
intolerance and diabetes, fat redistribution, hormone dysregulation) 
7/100, infections (viral, bacterial, skin) 15/100 and musculoskeletal 
morbidity (osteoporosis, osteonecrosis, myopathy) 4/100 (49).  
2.1.3 Clinical features of GCA 
The first description in the medical literature of a case thought to be due 
to GCA is by Hutchinson in 1890 (50). He described an elderly man with 
red streaks on his head who was unable to wear a hat due to pain. These 
streaks extended from the temporal region to almost the middle of the 
scalp, with several branches of each artery unable to be traced. The 
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pulses in the affected vessels were feeble initially, but after a week they 
were left as impervious cords. It was not until 1932 that the 
characteristic histological appearance of giant cells was described and 
only in 1938 that blindness was recognised as complication of the disease 
(51, 52). 
Although temporal artery biopsy is often considered the gold standard, 
even today, a diagnosis is made typically on clinical grounds in a patient 
older than 50 years of age developing a new onset headache (although 
headache is not a prerequisite for the condition) in association with 
elevation of the erythrocyte sedimentation rate and/or CRP (53). Other 
clinical features include myalgia and stiffness (suggestive of co-existing 
PMR), visual disturbance, weight loss, jaw claudication, low grade fever, 
fatigue and depression (54, 55). Haematological and biochemical analysis 
often reveals raised inflammatory markers, with or without 
thrombocytosis, and sometimes anaemia (56).  
Temporal artery biopsy, demonstrating granulomatous inflammation with 
or without giant cells, may confirm the diagnosis but this investigation is 
not carried out in all cases and because the pathological changes are not 
continuous, meaning the inflamed part of the artery is not captured 
within the specimen, may give a false negative result (57). Untreated 
GCA can lead to blindness and can occur prior to prompt treatment in up 
to 20% of cases, despite the use of steroids (58). 
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As in PMR, newer imaging modalities are proving useful in the diagnostic 
approach to GCA. The use of ultrasound, 18F-FGD-PET, CT angiography 
and MRI reveal distinctive clinical features and help to display the extent 
and distribution of the vascular lesions in the disease (59). A multi-centre 
study evaluating the use of ultrasound to temporal artery biopsy 
concluded that ultrasound was more sensitive but less specific than 
biopsy in the diagnosis of GCA (60). Results from a meta-analysis of 18F-
FGD-PET revealed a pooled sensitivity of 83.3% and specificity of 89.6% 
for a diagnosis of GCA (61). Although, these expensive tests are not used 
in diagnosing every case in routine practice they do at least reveal the 
distribution of vascular involvement possible in GCA. 
2.1.4 Anatomical distribution of vascular involvement in 
GCA 
Giant cell arteritis is considered a large vessel vasculitis as it 
predominantly affects the aorta and its major branches (62). Other 
commonly affected arteries are the carotids, subclavian and axillary 
arteries and aorta (63). Several historical autopsy studies and case series 
have described the arterial burden of GCA, with aortic involvement 
described most commonly (64-66).  
Aortic aneurysm or dissection is a relatively common complication of GCA 
thought to occur in 18 patients per 1000 person years at risk (67, 68). 
The increasing use of 18F-FGD-PET combined with computer tomography 
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(18F-FGD-PET CT) is revealing the extra-cranial extent of large vessel 
involvement. In a French case series, positive 18F-FGD-PET CT findings 
were demonstrated in 69/130 patients with GCA with the 78% of patients 
having thoracic aorta involvement, 72% with subclavian involvement and 
55% with abdominal aorta involvement (69). Positive 18F-FGD-PET CT 
findings at diagnosis were correlated with subsequent aortic 
complications during follow-up (all nine cases of aortic complication had a 
positive 18F-FGD-PET CT at baseline) (69).  
Arterial patterns of involvement appear to be different for GCA compared 
to the closely related large vessel vasculitis, Takayasu’s arteritis. In a 
study of arteriographic lesions between 145 patients with Takayasu’s and 
62 patients with GCA, cluster analysis revealed a symmetrical pattern of 
involvement and disease of subclavian and axillary arteries more 
commonly in patients with GCA than Takayasu’s (70).   
Case series describe vasculitic lesions typical of GCA affecting the aorta, 
its major branches and more distal branches in the head and neck, 
including the arterial supply to the eye (69). Perhaps the most feared 
complication associated with GCA is blindness associated with ischaemia 
of the medium and small vessels which form the arterial supply to the 
eye. GCA is known classically to involve the superficial temporal artery 
which is around 2 mm in outside diameter in keeping with the size of a 
medium vessel (71). The ophthalmic artery is smaller still, with a 
diameter of 1.54 mm in males and 1.31 mm in females from one 
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anatomical series of 71 Caucasian patients (72). Branching from the 
ophthalmic artery, the central retinal artery has a diameter of around 160 
microns (73).  In summary, it would be wrong to conclude that GCA is 
purely a large vessel vasculitis and the Chapel Hill Nomenclature makes 
note of this (62). 
2.1.5 Arterial supply to the eye 
The blood supply to the eye is particularly at risk in GCA. The arterial 
supply of the globe arises from branches of the ophthalmic artery, which 
branches from the internal carotid artery once the latter has entered the 
skull through the carotid canal. There is considerable variation in the 
course and subsequent branching pattern from the ophthalmic artery 
(74, 75). However, generally on exiting the skull vault through the optic 
canal, the branches of the central retinal artery and posterior ciliary 
arteries arise from the ophthalmic artery (74-76) See Figure 2.1. Both 
the central retinal artery and the posterior ciliary arteries can supply the 
nutritive collaterals to the optic nerve, with only the central retinal artery 
then entering the optic nerve (intraneural course), prior to dividing 
further close to the surface of the optic disc to form the central retinal 
branches (usually two superior and two inferior vessels) (74-76). The 
posterior ciliary arteries, usually two or three (as many as five), run 
forward, pierce the sclera and supply the choroidal vessels and are 
responsible for 70 to 80% of blood flow to the retina (74, 76, 77).   
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Figure 2.1 eye vasculature 
 
2.1.6 Arterial distribution in relation to blindness 
The commonest ocular complication from hospital case series analysis is 
anterior ischemic optic neuropathy (AION), although central arterial or 
branch retinal occlusion (CRAO), choroidal ischaemia and posterior optic 
neuropathy (PION) have all been reported (28). Previous autopsy series 
have revealed that the ophthalmic artery is most commonly affected by 
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GCA. Case series from the 1940s describe 18 cases with post-mortem 
findings describing involvement of the ophthalmic artery and its branches 
(see Table 2.1). Of the case reports with histological assessment of the 
eyes, only three cases from the 18 described reveal inflammatory 
changes affecting the retinal branches on the fundus. The reasons for this 
apparent tropism are unknown. 
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Table 2.1  Histopathologic features of eye vascular involvement from autopsy series 
Author Study type Extent of arterial involvement Histopathologic changes 
Cooke et al 1946 (66) Description of seven case, two of 
which underwent post-mortem 
examination, with only one examining 
the vessels to the eye 
Both eyes, retinal arteries and its 
branches 
Infiltration with inflammatory cells 
with giant cells affecting the 
adventitia and media. Fragmentation 
and calcification of the internal elastic 
lamina.  
Cardell and Hanley 1951 (78) One case – post mortem examination Left eye, ophthalmic and right eye 
posterior ciliary arteries 
Typical changes of giant cell arteritis 
with inflammatory cell infiltrate 
together with periadventitial giant 
cells around the left ophthalmic 
artery.  
Kreibig 1953 (79) One case – post mortem examination Ophthalmic artery and vessels of the 
circle of Zinn 
Severe pan-arteritis with 
granulomatous formation and 
proliferation of the intima.  
Heptinstall et al 1954 (80) Case series of 14 cases two with post 
mortem examinations. 
One case (case 14) had involvement of 
right and left ophthalmic arteries 
Inflammatory cell infiltrate with 
fragmentation of the internal elastic 
lamina. 
Crompton 1959 (81) One case – post mortem examination Both eyes were examined. Left eye: 
ophthalmic, posterior ciliary, circle of 
Zinn, central retinal artery and branches 
over the disc rim. Right eye: similar to left 
including a nasal branch of central retinal 
artery. 
Lymphocytic infiltrate with presence 
of giant cells. 
Spencer and Hoyt 1960 (82) One case – post mortem examination Both eyes were examined with 
involvement of the ophthalmic and 
posterior ciliary arteries.  
Chronic inflammatory infiltrate 
affecting the media. Intimal 
thickening and giant cells with 
granulomatous necrosis was also 
noted. 
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Author Study type Extent of arterial involvement Histopathologic changes 
Cullen 1963 (83) Five cases reports of which one case 
had a post mortem examination 
Both eyes were examined revealing 
involvement of the ophthalmic, posterior 
ciliary and central retinal artery at its 
origin. 
Typical lesions of giant cell arteritis. 
Manschot 1965 (84) One case – post mortem examination Right eye – central retinal artery 
intradural course and one posterior ciliary 
artery 
Loss of internal elastic lamina, 
reduplication of the intima and 
thrombus formation in the lumen 
leading to central retinal artery 
occlusion.  
Wolter and Phillips 1965 (85) One case – histopathologic 
assessment of the right eye following 
enucleation due to haemorrhagic 
glaucoma. 
Right eye – ophthalmic and posterior 
ciliary arteries  
Inflammatory cell infiltrate, giant cell 
and thickening and fractures of the 
internal elastic lamina. 
MacFaul 1967 (86) One case – post mortem examination Right eye – short ciliary arteries 
Left eye – ciliary arteries around the optic 
nerve  
Right eye – short ciliary arteries 
showed intense inflammatory cell 
infiltrate with giant cells 
Left eye – giant cells 
Wilkinson and Russell 1972 (87) Four cases – post mortem series Three out of four had ophthalmic artery 
involvement, two with central retinal 
involvement and two with posterior 
ciliary artery involvement.  
Typical changes of giant cell arteritis 
Butt, Cullen and Mutlukan 1991 
(88) 
Three cases – two of which 
underwent post-mortem examination 
Case one – both eyes – ophthalmic and 
posterior ciliary vessels. Case two – right 
eye – ophthalmic artery but not central 
retinal artery 
Inflammatory cell infiltrate principally 
in the media with destruction of the 
internal elastic lamina and intimal 
thickening. 
 19 
 
2.1.7 Treatment of GCA 
High dose glucocorticoids (GCs) are the mainstay of treatment, with 
evidence of benefit demonstrated since the 1950s (89, 90). However, 
there is no consensus on the optimal treatment for GCA, and there is 
considerable variation in clinical practice with regard to the initial 
(starting) dose, and subsequent rate of dose-reduction of GCs (91). Both 
the European League Against Rheumatism (EULAR) and British Society 
for Rheumatology (BSR) and have produced guidelines on GCs dosing. 
The guidelines were developed through extensive literature search using 
a modified Delphi technique. Recommendations were based on data from 
clinical trials and expert opinion of the panel members (92, 93). The 
EULAR guideline advises treatment with prednisolone 1 mg/kg/day 
(maximum 60 mg/day) continued for 1 month before entering a tapering 
phase over several months (92). The BSR recommends prednisolone 40 
to 60mg (not <0.75 mg/kg) daily until the resolution of symptoms and 
laboratory abnormalities in patients without visual loss; 500mg to 1g of 
intra-venous methylprednisolone in those with evolving visual loss; and 
at least 60mg a day for those patients with established visual loss before 
then entering a tapering phase (93). The BSR guidelines and currently 
being revised and are due to be published in 2017.  
Steroid sparing agents have been trialled in the treatment of GCA with 
formal randomised studies of IV-methylprednisolone, methotrexate, 
dapsone, hydroxycholoroquine, and two anti-TNF agents (infliximab and 
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adalimumab). The results have not shown a benefit for the use of adjunct 
agents at the time of diagnosis but methotrexate may have a marginal 
benefit for subsequent relapse (94, 95). A randomised trial of the IL-6 
blocker tocilizumab in the treatment of GCA (GiACTA) is due to report in 
due course (96) but the preliminary results presented at the American 
College of Rheumatology look promising. Lack of positive results from the 
clinical trials, may in part, be due to methods of case selection and 
definitions of disease. 
2.2.0 CLASSIFICATION AND DIAGNOSTIC CRITERIA 
Whilst there are many classification sets, no criteria have been fully 
validated for clinical diagnosis of PMR and GCA. Rather, a diagnosis is 
made, based on typical patterns of disease and usually rapid response to 
steroids. Those case which are then diagnosed with the condition can 
then be scrutinised by classification criteria to produce a sample of 
patients which should be representative to other studies who have used 
similar methods of case ascertainment, selection and definition. If these 
methods differ between studies, then comparison of factors for both 
disease onset and progression can be difficult to interpret.  
2.2.1 Classification criteria for PMR and GCA 
Both conditions are difficult to define not least due to the lack of a single 
sensitive and specific diagnostic test. In addition there are different 
classification criteria sets in existence used to define the two conditions, 
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and particularly for PMR, helping to contribute differences in the way the 
studies were designed and the ultimately the estimates derived (see 
Table 2.2).  
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Table 2.2  Classification Criteria for Polymyalgia Rheumatica 
Authors & 
Year 
Proposed Criteria Requirement for Classification 
Bird et al. 
(1979) (97) 
Age ≥65 years 
Bilateral shoulder pain and stiffness; acute or subacute onset (<2 wk); morning stiffness >1 hr depression and/or 
weight loss; bilateral tenderness in upper arm muscles 
ESR >40 mm/hr 
Any three, or any one plus temporal artery 
abnormality (including decreased pulsation, 
tenderness, beading or bruit). 
Jones and 
Hazleman 
(1981) (14) 
Shoulder and pelvic girdle pain; morning stiffness >1 hr; exclusion of rheumatoid arthritis or other inflammatory 
arthropathy, myopathy, malignancy 
ESR >30 mm/hr or CRP >6 mg/L 
Rapid response to corticosteroids  
All criteria must be met 
Chuang et 
al. (1982) 
(98) 
Age ≥50 years 
>1 month bilateral aching and stiffness of at least two of the following areas: Neck or torso, shoulders or proximal 
arms, hips or proximal thighs; exclusion of other causes 
ESR >40 mm/hr 
All criteria must be met 
Healey and 
Wilske 
(1984) (15) 
Age ≥ 50 years  
>1 month of neck, shoulder, or pelvic girdle pain (any two areas); morning stiffness >1 hr; exclusion of other 
diagnoses 
ESR ≥40 mm/hr 
Rapid response to daily, low-dose steroid therapy (i.e. prednisolone ≤20 mg) 
All criteria must be met 
Doran et 
al. (2002) 
(16) 
Age ≥ 50 years;  
Bilateral aching and morning stiffness (lasting ≥ 30 min) persisting for at least 1 month and involving 2 of the 
following areas: neck or torso, shoulders or proximal regions of the arms, and hips or proximal aspects of the thighs 
ESR > 40 mm/hr OR rapid response to corticosteroids 
All criteria must be met 
Dasgupta 
et al. 
(2012) (99) 
EULAR/ACR criteria: Morning stiffness  ≥ 45 minutes (2 points); Hip pain, limited range of movement (1 point) 
Absence of other joint pain (1 point) 
Negative RhF or ACPA (2 points) 
Ultrasound criteria: at least 1 shoulder with sub-deltoid bursitis and/or biceps tenosynovitis and/or glenohumeral 
synovitis AND at least 1 hip with synovitis and/or trochanteric bursitis (1 point); both shoulders with subdeltoid 
bursitis, bicep tenosynovitis or glenohumeral synovitis (1 point) 
All patients must be: Age ≥50 years, have 
bilateral shoulder aching and abnormal 
ESR/CRP 
Scoring algorithm without ultrasound score 
of 4 needed – with ultrasound score of 5 
needed 
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The current classification criteria for GCA were published in 1990 by the 
American College of Rheumatology (ACR) (100). They comprise the 
following features:  
1. Age at disease onset >=50 years,  
2. New headache,  
3. Temporal artery abnormality (tenderness to palpation or decreased 
pulsation, unrelated to arteriosclerosis of cervical arteries),  
4. Elevated ESR (>=50 mm/hour by the Westergren method),  
5. Abnormal artery biopsy (showing vasculitis characterized by a 
predominance of mononuclear cell infiltration or granulomatous 
inflammation, usually with multinucleated giant cells) (100).  
For purposes of classification, a patient shall be said to have giant cell 
arteritis if at least three of these five criteria are present. The presence of 
any three or more criteria yields a sensitivity of 93.5% and a specificity 
of 91.2%. 
Any objective enquiry into the epidemiology of PMR and GCA requires a 
consistent approach to case definition. This is difficult for diseases which 
are almost entirely recognised based on their clinical features. Although 
diagnostic tests are available they lack specificity and the gold standard 
for GCA (temporal artery biopsy) lacks sensitivity. The classification 
criteria sets reflect commonly acknowledged aspects of disease, although 
differences in their criteria are likely to result in variation of measures of 
disease occurrence. 
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2.3.0 PREVALENCE OF PMR AND GCA 
Prevalence and incidence estimates for PMR and GCA vary widely. This 
may, in part, represent true geographic or genetic differences in the 
populations studied (see Table 2.3).  Only one study on the community 
prevalence of GCA and PMR in the UK has been conducted by Kyle et al 
from a single Cambridgeshire practice in 1985 and has not been repeated 
since (101). The prevalence estimate of GCA was 1.23% for those aged 
≥65 years (101) and for GCA combined with PMR was 3.5% (101). 
However, that study pre-dates the current ACR classification criteria set 
and failed to include participants younger than 65 years.  More recent 
data from Europe and the USA have given an over 30-fold discrepancy in 
prevalence estimates, (see Table 2.3). Data from the Mayo clinic from all 
incident cases of GCA from Olmsted County (years 1950 to 1999) 
revealed 173 cases of GCA in those aged ≥50 years. This resulted in a 
prevalence estimate for GCA of 0.23% and for PMR of 0.74% (95% CI 
0.67 to 0.81) (16, 102, 103). An invited questionnaire population survey 
of household residents in Portugal gave a prevalence estimate of 0.1% 
(95% CI 0.0 to 0.2) for PMR: however since 41.5% of those surveyed 
were aged 50 years, restricting this to those aged older than 50 years 
would result in a higher prevalence estimate (104).  In 2006, 
questionnaires sent to hospital departments and insurance companies in 
Germany revealed a prevalence for GCA of 0.04% (95% CI 0.04 to 0.05) 
(105). 
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Table 2.3  Published estimates for PMR and GCA prevalence 
Author Country; survey type; age threshold PMR and GCA prevalence Classification 
Branco et al 2016 (104) Portugal; Survey of one adult per 
household with questionnaire and possible 
review by clinician >18 years. 
PMR: 0.1% (0.0% to 0.2%) PMR Bird et al 
Romero-Gomez et al 2015 (106) Spain; Single hospital in Marbella 2010 
point prevalence; ≥50 years 
GCA 0.01% (95% CI 0.006 to 0.02) GCA: ACR 1990 
Herlyn et al 2014 (105) Germany; Survey of hospitals, private 
physicians and insurance companies in 
2006;  ≥50 years 
GCA: 0.04% (95% CI 0.04 to 0.05) GCA: ACR 1990 
Mohammad et al.  2011 (107) Sweden; survey of Skåne cumulative 
incidence 1997 – 2010; ≥50 years 
GCA:  0.11% (95% CI, 0.10-0.12). GCA: Temporal artery biopsy positive 
only 
Bernatsky et al 2009 (108) Canada; hospital record survey,  cumulative 
incidence 1995 -2006; ≥50 years 
PMR: 0.64% (urban); 0.86% (rural)  PMR: Physician billing twice within 2 
months or stated on hospital discharge. 
Pamuk et al 2009 (109) Turkey. Single rheumatology department in 
a tertiary referral centre,  cumulative 
incidence, ≥50 years 
PMR and GCA: 0.02% PMR: Chuang et al  
GCA: ACR 1990 
Lawrence et al 2008 (102) 
Salvarni et al, 1999 (103). 
Doran et al 2002 (16). 
USA; Olmsted County survey of cumulative 
incidence 1950 -1999; ≥50 years 
PMR: 0.74% (95% CI, 0.67–0.81)  
GCA: 0.28% (95% CI, 0.19–0.27) - 
 
PMR: Doran et al  
GCA: ACR 1990 
 
Salaffi et al 2005 (110) Italian MAPPING study; population survey; 
age ≥65 years 
PMR:  0.37% (95% CI 0.29-0.44) PMR: Bird et al 
Koboyashi et al 2003 (111) Japan;  Hospital only treated patients in 
1997; ≥50 years 
GCA:  0.002% GCA: ACR 1990 
Kyle et al 1985 (112) UK; GP practice based survey;  ≥ 65 years. PMR: 1.69% (95% CI 0.70 to 2.68) 
GCA: 1.23% (95% CI 0.38 to 2.08) 
PMR: Jones and Hazleman  
GCA: Jones and Hazleman  
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2.3.1 Incidence of PMR and GCA 
Published incidence estimates for PMR and GCA are shown in Table 2.4, 
with incidence for both conditions increasing with age. Data from the 
Mayo clinic gave an incidence for PMR of 55.6 per 100,000 population 
aged over 50 years for men and 72.7 for women. The greatest annual 
incidence was seen in persons aged 70 to 79 years: 124.3, 181.7 and 
155.7 per 100,000 person years for men, women and overall, 
respectively (113). An Italian study from a large single hospital, serving a 
population of around 500,000 people, reviewed temporal artery biopsies 
to ascertain the incidence of GCA. The annual incidence for those aged 
older than 50 was 5.8 per 100,000 person years. The highest incidence 
was seen in people aged between 80 and 84 years, 16.7 per 100,000 
person years (95% 12.9, 21.4) (114).  
The wide variation in the estimates (see Table 2.4) may arise since 
earlier studies refer to patients with temporal arteritis or polymyalgia 
rheumatica as having the condition GCA, using the later as an umbrella 
term to encompass both conditions, leading to confusion and difficulty in 
making comparison to more contemporary studies (115, 116). The 
estimates from the Mediterranean countries are around a factor of ten 
lower than those from the Scandinavian countries, the UK and USA, and 
these differences cannot be explained through differences in study design 
alone. 
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Table 2.4  Published estimates for PMR and GCA incidence 
Author Country; survey type; age threshold PMR and GCA incidence per 
100,000 
Classification 
Raheel et al 2016 (113)  
Chandran et al 2015 (117) 
Salvarani et al 2004 (118) 
Chuang et al 1982 (98) 
USA; Olmsted County survey of annual 
incidence;  PMR 1970-1979 and 2000-
2014; ≥50 years  GCA; 1950-1999 and 
2000 – 2009; ≥50 years 
PMR: 63.9 (95% CI 57.4 to 70.4) and 
53.7 (43.5 to 65.6) 
GCA 18.8 (95%CI 15.9 to 21.6) and 
19.8 (95% CI 15.2 to 24.3) 
PMR: EULAR/ACR and Chuang et al  
                                                              
GCA: ACR 1990 
Catanos et al 2016 (114) Italy, histopathology review from single 
hospital in Reggio Emilia province, annual 
incidence 1986-2012, ≥50 years 
GCA: 5.8 (95% CI 5.1 to 6.5) - GCA: Temporal artery biopsy 
positive only* (91% fulfilled ACR 
1990) 
Elfving et al 2016 (119) Finland; Hospital treated patients with 
GCA from five hospitals serving Northern 
Savo annual incidence 2010; ≥50 years 
GCA: 7.4 (95% CI 6.3 to 8.7) GCA: ACR 1990 
Romero-Gomez et al 2015 
(106) 
Spain; Single hospital in Marbella GCA 
annual incidence 1994-2010; ≥50 years 
GCA 2.2 (95% CI 1.4 to 3.0) GCA: ACR 1990 
Smeeth et al 2006 (120) 
Petri et al 2015 (121) 
UK; GP research database, annual 
incidence, PMR 1990-2001; ≥50 years 
GCA 2010-2011; ≥50 years and GCA 1990 
to 2001; ≥50 years. 
PMR 84.2 (95% CI 83.0 to 86.0) 
GCA 22.0 (95% CI 21.0 to 23.0) and 
GCA 11.2 (95% CI 10.9 to 11.5) 
1 record of either GCA or PMR and 
at least 2 prescriptions for 
glucocorticoids (Smeeth) and GCA: > 
1 record for GCA and >1 
prescription for systemic 
glucocorticoid (Petri) 
Mohammad et al 2015 (122) Sweden; histopathology review of four 
health centres in county of Skåne annual 
incidence GCA; 1997-2010; ≥50 years 
GCA: 14.1 (95% CI 13.1 to 15.0) GCA: Temporal artery biopsy 
positive only* 
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Author Country; survey type; age threshold PMR and GCA incidence per 
100,000 
Classification 
Dunstan et al 2014 (123) Australia; histopathology review from 
three health centres in South Australia; 
annual incidence GCA 1992-2011; ≥50 
years 
GCA: 3.2 (95% CI 2.8 to 3.6) GCA: Temporal artery biopsy 
positive (all fulfilled ACR 1990) 
Bas-Lando et al 2007 (124) Israel; hospital record review from four 
hospitals in Jerusalem, annual incidence 
GCA 1980 -2004; ≥50 years  
GCA: 11.3 (95% CI 9.5 to 13.1)  GCA: temporal artery biopsy 
positive** or if diagnosed with GCA 
and met ACR 1990. 
Gonzalez-Gay et al 2007 (125) 
Gonzalez-Gay et al 2001 (126) 
Spain; single hospital record review in 
Lugo, annual incidence for GCA 1981-
1988 and 1981-2005, ≥50 years 
GCA 10.2 and 10.1 GCA: temporal artery biopsy 
positive 
Haugeberg et al 2000 (127) Norway; hospital record review from 
Vest Agder County, annual incidence GCA 
1992-1996; ≥50 years 
GCA: 32.8 () GCA: ACR 1990 (94% temporal 
artery biopsy positive) 
Gran and Myklebust 1997 
(128) 
Norway; clinical review of GP suspected 
cases annual incidence for GCA and PMR 
1987-1994, ≥50 years 
PMR 112.6 
GCA 29.0 
PMR: Bird et al                                                    
GCA: temporal artery biopsy 
positive only 
Elling et al 1996 (129) Denmark; national register review of 
hospital cases supplemented by 
histopathology department review in two 
hospitals annual incidence of PMR and 
GCA 1982-1994, ≥50 years 
PMR 41.3 (95% CI 30 to 67) 
GCA 20.4 (95% CI 19 to 23) 
PMR: Hospital recorded cases 
GCA: Hospital recorded cases, TAB 
positive rate 15% (for all TAB) 
Baldursson et al 1994 (130) Iceland; national register review 
supplemented with histopathology 
review of temporal artery biopsies, 
annual incidence of GCA 1984-1990, ≥50 
years 
GCA: 27.0 (95% CI 22.7 to 32.1) GCA: ACR 1990 (65% of temporal 
artery biopsies had giant cells 
present) 
Franzen et al 1992  Finland annual incidence of GCA 1984-
1988, ≥50 years 
GCA: 22.7 GCA: temporal artery biopsy 
positive 
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Author Country; survey type; age threshold PMR and GCA incidence per 
100,000 
Classification 
Salvarani et al 1991 (131) Italy; single hospital in Reggio Emilia 
province, annual incidence PMR and 
GCA; 1980-1988; ≥50 years 
PMR 12.7  
GCA 6.9 
PMR: Chuang et al  
GCA: Temporal artery biopsy 
positive and Clinical features of 
GCA*** 
Boesen and Sorensen 1987 
(116) 
Denmark; postal survey of all general 
practitioners and hospital departments in 
the county of Ribe, annual incidence of 
GCA 1982-1985, ≥50 years 
GCA 23.3 (temporal biopsy positive) 
Combined PMR with GCA: 76.6 
GCA: Clinical criteria or biopsy 
positive**** 
Kyle et al 1985 (112) UK; single GP practice based survey; 
annual incidence ≥ 65 years 
PMR 211.5  
GCA 153.8 
PMR: Jones and Hazleman  
GCA: Jones and Hazleman 
Bengtsson et al 1981 (115) Sweden; hospital record review from two 
hospitals in the city of Göteborg, annual 
incidence of GCA and PMR 1973-1975, 
≥50 years 
GCA: 18.3 
GCA and PMR combined: 28.6 
GCA: Clinical criteria and temporal 
artery biopsy positive cases*****.  
PMR: Clinical criteria† 
Jonasson et al 1979 (132) UK; Lothian region of Scotland annual 
incidence of biopsy positive GCA 1964-
1977 
GCA: 4.23 GCA: positive temporal artery 
biopsy** 
Cameron 1959 (133) Single GP practices in Kent of 3,700 
registered patients 21% > 60 years age 
GCA: 165 GCA: clinical diagnosis of the nine 
cases described 
Temporal artery biopsy defined studies used a single senior or experienced histopathologist to review specimen with only biopsies showing: inflammatory cell infiltrate or granulomatous inflammation 
with or without giant cells considered positive, except the following: *which included: segmental loss or disruption of the internal elastic lamina; compromise and/or obliteration of the arterial lumen; 
atrophy and scarring of the muscularis; and adventitial fibrosis as positive findings. **No definition of what constituted a positive biopsy are given. ***GCA required at least four of the following: 
abnormal temporal arteries (tender and swollen), loss of vision, jaw claudication, presence of PMR and response to glucocorticoids. ****temporal artery positive or clinical criteria: pain and stiffness in 
proximal muscle groups for at least 2 weeks without evidence of inflammatory arthritis or pain, tenderness or abnormal findings on palpation of the temporal artery. *****temporal artery positive 
definition: destruction of the internal elastic lamina and infiltration of mononuclear cells, clinical criteria (all needed to be met): pain and stiffness of proximal muscles without evidence of inflammatory 
arthritis, elevated ESR, no evidence of malignancy, RA, SLE or PAN, prompt and long-lasting response to glucocorticoids. †Clinical criteria for PMR: consƟtuƟonal symptoms with proximal muscle pain and 
stiffness, raised ESR, no signs of inflammatory arthritis and no head symptoms. 
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2.3.2 Comments 
The contemporary epidemiology data from the UK are old and 
inadequate, and there is need to apply classification criteria consistently 
if the results from studies are to be directly comparable.   
2.4.0 ESTIMATES OF OCULAR MORBIDITY 
Published information on the occurrence of eye disease in GCA has been 
based almost exclusively on small hospital-based patient series (134, 
135). No accurate data exist on the prevalence and nature of eye 
complications among patients in the community and no comprehensive 
assessments undertaken of the full range of ocular morbidity in patients 
with GCA due to both the disease process, and treatment with 
glucocorticoids. To date the focus has been on the disease process itself, 
rather than any iatrogenic associated outcome from long-term exposure 
to glucocorticoids. 
2.4.1 Ocular sequelae from GCA 
Recently published data from the Mayo clinic revealed that 47 from 204 
patients with GCA had visual symptoms prior to diagnosis of GCA. Of 
these, seven patients had monocular blindness and two had binocular 
blindness. AION was noted in 17 patients and CRAO in two patients as 
the cause of visual disturbance. This study data from residents from 
Rochester (Olmstead County, Minnesota USA) estimates that around 
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30,000 residents are aged >50yrs. Neither long-term data on eye disease 
nor the effect of steroids on eye morbidity are described (136). 
From information on the occurrence of eye disease in GCA based almost 
exclusively on small hospital-based patient series (134, 135), the most 
common reported outcome is of visual loss, reported in a number of 
ways, including transient or permanent, monocular or binocular 
involvement. Permanent visual loss occurs in 12% to 32% of patients. 
(137, 138). Definitions of severity of visual loss are also equally muddled 
as visual loss is reported either as reduced visual acuity or as loss of 
visual field. In addition, the lack of control group for these studies 
prevents calculation of relative and absolute risk estimates for visual loss 
in patients with GCA. Risk for eye complications appears to differ in 
subsets of patients with GCA, with those with isolated aortitis proving a 
particular diagnostic challenge (139-141).  
From hospital case series analysis, the most common ocular pathology 
(Table 2.5) is anterior ischemic optic neuropathy (AION), with central 
arterial or branch retinal occlusion (CRAO), choroidal ischaemia and 
posterior optic neuropathy (PION) also reported (28). 
Table 2.5 Common ocular complication in GCA 
Cause Mechanism 
AION Ischaemia of the posterior ciliary arteries which supply the optic nerve head 
CRAO Central retinal artery occlusion  
PION Ischaemia of the optic nerve within its intra-orbital, intra-canalicular, or 
intracranial tract 
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A prospective case series of 170 patients with biopsy-proven GCA 
revealed 69 had AION (40%), 12 had CRAO (7%) and 6 had PION (3%); 
55 had fluorescein angiography and 12 of these had cilioretinal artery 
occlusion (21%).  Most patients who fluorescein angiography showed 
evidence of posterior ciliary artery occlusion (28). Another retrospective 
study of 47 patients with GCA who had fluorescein angiography, showed 
22 had AION (47%), 17 had choroidal ischaemia (36%) and seven had 
CRAO (15%) (29).  
Use of MRI has revealed further changes affecting the eye: a study using 
high resolution MR imaging of the ophthalmic artery in 43 patients with 
GCA demonstrated that 20 (46%) of patients had mural enhancement, 
suggesting inflammation. Eleven of the 43 patients had an MRI scan prior 
to treatment with glucocorticoids, but no correlation was demonstrated 
between treatment prior to the scan and mural enhancement. In the 20 
patients with mural enhancement, ophthalmic examination involving 
fundoscopy revealed fundal changes in seven patients, including AION 
and CRAO. The MRI and ophthalmic examination were normal in fifteen 
patients. Nine patients had AION (20%) four CRAO (9%) and one PION 
(2%). MRI showed vessel inflammation in patients who had no symptoms 
of visual disturbance, whereas another eight participants were MRI 
negative but had typical changes of arteritis on ophthalmic examination. 
As suggested by the authors, differences in agreement between 
symptoms, ophthalmic examination and MRI may be due to the study’s 
imaging protocol. Only inflammation of the ophthalmic artery was 
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detected and not the small posterior ciliary arteries. Both the utility and 
significance of MRI changes require further evaluation (30).  
As patients with GCA may be managed exclusively in a primary care 
setting, without referral for either temporal artery biopsy or ophthalmic 
department examination, there are no accurate data on the incidence, 
prevalence and nature of eye complications among patients in the 
community, although sudden dramatic deterioration in vision should 
prompt the affected patient to seek urgent medical attention. 
Moreover, there have been no comprehensive assessments of the full 
range of ocular morbidity in patients with GCA due to both the disease 
process and treatment with glucocorticoids. It is therefore difficult to 
appreciate the risk of visual loss in patients with GCA, particularly those 
based in the community setting. In addition the absolute and relative 
risks are unknown making public health planning difficult. 
2.5.0 BIOLOGICAL MECHANISMS OF DISEASE ONSET 
Th-17 and Th-1 lymphocytes have been implicated in the pathogenesis of 
both diseases (142). Various cytokines have shown to be key in the 
development and maintenance of the inflammatory reaction within the 
vessel wall of patients with GCA, including IL-12, interferon gamma, IL-6, 
IL-17 and IL-21 (18, 143, 144). The triggers for the immune response to 
initiate disease onset are unknown. The major theories for the underlying 
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disease mechanism in PMR and GCA centre on the concepts of 
immunosenescence and endothelial dysfunction.  
2.5.1 Immunosenescence 
Although the causes of PMR and GCA are unknown, the strong positive 
association to older age suggests a role for immunosenescence. Thymic 
involution occurs with advancing age, with loss of T-cell development and 
decreased emigration of naïve T cells (145). 
Dendritic cells appear to be central to the maintenance of the 
inflammatory process and for granuloma formation (146-149). The 
activation of the dendritic cells, based in the adventitia of arteries, leads 
to activation of CD4 positive T cells to polarise into Th1 and Th17 cells, 
and recruitment of CD8 positive cytotoxic T-cells and Natural Killer cells 
(150). Activation of macrophages coalesce to develop into multinucleated 
giant cells, the presence of which lead to the descriptive name of GCA. In 
addition, there is downregulation of regulatory T cells and the activated 
T-cell population brings about production of IL-17, interferon gamma and 
growth factors leading to inflammatory cell maintenance and remodelling 
of the arterial wall, resulting in increased risk of aneurysmal formation 
and ischaemic complications (151, 152). Amongst GWAS studies in 
patients with GCA, the consistent identification of HLA-DR1*04 supports 
the central role for antigen presenting cells such as dendritic cells (153). 
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Dendritic cells are found in healthy arterial tissue at the adventitial-media 
border (a similar site to calcification deposits), but remain in an 
inactivated state. Dendritic cells are not usually found in healthy veins, 
but have been identified in venous pathologies such as at the sites of 
varicosities and in stenosis of venous coronary artery bypass grafts (154, 
155). It is possible that endothelial damage may partially explain the 
activation of dendritic cells within arterial vessel walls. In addition, 
recruited T-Cells and macrophages activate endothelial cells of the vasa 
vasorum to express high level of adhesion molecules such intercellular 
adhesion molecule -1 (ICAM1) and ICAM2, P- and E- Selectin and VCAM-
1 causing further immune cell recruitment (156), moreover, 
concentrations of soluble ICAM1 correlate with disease activity (157). 
2.5.2 Endothelial Damage 
The experimental laboratory studies and epidemiological data implicate 
endothelial dysregulation as being important drivers for disease 
development, particularly for GCA but also PMR. Moreover the relatively 
confined vascular tropism of GCA strongly suggests a role for the 
microenvironment, rather than purely a cell-mediated driven immune 
response. Previous histopathological studies of temporal artery biopsies 
identified calcific deposits in the internal elastic membrane, which in 
some cases had a focal giant cell reaction towards them (158).  These 
calcific deposits are also present in the temporal arteries of individuals 
not thought to have GCA, more common in women and positively 
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correlated with increasing age (159). Plausible risk factors for endothelial 
damage include smoking, alcohol and obesity and other typical traditional 
cardiovascular risk factors, including hypertension and diabetes (160). 
These factors have been associated with alterations in systemic 
inflammation and endothelial function. Chemicals produced during 
cigarette smoking have been shown to be pro-inflammatory in human 
and animal models to be pro-inflammatory (161, 162). Obesity is 
recognised as a risk factor for the metabolic syndrome, with studies 
showing increased inflammatory cytokines, such as serum IL-6 and TNF 
(163). Moderate alcohol consumption has been shown to be 
cardioprotective in terms of coronary heart disease and may be 
protective in terms of reducing endothelial damage (164). It is possible 
therefore that these biological mechanisms are important in both GCA 
and PMR pathogenesis. However without more definitive data on risks 
and outcomes, all these mechanisms remain speculative. 
2.6.0 RISK FACTORS FOR DISEASE DEVELOPMENT – ONSET AND 
PROGRESSION 
This section summarises the risk factors for disease onset, in terms of 
associations with PMR and or GCA and disease progression, namely for 
ocular morbidity in GCA and inflammatory polyarthritis after a diagnosis 
of PMR. The risk factors are divided into non-modifiable and modifiable 
factors. 
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2.6.1 Non-modifiable risk factors-Genetic Determinants 
Both PMR and GCA are considered auto-immune diseases. The highest 
incidence figures (See Table 2.4) are from Scandinavian countries whose 
population with PMR and GCA are almost exclusively Caucasian (165). 
Genome-wide association studies (GWAS) have been published and have 
been consistent in identifying the major histocompatibility complex (MHC) 
class II molecule and protein tyrosine phosphatase, non-receptor type 22 
(PTPN22) gene loci as important genetic determinants of interest (166). 
Genetic studies of PMR and GCA have revealed an association between 
the human leukocyte antigen (HLA)-DRB1*04 allele but results have not 
always been consistent, particularly for PMR from southern European 
populations (167-173).  There does appear to be a different genetic 
profile between GCA and the other closely related large vessel vasculitis 
of Takayasu’s arteritis. GCA associates to HLA Class II, whereas 
Takayasu’s most strongly associates with HLA Class I, suggesting a 
difference in the underlying genetic risk profile (174). Outside of the HLA 
region both types of LVV showed an association between a polymorphism 
located nearby the IL12B gene (174). In addition, in patient with GCA, 
other GWAS Single Nucleotide Polymorphism (SNP) loci outside of the 
HLA region include those involved in the plasminogen gene and collagen 
prolyl 4-hydroxylase 2 (P4HA2) the expression of which is controlled by 
hypoxia-inducible factor 1 (HIF-1) (175), the latter of which is involved in 
vascular remodelling by smooth muscle cells. 
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2.6.2 Genetic studies of PMR 
A study of 55 patients satisfying Bird’s criteria for PMR from southern 
France revealed an association between HLA-DRB1*01 but not HLA-
DRB1*04 (odds ratios and 95% CI: 2.6 (1.3, 5.2) and 1.4 (0.7, 2.8) 
respectively) (172). In contrast, a study of 46 patients with PMR from the 
USA revealed a positive association with HLA-DRB1*04 but was 
negatively associated with HLA-DRB1*01 (percentage frequencies 
between cases and controls, 67.4% vs 23.6% and 10.9% vs 27.8% 
respectively) (169). 
A SNP of the endothelial nitric oxide synthase gene (NOS3) known as T-
786C predisposes to cardiovascular disease by reduced expression of 
nitric oxide synthase in response to sheer stress. This variant has been 
shown to be positively associated with PMR with an odds ratio of 2.48 
supporting a role of endothelial dysregulation in patients with PMR (176). 
2.6.3 Genetic studies of GCA 
A UK GWAS study of 225 patients with GCA and 1378 controls revealed 
an association between HLA-DRB1*04 carriage and GCA (odds ratio 2.69, 
95%CI 2.02 to 3.58) (153). A meta-analysis of 14 previous published 
studies revealed an odds ratio of 2.45 for HLA-DRB1*04 and GCA (153). 
In addition, familial aggregation has been reported for GCA with a 
literature review concluding, from published cases reports, the 
prevalence for familial GCA to be 1 in 83 (compared 1 to 250-500 
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expected by chance only) (177) with 18 of the 32 patients genetically 
screened carrying the HLA-DR4 antigen.  
The adventitia of arteries affected by GCA is an important area involved 
in immunogenicity and is the only region of the vessel wall that is 
vascularised by the vasa vasorum (178). Dendritic cells are found within 
the arterial wall, particularly at the adventitia-media border (147). MHC 
class II is typically found on professional antigen presenting cells, such as 
dendritic cells which are responsible for naïve T-cell differentiation and 
development (179). 
2.6.4 Other non-modifiable risk factors for onset 
 Increasing age is a risk factor: these diseases are rarely diagnosed 
in those younger than 50yrs old, with this age cut-off forming one 
of the principal criteria for classifying both PMR and GCA. With 
incidence increasing with age, this association suggests that 
cumulative endothelial damage, immunosenescence and 
inflammation may be important in the development of both 
diseases in susceptible individuals.  
 Sex: both conditions are commoner in women (107, 180, 181). 
 Seasonal variation appears to influence diagnostic rates in some 
countries and although not confirmed, infective agents have been 
suggested as causal factors but not confirmed (182-184).  
Moreover data from the THIN database, infection per se, rather 
than individual microbes is associated with subsequent increased 
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incidence of GCA, with an apparent dose affect. The incidence rate 
ratio was 2.18 with more than five infections in the past (185). 
However, it is unknown whether infections cause GCA or whether 
those who have a lot of infections have a dysregulated immune 
system that puts them at both increased risk of infection and GCA.  
 
2.6.5 Modifiable risk factors 
 BMI has been examined in only one study and no association has 
been found (186). 
 Cigarette smoking (former and current) has been associated with 
GCA with odds ratios ranging from 1.29 to 6.32 (180, 187, 188). 
For PMR there has been one case-control study identified smoking 
as a risk factor but only in women OR of 3.64, 95% CI 1.07-12.40 
(189). 
 Lower socioeconomic status showed a positive association with a 
risk of visual ischaemic complications associated with GCA in one 
study (190). 
 Cardiovascular disease was shown to be a risk factor for GCA but 
only in women (191). 
 Peripheral vascular disease has been associated with PMR but 
findings are inconsistent (192). 
 There have been no studies assessing dietary factors 
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 Multiparity was associated with a reduced chance of GCA diagnosis 
from one study (193). 
 Pharmacological influences: several retrospective case-series 
studies and one case-control study have assessed the effect of 
statins on GCA incidence and complications (including relapse 
rates, risk of blindness, and mortality). These studies showed 
decreased risk of GCA in those individuals taking statins (OR 0.31 
95% CI 0.15 to 0.6), but no change in the disease outcomes or 
mortality (194-197). 
2.6.6 Comments 
Most of the studies investigating risk factors were of case-control design 
with problems of recall bias for exposures, and difficulty in finding 
representative control groups. In addition most cases comprised hospital-
treated patients, leading to difficulties of generalisability to other groups, 
particularly those treated in the community who may display a different 
phenotype and have an alternative morbidity profile. There have been 
relatively few studies, which have assessed risk factors for disease 
progression, namely visual loss associated with GCA and inflammatory 
polyarthritis associated with PMR. 
2.6.7 Risk factors for ocular morbidity 
To date, risk factors for visual loss have been studied mainly amongst 
cohorts of patients from single centres. The literature shows an 
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association between laboratory markers and subsequent blindness: 
greatest risk is associated with relatively lower inflammatory markers at 
diagnosis, anaemia and thrombocytosis as well as constitutional 
symptoms (58, 198, 199). Comorbidity is also associated with visual loss 
in GCA, with hypertension and ischaemic heart disease implicated as 
increasing the risk of blindness (188, 198, 199).  
However not all studies confirm an association between cardiovascular 
risk factors and ischaemic manifestations, including ocular morbidity in 
GCA. A multi-centre retrospective study of 271 cases of GCA in the UK, 
reviewed contemporaneous patient care records for the presence of 
ischaemic complications: of these, 222 (81.9%%) had ischaemic 
manifestations, of whom 100 had transient visual loss, and 46 (17%) 
suffering irreversible visual loss (190). Also recorded were data on 
hypertension (on anti-hypertensive agents or BP > 140/90 mmHg on two 
or more occasions), atherosclerosis (clinically recorded myocardial, 
cerebral or limb ischaemia not directly attributable to GCA), deprivation 
(index of multiple derivation 2007), smoking (current, former, never) and 
duration of symptoms prior to treatment with glucocorticoids. After 
adjustment for age and sex, neither hypertension nor atherosclerosis 
were associated with irreversible ischaemic complications (irreversible 
visual loss including; limb arterial stenosis n=6, irreversible diplopia n=5, 
stroke n=3, and myocardial infarction n=1) (190). However, logistic 
regression analysis comparing the most-deprived with the least-deprived 
quartile resulted in an odds ratio of 3.0 (95% CI 1.1, 7.9; p=0.029) 
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(190) which the authors concluded was partly due to delays in presenting 
to medical services for treatment. Statins prescribed prior to diagnosis of 
GCA appeared to have little effect on those who subsequently develop 
ischaemic manifestations, compared with those not on statins OR for 
ischaemic manifestations 0.74 (95% CI 0.34, 1.62; p=0.46). Although 
prescription of aspirin was associated with an increased odds ratio for 
ischaemic manifestations OR = 2.81 (1.06, 7.45; p=0.038) (190), it is 
important to note that as these were unadjusted odds ratios, this result 
may have been biased through confounding by indication. No propensity 
score matching was attempted.  
A Swedish study using the Skåne Healthcare Register identified 840 
patients with temporal artery biopsy-positive GCA diagnosed between 
1997 and 2010. International Classification of Disease tenth edition (ICD-
10) codes for visual complications recorded in GCA cases were matched 
(in a nested case-control analysis) to one control (without ICD-10 
recorded visual complications) on the basis of calendar year of birth (+/- 
five years), sex and year of diagnosis (200). A second analysis using a 
matched-cohort design, matched all 840 cases of GCA (age, sex area of 
residence and index year) to four randomly selected controls without a 
diagnosis of GCA, in order to calculate rate-ratios for visual impairment. 
Follow-up time was from date of index case to either date of visual ICD-
10 code entry, death or end of follow-up period (31st December 2011) 
(200). Using logistic regression, several medications and their association 
with visual impairment were analysed. A review of the case notes 
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revealed 85 cases (10.1%) with ICD-10 codes for visual impairment 
following their diagnosis of GCA: 18 patients (2.1%) had complete visual 
loss, two of whom with binocular visual loss (200). The rate ratio for ICD-
10 coded visual complications compared with the matched controls was 
3.0 (95% CI 2.3, 3.8; p=<0.001) (200). Logistic regression analysis in 
the nested case-control analysis revealed an univariate odds ratio of 2.77 
(95% CI 1.29, 5.95; p=0.009) for ICD-coded visual complication and 
beta-blockers which increased to 6.98 (95% CI 1.29, 37.8; p=0.02) once 
headache, fever, abnormal temporal artery on clinical examination, 
presence of PMR, and ACE-i prescription were included in the model. In 
keeping with the UK study, no attempt was made to address confounding 
by indication due to beta-blockers and their use in treating cardiovascular 
disease.  
2.6.8 Risk factors for inflammatory arthritis following a 
diagnosis of PMR 
The relationship between PMR and inflammatory polyarthritis (IP) 
remains a source of debate: although they have been classified as two 
distinct entities, they share many clinical features (33, 201-203). It 
remains unclear as to whether synovitis is part of a spectrum of PMR, or 
if the symptoms of PMR are early manifestation of rheumatoid arthritis 
(RA). Alternatively the development of synovitis might represent a 
phenotypic transformation in susceptible individuals.  
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Studies conducted in secondary care suggest that patients initially 
diagnosed with PMR develop IP within twelve months of diagnosis (17, 
204, 205) with the presence of peripheral small joint synovitis, at time of 
PMR diagnosis, the most consistent risk factor.  The greatest risk of 
diagnostic switch shown is from a single centre self-referred study of 62 
patients with PMR from the USA, with 52 (84%) developing synovitis in 
who were diagnosed with rheumatoid arthritis (RA) within an average of 
nine months from their PMR diagnosis date (33).  
2.7.0 EVIDENCE GAPS 
There is wide variation in the published incidence and prevalence 
estimates for PMR and GCA with few studies involving community-based 
patients. 
The is a genetic contribution to both diseases particularly involving MHC-
Class II but other cellular processes including immune cell signalling and 
vascular remodelling, although none fully explain the reasons for disease 
development (206). Since the majority of published data on risk factors 
for PMR and GCA development are based on cross-sectional case control 
studies conducted in a hospital setting, and so prone to selection bias and 
difficultly in establishing causation, interpretation is problematic.  
Population data from registries (for example the Ontario Health Insurance 
Plan, UK-based CPRD, and Scandinavian disease registries) are limited by 
problems of case ascertainment, disease definition and validation, since 
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diagnoses are recorded by GPs pragmatically and therefore researchers 
are unable to apply classification criteria.  No study has captured risk 
data prior to disease onset.   
There are no accurate data either on the incidence and significance of 
sub-clinical ocular involvement, or the risk of progression of eye disease 
over time, nor has an evaluation been made of the relative frequency of 
eye morbidity related to treatment. Therefore there is difficulty in 
gauging the true risk of eye complications in PMR and GCA. The factors 
which might predict the onset and progression of eye disease in GCA are 
unknown, and there is little understanding of how best to monitor 
patients over time for the development of eye disease over time.  
It is important to distinguish clinically the nature of IP following a 
diagnosis of PMR and may help identify patients who might benefit from 
the early introduction of disease-modifying drugs (DMARDs). However, 
problems arise interpreting the studies to date because of the potential 
influence of referral and diagnostic suspicion bias inherent in hospital-
based series as well as small samples sizes and relatively short follow-up 
intervals. Longer duration studies need to take account of mortality in 
what is an older patient population. 
2.8.0 THE NEW DATASETS 
The limitation of small hospital series can be overcome by large datasets 
that have recently become available. However, the problems outlined 
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around definition of cases and requirement of community-based 
populations needs considerable effort in order to generate analysable 
data. The new datasets used in this thesis are outlined below with further 
in-depth description on participant recruitment and case ascertainment 
and definitions provided in the subsequent Methods chapter. The brief 
section below gives an overview of the considerable effort in order to 
achieve the desired outcome of a robust community-derived data source 
in order to study the epidemiology of PMR and GCA, with more detailed 
description in the Methods and Results chapters. 
2.8.1 GCANS – Giant cell arteritis in Norfolk Study 
To provide a community-based survey population, the GCANS project 
was set-up at a large two-site Norfolk general practice. GCANS’s 
objectives were to ascertain community-derived estimates of occurrence, 
and understand the frequency of clinical features associated with PMR 
and GCA within the population.  
The most recent prevalence for PMR and GCA for the UK was published in 
1985 by Kyle et al (112), within a single general practice of 5,500 
patients, with 650 (11.8%) aged 65 years or older. All were interviewed, 
with those with responses suggestive of PMR or GCA undergoing 
venesection for ESR testing, with those having an ESR of 30 mm/hr or 
greater being reviewed clinically, with those meeting the Jones and 
Hazleman criteria considered to have PMR and or GCA.  The most recent 
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census data available for Norfolk reveal that 25.7% are aged 65 years or 
older, over twice as many compared to the Kyle et al study.  
To update the community-based prevalence estimates for both PMR and 
GCA, case record review was used, supplemented by population survey 
via questionnaire and subsequent clinical examination by a 
rheumatologist, similar to the approached used by Kyle et al. Practice 
case records at the surgery were reviewed and in addition a population 
survey was undertaken to capture any unknown or undiagnosed cases of 
PMR or GCA within the practice population. 
Despite its relatively small size (n=5,159) this project was strengthened 
by the use of the population survey, clinical review and access to 
haematological and biochemical test results, with more detail given in 
chapters 4.2.0 and 5.1.0.   
Full ethical approval was granted from Norwich Research Ethics 
Committee, with participants giving written informed consent. 
2.8.2 PMR and GCA in EPIC-Norfolk 
For 20 years epidemiologists have focused on the Norfolk population to 
study common chronic diseases because of its relative stability, with little 
outward migration.  Healthcare is mostly sought within the region, with 
the most encountering secondary care at a single central hospital 
(Norfolk and Norwich University Hospital). All the processing of 
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haematological, biochemical and pathological samples is carried out 
within the hospital’s laboratory. The Norfolk Arthritis Register has 
provided definitive data on the incidence of inflammatory arthritis and RA 
within this population. Similarly the Norfolk Vasculitis Register has 
provided data on the incidence of rare vasculitides (207, 208). 
Norfolk is also a site for the UK centre for the European Prospective 
Investigation into Cancer (EPIC).  EPIC-Norfolk is a cohort of 30,445 men 
and women resident in East Anglia, aged 40–79 years, between 1993 and 
1997). Participants from 35 GP practices and have taken part in serial 
screening assessments which included measures of nutritional and 
environmental exposures. Initially set up to study the aetiology of cancer, 
in subsequent years the study has been broadened to include chronic 
diseases.  
Extensive work was needed to set-up and identify participants within 
EPIC-Norfolk who had been diagnosed with PMR and GCA in order to take 
advantage of what could be a rich data source with fine granularity. A 
more detailed description of the process involved is given in the Methods 
(4.3.0) and Results (5.2.0) chapters. 
The eye data captured as part of the EPIC eye study are particularly 
valuable for PMR and GCA studies.  This cohort of a total of 8,623 
participants aged 48–92 years have undergone extensive eye testing 
including retinal digital imaging. Examination of retinal blood vessels 
offers an opportunity to view and image the circulatory system directly.  
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In patients with GCA, typical histopathologic changes in affected arterial 
segments include inflammatory cell infiltrate, with or without the 
presence of giant cells, reduplication of the intima and fractures of the 
internal elastic lamina. The inflammatory cell infiltrate is from the 
adventitia towards the lumen and is focused around dendritic cells within 
the arterial wall. No venous pathological changes are reported in patients 
with PMR or GCA which may be due to the lack of dendritic cells in the 
vessel walls of veins. However, peripheral vascular disease is reported in 
patients following their diagnosis of PMR and / or GCA, but the biologic 
mechanisms and process of this association have yet to be clarified. 
Few autopsy studies have charted the anatomical involvement of arteries 
in GCA (see Table 2.1). Most frequently affected are the large arteries, 
particularly the aorta and its superior branches, the subclavian, common 
carotids, internal carotid and ophthalmic artery and its branches. 
Involvement of the arterial supply to the eye may lead to the most feared 
complication in GCA of blindness, most commonly through the 
consequence of anterior ischaemic optic atrophy, affecting around 1/12 
patients with GCA. More frequent is less severe visual impairment but the 
estimates vary widely. It is unknown whether typical histopathological 
changes of GCA affect the retinal vessels. 
Vasculitic changes may affect the retinal arterioles in patients with GCA 
and detailed ophthalmological reports reveal relatively thin arteriole 
vessels in affected patients. Of greater interest to study may be the nasal 
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vessels due to their close proximity to the disc and the fact that retinal 
artery involvement has been reported (See Table 2.1 for details). 
Additionally, the presence of anomalies such as ciliary retinal arterioles 
may be of interest since they are derived from the posterior ciliary 
vessels, more frequently affected in patients with GCA (209). Any 
findings found by manual grading could be used in a validity assessment 
against the QUARTZ (automated processing software – more detail given 
in section 4.5.3) produced data. In addition an atlas of changes could be 
derived.  
2.8.3 Diagnosis and Classification Criteria in Vasculitis 
Study (DCVAS) 
This study used participants recruited into the Diagnosis and 
Classification Criteria in Vasculitis Study (DCVAS), an international 
register capturing demographic and detailed clinical information from 
consecutive patients with vasculitis from around the world, presenting to 
clinic-based physicians. Reasons for referral, clinical signs and symptoms 
present at the time of clinical review are recorded. A detailed description 
of the DCVAS dataset and the definitions of disease are given in the 
Methods chapter section 4.4.0. 
2.8.4 Advantages of the datasets 
The use of the above data sources for the purposes of studying the 
epidemiology of PMR and GCA has potential for significant advances in 
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the knowledge base. The creation of a community-based cohort allows for 
a robust assessment for both incidence and prevalence estimates.  
Extending the EPIC-Norfolk cohort to PMR and GCA provides the 
significant advantages of a prospective cohort study in order to 
investigate the aetiology of both conditions from community-treated 
patient populations. The problems of recall bias and unrepresentative 
control groups from previous case-control work will be negated by the 
use of a prospective cohort. The investigation of factors associated with 
blindness from the large international DCVAS will produce estimates 
which should have much greater value in terms of generalisability 
compared to the small studies from single centres to date. Updated 
community-based estimates for disease incidence and prevalence will 
allow for great understanding of the public health consideration required.   
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2.8.5 Thesis originality 
There are identified evidence gaps and uncertainty in the published 
estimates regarding the descriptive epidemiology of these two important 
related conditions warranting further scientific endeavour. The 
prospective and community-based features of the EPIC-Norfolk cohort 
are fundamental to the originality of this work. In addition establishing 
GCANS is important in order to derive modern estimates, based on 
current classification criteria for the diseases of interest. The most novel 
aspect of this body of work is the use of retinal fundal images to assess 
for vascular changes, either morphological associations of disease or 
robust indicators of end organ damage associated with hypertension. 
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CHAPTER 3   AIMS 
3.0 SUMMARY 
This chapter sets out the overall justification and purpose for the thesis, 
detailing the broad and specific aims of this work. 
3.1.0 Aims and purpose.  
The broad aims for this thesis are to update incidence and prevalence 
estimates for PMR and GCA from community treated patients, using 
accepted definitions of disease and ability to apply current classification 
criteria. In addition, rates of disease progression associated with GCA and 
PMR will be reported, with investigation of risk factors for blindness in 
GCA and inflammatory polyarthritis in PMR. 
The specific aims are as follows: 
 provide definitive data on the absolute rate of occurrence of PMR 
and GCA and the risk of associated ocular complications  
 assess key risk factors for disease onset and progression:  the 
thesis will address a number of specific aetiological hypotheses 
assessing previously reported risk factors, including both non-
modifiable and modifiable factors: 
o Smoking is associated with an increased risk for both PMR 
and GCA. 
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o Traditional cardiovascular risk factors (hypertension, 
hypercholestrolaemia, diabetes, high BMI) are associated 
with an increased risk for both PMR and GCA. 
o Statins are associated with a reduced risk for PMR and GCA 
and in addition a favourable disease course with reduced 
morbidity. 
o Subsequently to investigate other commonly prescribed 
mediation including anti-hypertensive agents. 
o Multiparity is associated with a decreased risk for later PMR 
and GCA development. 
 examine ocular outcomes in PMR and GCA to establish the rate of 
occurrence and significance of subclinical vascular retinal disease, 
and to assess these complications with the use of digital retinal 
images 
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CHAPTER 4   SUBJECTS AND METHODS 
4.0 SUMMARY 
This section provides a summary of three datasets analysed for this 
project comprising a community-based cohort from a single GP practice, 
a prospective cohort study – the European Investigation into Cancer and 
Nutrition Study (EPIC-Norfolk), and a large international consortium – 
Diagnosis and Classification criteria in Vasculitis Study (DCVAS).  
The chapter includes details of the recruitment of participants, how 
individuals were ascertained and then defined as having the disease of 
interest. Analytical methods used to calculate prevalence, incidence and 
to investigate aetiological factors are discussed.  
A novel aspect of this project was the use of fully automated software to 
generate measure of retinal vessel widths and the manual review of 
retinal fundal images to record morphological features. The process 
involved as part of this review is described in detail. 
4.1.0 Overview of the Data 
The limitations of existing data have been discussed in the Chapter 2, 
foremost of which are the use of selected often clinic based populations 
and small sample sizes. Where large dataset have been used often 
classification sets have not to define disease.  
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The three datasets that form the basis of this study address these issues 
and comprise GCANS, EPIC-Norfolk and DCVAS. They are used to firstly 
address the descriptive epidemiology, namely providing up to date 
estimates of incidence and prevalence of PMR and GCA and the 
complications of visual loss in GCA and inflammatory arthritis in PMR and 
to estimate aetiological factors involved in the development of disease 
and outcomes. 
4.2.0 COMMUNITY-BASED SURVEY - GCANS 
GCANS (Giant Cell Arteritis and polymyalgia rheumatica in Norfolk Study) 
was conducted at a large dual site general practice in Norfolk on the 
outskirts of Norwich providing care for approximately 13,000 individuals, 
which includes urban and rural areas, residential suburbs and extends 
into outlying villages. Case ascertainment comprised GP record review 
supplemented by postal survey and selected clinical examination. 
4.2.1 GP case record review 
Cases of PMR and GCA were identified through a GP database review, 
including all individuals aged ≥ 55 years. The electronic GP register was 
interrogated using Read code analysis (GCA: G755., G7550, G7551, 
G7552, G755z and PMR: N20.., N200.) and key word searches 
(polymyalgia rheumatica, giant cell arteritis, temporal arteritis). In order 
to satisfy a GP diagnosis of either GCA or PMR, patients needed to have 
received treatment with glucocorticoids and a diagnosis that was not later 
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refuted. Those whose diagnoses were later refuted were considered not 
to have the conditions. 
4.2.2 Supplementary postal survey 
No questionnaire exists for diagnosing patients with PMR or GCA so one 
was required, sensitive to the cardinal features of PMR and GCA.  In 
order to capture undiagnosed cases, the questionnaire needed to be 
sensitive to the detection of the broadest possible range of symptoms of 
PMR and GCA. The diagnosis could later be confirmed or refuted by 
applying clinical judgement during a patient visit. By adapting the 1985 
questionnaire used by Kyle et al, a new questionnaire was developed to 
include the 1990 American College of Rheumatology (ACR) criteria set for 
GCA (210) and informed by a review of the nature and frequency of 
symptoms reported from PMR and GCA cohorts published in the 
literature. This new questionnaire captured the following symptoms: 
shoulder pain and stiffness, myalgia, weight loss, general malaise, 
headache, visual disturbance, scalp tenderness, symptoms suggestive of 
jaw claudication, and important potential discriminative symptoms of 
migraine; participants were also asked whether they had ever been 
diagnosed by their GP with either PMR or GCA.  Its face validity was 
confirmed in a hospital sample of ten patients with PMR and or GCA, and 
among three rheumatologists and two rheumatology nurse practitioners 
specialising in vasculitis (see Appendix 1).  
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The postal questionnaire was sent to all patients registered with the 
practice over the age of 55 years old. Exclusion criteria included patients 
with dementia, a terminal illness, were living in a nursing home or who 
had previously informed the practice they did not wish to take part in 
research.  Non-responders were sent a reminder invitation and another 
questionnaire after three months. 
4.2.3 Clinical review of potential cases 
All participants who answered positively to questions on jaw claudication 
AND scalp tenderness AND visual disturbance, with or without the 
presence of headache and who were not already known to the practice as 
having a diagnosis of GCA were invited for clinical review by a 
rheumatologist (the author).  This group was considered as having a high 
likelihood of having a diagnosis of GCA.  Those answering positively to 
one or more questions were considered at intermediate likelihood of 
having PMR or GCA. A random sample (Excel Microsoft Corporation 
random number generator) of these was invited for clinical review, 
included in which potentially undiagnosed cases of PMR or GCA would be 
expected. 
4.2.4 Case definition 
Following the process of cases ascertainment, cases of PMR and GCA 
were defined as those cases with a diagnosis of either PMR or GCA in the 
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GP electronic record who had received treatment with glucocorticoids and 
in whom the diagnosis had not been later refuted. 
Secondly as part of a sensitivity analysis, those cases of PMR 
subsequently fulfilling the common criteria sets are presented (See Table 
2.2) although due to the lack of testing for rheumatoid factors and anti-
CCP antibodies cases will not be scrutinised by the current EULAR/ACR 
criteria. Cases of GCA will be analysed using the 1990 American College 
of Rheumatology (ACR) classification criteria (210) (see Table 4.1).  
Table 4.1 The 1990 ACR classification criteria set for GCA 
1. Age at disease onset >=50 years (Development of symptoms or 
findings beginning at age 50 or older) 
2. New headache (New onset of or new type of localized pain in the 
head) 
3. Temporal artery abnormality (Temporal artery tenderness to 
palpation or decreased pulsation, unrelated to arteriosclerosis of cervical 
arteries) 
4. Elevated erythrocyte sedimentation rate (Erythrocyte 
sedimentation rate >=50 mm/hour by the Westergren method) 
5. Abnormal artery biopsy (Biopsy specimen with artery showing 
vasculitis characterized by a predominance of mononuclear cell infiltration 
or granulomatous inflammation, usually with multinucleated giant cells) 
For purposes of classification, a patient shall be said to have giant cell 
arteritis if at least three of these five criteria are present. The presence of 
three or more criteria yields a sensitivity of 93.5% and a specificity of 
91.2% (210). 
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4.2.5 Sample size and analytical approach 
Minimum cumulative prevalence estimates were calculated for both 
diseases. This method assumes that all known cases are identified, those 
who died within the population, prior to the end of the follow-up period, 
are excluded and that non-responders to the survey do not have the 
disease of interest and contribute to the denominator. Cumulative 
prevalence estimates were expressed as a proportion; confidence 
intervals were calculated based on the Poisson distribution. 
The five electoral wards covered by the practice have a combined 
population (from the 2011 Census) of 15,102 of whom 5,108 (34%) were 
aged ≥55 years and 2,983 (20%) were aged ≥65 years. The practice is 
representative of the Norfolk population in terms of ethnicity, gender 
ratio and age structure (36% of the Norfolk population are aged ≥55 
years). A sample size of 4,000 allowed the detection of an anticipated 
prevalence of 0.3% for GCA with 95% confidence interval ranging from 
0.13% to 0.47%. A greater level of precision would be possible for PMR 
as it is more common than GCA. 
4.2.6 Participant flow 
The number of participants involved in the GCANS study is displayed in 
Figure 4.1  
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Figure 4.1  Participant flow chart for GCANS 
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4.3.0 EPIC-NORFOLK 
The European Prospective Investigation into Cancer and Nutrition (EPIC) 
is a large prospective cohort set up in the 1990s across 10 European 
countries, recruiting around half a million individuals and EPIC-Norfolk 
represents one of the recruitment areas (in Norfolk, UK). Individuals were 
recruited from 35 GP practices across rural, sub-urban and inner city 
areas. A total of 30,445 men and women were consented with 25,639 
participants, aged 40-79 years, recruited between the years 1993-1997 
(211).  
The cases of PMR and GCA need to be identified and clinical information 
scrutinised in order to carry out case ascertainment and definition. 
During baseline nurse-led health check clinics and by using validated 
questionnaires, participants provided detailed information on 
demography, height, weight, smoking and alcohol intake. The Norfolk 
Health Authority granted ethical approval at the time of study set-up, 
with subsequent revisions over the past 25 years. 
4.3.1 Case ascertainment 
Three methods were used to identify incident cases of PMR: 
1. Potential cases of PMR using ICD 10 codes (M35.3 and M31.6, PMR 
and GCA with PMR respectively). This identified those patients who 
had a referral to secondary care and had been diagnosed with 
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PMR, either following a direct referral for suspected PMR or if 
mentioned within their previous medical history. 
2. Potential cases from out-patient clinic letters using a keyword 
search with Boolean operators for “polymyalgia” and “rheumatica” 
in letters from clinicians based in geriatrics, ophthalmology, 
neurology or rheumatology.  
3. EPIC-Norfolk follow-up questionnaires: Q12 enables participants to 
provide free text information on diagnosis occurring after the 
baseline questionnaire. This was sent to participants at baseline, 
three, five and ten year follow-up. 
Four methods were used to identify incident cases of GCA: 
1 Potential cases of GCA using ICD 10 codes (M31.5 and M31.6, GCA 
and GCA with PMR respectively). This identifies those 
patients in the EPIC cohort who have had a referral to 
secondary care and subsequently diagnosed with GCA. 
2 Potential cases from out-patient letters. This was based on a 
keyword search with Boolean operators for “arteritis” OR 
“giant” in any clinic letters from clinicians based in 
geriatrics, ophthalmology, neurology or rheumatology.  
3 Participants in EPIC who have had a temporal artery biopsy using 
operating procedure code (OPCS) L67.1 (temporal biopsy). 
4  From EPIC-Norfolk follow-up questionnaires: Q12 enables 
participants to provide free text information on diagnosis 
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occurring after the baseline questionnaire. This was sent to 
participants at baseline, three, five and ten year follow-up. 
This has found 712 potential cases of PMR and / or GCA (516 participants 
with PMR, 196 participants with GCA). 
4.3.2 Hospital records review 
The classification sets for PMR and GCA require results of blood tests and 
for GCA, results of temporal artery biopsy. These criteria were then 
applied to potential cases of PMR and GCA identified from the cohort. 
As part of the agreement with practices in EPIC-Norfolk, direct access to 
GP records is not permitted. However, 94.9% of outpatient visits for 
EPIC-Norfolk participants occur at the Norfolk and Norwich University 
Hospital, which performs biochemical and haematological laboratory 
assessment for all primary or secondary-care based clinicians. Therefore 
even where a GP had exclusively managed their patient with PMR or GCA 
in the community, it is possible to gain access to any patient blood test 
results. 
4.3.3 PMR case definition 
There are several sets of diagnostic and classification criteria for PMR, 
which include both clinical features and biochemical factors [37-40] with 
inflammatory markers (CRP or ESR), age > 50 years and bilateral 
shoulder pain common across the published criteria. For the purposes of 
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this study individuals who self-identify as having PMR on the EPIC 
questionnaire and are treated as such by their GP with at least six 
months of steroid therapy and have raised inflammatory markers (CRP 
>6 mg/L and / or ESR >40 mm/hr) and are aged >50 years at time of 
diagnosis will be considered to have the condition and are referred to 
PMR50 from now on in the text. Secondly, as part of a sensitivity 
analysis, those cases of PMR subsequently fulfilling the European League 
Against Rheumatism / American College of Rheumatology (EULAR/ACR) 
classification set for PMR will be analysed.  
4.3.4 GCA case definition 
For the purposes of this study, individuals who self-identify as having 
GCA on the EPIC questionnaire and are treated as such by their general 
practitioner with at least 6 months of steroid therapy and are aged >50 
years at time of diagnosis will be considered to have the condition are 
referred to GCA50 from now on in the text. 
Secondly as part of a sensitivity analysis, those cases subsequently 
fulfilling the 1990 American College of Rheumatology (ACR) classification 
criteria (210) (see Table 5.4) will be analysed. The criteria are based on 
clinical, biochemical and histological features of the disease.  
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4.3.5 Baseline exposures recorded for the EPIC cohort 
 Smoking status – divided into current, former and never 
categories. 
 BMI (kg/m2) – set for standardised categories as defined by the 
World Health Organisation. 
 Diabetes mellitus (both Type I and Type II) – those with / those 
without at the time of recruitment. 
 Hypertension – those on medication for hypertension / those not 
 Alcohol consumption – measured in the food frequency question 
divided into standardised categories. 
 Dietary fatty acids divided into quintiles of dietary intake from 
seven day food diaries. 
 Medication at the time of recruitment – statins and hypertensives 
were chosen to be included in the analysis from the previously 
published data. 
 High-sensitivity CRP measured at the first health-check 
The data were collected at the first health check, with CRP measured on 
serum blood samples using the Olympus AU640 assay, able to measure 
high-sensitivity CRP over the range of 0 to 160 mg/L (212).  
 68 
 
4.4.0 INTERNATIONAL CONSORTIUM OF VASCULITIS - DCVAS 
This study used participants recruited into the global Diagnosis and 
Classification Criteria in Vasculitis Study (DCVAS), which captures 
consecutive patients presenting to clinic-based physicians.  
4.4.1 Case recruitment and setting 
DCVAS was set-up in 2010, recruiting patients from 129 sites worldwide 
(see Figure 4.2).  
Figure 4.2 DCVAS recruitment 
 
The purpose of DCVAS is to develop and validate diagnostic and 
classification criteria for systemic vasculitis for use in daily clinical 
practice and in clinical trials. Physicians recruit patients with diagnoses of 
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vasculitis or comparator conditions at the time of diagnosis. Information 
collected includes clinical, serological, pathological and radiological data 
and records demographic and detailed clinical information, reasons for 
referral and clinical signs and symptoms present at the time of clinical 
review. 
4.4.2 Case ascertainment and definition of GCA 
The DCVAS protocol required the examining physician to submit an 
assessment of their level of diagnostic certainty (very certain, ≥75%; 
moderately certain, 50-74%; uncertain, 25-49%; very uncertain, <25%) 
for each participant at baseline and after six months. Musculoskeletal 
features were also recorded including whether patients had a prior 
diagnosis of polymyalgia rheumatica. Inclusion criteria were a new 
baseline diagnosis of GCA (i.e. not relapsing disease), which was 
confirmed after six months with a confidence level of ≥75%. The results 
of temporal artery biopsy (TAB) were also available, allowing patients to 
be classified using the 1990 ACR criteria set for GCA (210). A positive 
TAB was defined as the presence of inflammatory cell infiltrate and / or 
presence of giant cells in line with 1990 ACR criteria. 
4.4.3 Previous medical history 
For all patients the DCVAS protocol records specific medical conditions 
present before the onset of the current illness, including coronary heart 
disease, heart failure, peripheral vascular disease, hypertension requiring 
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medication, chronic obstructive pulmonary disease, asthma, diabetes 
mellitus, cerebrovascular accident, dyslipidaemia and malignancy. In 
common with many large registry datasets, these diagnoses were 
defined, a physician-recorded entry in the patients’ care record. 
4.4.4 Definition of blindness 
The Vasculitis Damage Index (VDI) was used to assess new onset 
blindness, defining blindness in one or both eyes as complete loss of 
vision (213). Also recorded at baseline were data on ophthalmic features 
(amaurosis fugax – transient monocular blindness, sudden ongoing visual 
loss – loss of vision either visual field defect or blindness, blurred vision, 
or diplopia – double vision). VDI records diplopia and visual impairment 
as a single item but this was not included as a primary outcome measure 
due to the lack of consistency in definition and potential for 
misclassification bias. 
4.5.0 EPIC-Eye Study 
A total of 8,623 participants aged 48-92 years attended the Eye Study 
(nested within EPIC-Norfolk, carried out between 2004-2011) as part of 
the third health check, and underwent assessment of visual acuity, 
autorefraction, biometry, tonometry, corneal biomechanical measures, 
scanning laser polarimetry, confocal scanning laser ophthalmoscopy, 
fundal photography and automated perimetry (214). See Figure 4.3 for 
numbers of participants attending the health checks. 
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Figure 4.3  Flow diagram of EPIC-Norfolk participants 
 
D –death, NC – not contacted, R – refused, hc n – health check number. 
 
30,445 consented 
25,639 attended hc 1 N=4806 
Questionnaire only 
N=3774 
Questionnaire only 
19,560 consente for hc 2 
15,786 attended hc 2 
23,927 continuing in study 
18,380 approached for hc 3 
10,826 consented for hc 3 
8623 attended hc 3 N=2203 
Questionnaire only 
27,399 continuing in study 
D=1214 
NC=1076 
R=756 
D=1029 
NC=1656 
R=495 
D=3252 
NC=1608 
R=687 
 72 
 
This third health check occurred between the years 2004 to 2011, 
roughly a midway point between initial participant recruitment (to EPIC-
Norfolk) and the present day. Therefore it is to be expected that 
approximately half of the participants with either a diagnosis of PMR or 
GCA will have had their third health check prior to their diagnosis of PMR 
or GCA. This allows for examination of both aetiological and long-term 
sequelae hypotheses in respect of retinal morphological changes.  
4.5.1 EPIC-Eye visual acuity assessment 
Habitual (that is uncorrected by glasses or contact lenses) monocular 
visual acuity (VA) was measured using a logarithm of the minimum angle 
of resolution (LogMAR) chart (Precision Vision, LaSalle, Illinois, USA) with 
the aid of the participants' available distance correction at 4m (or 2m 
then 1m if unable to read any letters). VA for both eyes was recorded. 
WHO defines low vision as worse than 0.5 LogMAR but equal or better 
than 1.3 LogMAR in the eye with the best vision, or visual field loss 
corresponding to less than 20 degrees in the better eye. Blindness is 
defined as either LogMAR equal or greater than 1.3 or visual field of 10 
degrees or less around central fixation in the eye with best vision. Visual 
impairment includes both blindness and low vision. LogMAR values 
corresponding to counting fingers (CF), hand movements (HM), 
perception of light (PL) and no light perception (NLP) were substituted as 
LogMAR, 2.10, 2.40, 2.70 and 3.00 respectively (215). 
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Blindness associated with GCA is often unilateral and therefore visual 
impairment for left and right eyes as well as for the total number of 
participants affected is reported. 
4.5.2 Retinal fundal images  
The EPIC Eye study participants had numerous measures related to eye 
health recorded, including measures of visual acuity and digital retinal 
photographs and analysis of these retinal photographs forms a significant 
proportion of the work in this thesis. Non-mydratic images were taken 
using a TRC-NW65 Topcon fundus camera with a 45 degrees field-of-
view. The participants had photographs of both left and right eyes, 
sometimes with each eye being photographed more than once. The 
images are centred on the fovea, typical for the diabetic retinopathy 
screening programme (see Figure 4.4 for an example of a retinal image – 
source UK Biobank). 
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Figure 4.4 Retinal fundal image 
 
Retinal fundal image of a right eye. Image from UK Biobank (© UK biobank). Macula centred image. 
The optic disc on the right shows a bright white centre called the optic cup. The central retinal reflex 
can be seen as a white line in the arterioles. 
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4.5.3 QUARTZ 
In collaboration with researchers based at St George’s Hospital and 
Kingston University, a software program called QUARTZ (Quantitative 
Analysis of Retinal Vessel Topology and size) has been developed to 
measure retinal vessel widths. It is able to process digital retinal images, 
identify the optic disc location and characterise the vessels into arterioles 
and venules and measure vessel widths. 
The QUARTZ program was developed due to the need for a fully 
automated system able to process large numbers of retinal images for 
the purposes of epidemiological research (216). The program is able to 
record: 
o Left or right eye (via location of the optic disc in macula 
centred images) 
o Classification of vessels into arterioles and venules 
o Vessel segmentation 
o Centreline coordinates of vessel segments 
o Vessel widths at each centreline coordinate 
Developed in Matlab, the software uses a multi-scale line detector using 
average grey-level of each pixel (216). The average pixel intensity is 
measured along lines of a certain length in 12 different planes spaced at 
15 degrees. The line with the highest average pixel intensity is selected, 
then the process repeats for different line lengths and the final line 
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placement based on the highest average grey value of a square sub-
window centred at the target pixel to identify the central vessel reflex.  
The algorithm then performs hysteresis morphological reconstruction to 
produce a line strength image (LSI). The LSI has two levels of grey-value 
threshold applied to it in a two-step process. Firstly the threshold is 
selected at a narrow threshold range for the high object confidence pixels 
(those with the greatest value for grey-value or brightness). The 
resultant image is named as a marker image and includes the vessels 
and false negatives. A second threshold is then applied, which has a wide 
threshold range to the greyscale image. Centre lines of the vessels are 
then applied to the image with those pixels with the brightest intensity 
selected. Vessel segments are then devised from the centre-lines with a 
thinning operation, whereby spurs (<10 pixels), short segment lengths 
(<15 pixels) and cross-over or bifurcation points are removed (217). 
The QUARTZ program classifies vessel segments into two groups of either 
arteriolar or venular. It uses an ensemble classifier of bagged decision 
trees based on colour features of each segment. The decision tree uses 
three parameters: the central line pixel intensity, the variation in the 
brightness of the pixels away from the centre-line and the variation in 
pixel intensity along the segment in order to make judgements on the 
probability that the segment in question is an arteriole or venule. The 
intensity of each pixel is calculated in each of the Red, Green, Blue (RGB) 
colour and Hue, Saturation, Intensity (HIS) channels. Through training 
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rounds of the classifier algorithm it was established that 16 is the 
optimum number of decision trees used for vessel classification (218).  
Finally, measures of vessel width are determined using a Gaussian 
function. The central line of the vessel has the brightest value with a 
dropping in the intensity further away from the centre line. The inflection 
points of the Gaussian curve are calculated which correspond to the 
vessel edges (219). The resultant output produces measures of vessel 
width in the number of pixels for each segment.  
4.5.4 Retinal Morphology 
In addition to the automated reading of images a manual review of the 
digital retinal images was carried out in order to record any changes seen 
within the retinal field, including retinal vessel characteristics. This is 
important since the QUARTZ program removes all bifurcation and cross-
over points of vessels which are known to have clinical utility, such as 
arteriovenous nipping in individuals with hypertension. All retinal images 
of participants with a diagnosis of PMR and or GCA were reviewed in 
addition to matched control cases for those individuals with incident 
diagnoses of PMR or GCA (i.e. occurring after their retinal photograph 
was taken). Characteristics recorded were based on a modification of the 
National Health and Nutrition Examination Survey (NHANES) programme 
to capture vascular lesions such as focal narrowing and arteriovenous 
nipping (See Appendix 2 for scoring sheet). 
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4.5.5 Validation of retinal findings 
All retinal images of the participants were analysed at Moorfields eye 
hospital with the author reviewing all the cases and control images. In 
addition an independent review of all the images was undertaken by a 
retinal screening programme technician. Where any cases of 
disagreement occurred a third, senior technician reviewed the images 
who had the final say on any morphological features present.  
4.6.0 Construction of the PMR cohort to monitor for polyarthritis 
development 
The European Prospective Investigation in Cancer and Nutrition Norfolk 
(EPIC-Norfolk) is a prospective cohort study of 24,068 participants 
recruited from 35 general practice sites in the years 1993 to 1997 (211).  
Of secondary care outpatient attendances for EPIC-Norfolk participants, 
94.9% are at a single hospital in the region (Norfolk and Norwich 
University Hospital). The study period was restricted to the interval 
between 1st February 2002 and 31st January 2015 when laboratory data 
were available on all subjects. 
4.6.1 Identification and definition of incident 
polyarthritis 
All cases of PMR identified within the EPIC-Norfolk cohort underwent 
hospital records review. To satisfy a diagnosis of PMR, patients were 
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required to be older than 40 years and to have received at least two 
prescriptions for oral glucocorticoids within six months of the index date 
of diagnosis. This approach has been validated in the Clinical Practice 
Research Datalink (CPRD) (120). Case assignment for PMR was carried 
out independently by two rheumatologists (MY, RW). Potential cases were 
excluded from the analysis if the diagnosis in the case record was 
refuted, or changed within the first six months to an alternative diagnosis 
other than inflammatory polyarthritis (IP). IP was defined on the basis of 
rheumatology records which documenting wrist and/or peripheral joint 
synovitis with a decision to start DMARD therapy (most commonly 
methotrexate). Case assignment for IP was carried out independently by 
two rheumatologists (MY, JK). Participants with a diagnosis of IP prior to 
PMR were excluded from subsequent analysis.  
4.7.0 OVERVIEW OF THE ANALYTICAL APPROACHES 
The datasets analysed as part of this thesis comprise both cross-sectional 
and cohort studies, which allows for and dictates the form of analysis 
possible. From the observed data, inferences are used to make 
predictions of the probability or chance for the outcome following 
exposure to the risk factor for future or unobserved individuals. Therefore 
any analysis of a sub-section of a population (commonly referred to as 
the sample) is assumed to be representative of the total population from 
which it is drawn. Controls which are unrepresentative of the population 
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from which cases derive can introduce bias with uncertainty in the 
resulting estimate. 
The initial Results Chapters deal with the descriptive epidemiology for 
PMR and GCA namely their prevalence and incidence and subsequently 
the absolute and relative risks for visual impairment. The later Results 
chapters describe the factors associated with both disease onset and 
progression. Since the three datasets comprise cross-sectional and cohort 
data, the analytical approaches differ and are set out below.  
4.7.1 Cross-sectional data 
By definition, cross-sectional studies capture single-time point data. 
Cases, defined as having the outcome of interest, are compared to 
controls, those without the outcome. Exposure to certain risk factors is 
compared between the two groups to derive an inference regarding that 
particular exposure and its association to the outcome. Since the date of 
the outcome of interest is not calculated with duration of exposure, rates 
cannot be estimated. Cross-sectional or more commonly case-control 
studies can be analysed to estimate odds or risk (220).  
Case-control studies are considered an ideal design for studying rare 
diseases, where a cohort study would be required to be very large and 
have a long duration of follow-up making it costly and logistically difficult. 
The main limitations of case-control studies are difficulty in finding 
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representative control groups and that rates of disease cannot be 
calculated. Other problems include recall and reverse causation bias. 
However, this study design is used in analysing the GCANS and DCVAS 
data since they are cross-sectional studies. The minimum period 
prevalence for PMR and GCA can be calculated from GCANS and the 
prevalence of blindness in patients with GCA recruited to DCVAS. In 
addition since EPIC-Eye is a case-control study nested within the cohort 
study of EPIC-Norfolk, the relative and absolute risks for visual 
impairment can be calculated.  
4.7.2 Cohort data 
Cohort data comprise a group of individuals of whom none have the 
outcome of interest at the start of the observation period. The cohort is 
then monitored for a period of time, at the end of which those with the 
outcome are compared to those without and comparisons are made in 
the exposures between the two groups in order to draw inference about 
their associations. The data have the duration of time an individual is 
potentially exposed to the risk factor, so rates of disease and risks can be 
calculated unlike case-control studies. Cohort studies have the further 
advantage of being able to be analysed to calculate both absolute and 
relative risks for an exposure for a given population (220). Analytical 
methods need to take account of longitudinal nature of exposure and 
censorship. These methods apply to the EPIC-Norfolk data. Due to the 
 82 
 
longitudinal set-up the incidence of PMR and GCA can be investigated and 
is reported for the EPIC-Norfolk cohort. 
4.8.0 ESTIMATES OF FACTORS ASSOCIATED WITH ONSET AND 
PROGRESSION OF DISEASE 
In addition to describing the descriptive epidemiology, it is possible to 
measure both rates and risks for factors associated with disease onset 
and progression. The data sets allow studies of both case-control design 
and survival methods for modelling of risk factors. 
4.8.1 Case-control studies 
Case-control studies can be used to investigate factor associated with 
disease outcome. In this thesis, factors associated with disease onset and 
progression will be assessed using logistic regression with risk estimated 
using odds ratios. These include cardiovascular risk factors and 
medication associated with diagnosis of PMR and GCA, and factors 
associated with blindness in GCA.  
4.8.2 Survival analysis 
Risk can be estimated from cumulative incidence and incidence density. 
However, incidence density has advantages over cumulative incidence 
since, the latter allows for losses to follow-up, competing risks and 
differential follow-up time for participants. This is particularly important 
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for analysis of the EPIC-Norfolk cohort which had a relatively long 
enrolment period and long-duration of follow up. In addition expression 
of incidence density estimates for disease outcome has advantages in 
being comparable to other studies which have also produced estimates 
using this method. 
Generally the longer individuals are observed, the more chance they will 
have of developing the outcome of interest. Therefore it would be 
misleading to compare one study with five years of follow-up for the risk 
for a particular exposure to another that had ten years of follow-up. In 
addition, once the outcome of interest has developed, that particular 
individual can no longer be at risk and it cannot be known when that 
outcome developed (right censored). For this reason risks cannot take 
account of time-varying exposures, so called time-dependent variables 
(220). 
The cohort data from the EPIC-Norfolk study allows for calculation of 
estimates of disease incidence rate. Due to the dynamic nature of the 
cohort (i.e. long enrolment phase and long duration of follow-up), 
incidence density is the most appropriate form for expressing new 
disease occurrence. However, there are several steps required in the 
process of building a model which are described below. 
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4.9.0 MODELLING ASSOCIATIONS 
Several plausible biological risk factors exist for both disease onset and 
progression in PMR and GCA. Previously published estimates are 
hampered by small sample size, unrepresentative control groups, lack of 
community-based estimates, and recall bias. Several methods of 
modelling are available to test associations between putative risk factors 
and outcomes of interest. In the datasets of case-control design used in 
this project, logistic regression is suitable for the purpose of modelling 
associations with the outcomes available. The computer program STATA 
estimates the parameters in a multivariate logistic regression model 
using maximum likelihood. The output displays p values based on the 
Wald test. 
Stepwise logistic regression is used with likelihood ratio tests to examine 
whether the model steps are significantly different in their output. 
However, often data for variables is missing and therefore it is not 
possible to perform a likelihood ratio test because the more complicated 
model needs to be nested within the simpler version.   
Analytical methods using survival analysis are more complicated. 
Depending on the methods used there are several assumptions to be 
aware. Incidence density is the most appropriate measure of disease 
occurrence in EPIC-Norfolk, this will be used for analytical modelling 
purposes. Since age and sex are likely to be strong confounders in the 
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development of both PMR and GCA, the relationship between these two 
factors will need to be investigated. Using Lexis expansion, age bands are 
created so that each resulting record contains the follow-up on one 
subject through one time band allowing for adjustment due to 
confounding by age. Participants are censored (no longer contribute at 
risk time) when they develop either disease of interest or die. The rate 
ratios for disease onset can be calculated to test the assumption of 
whether the effect of sex differs across age bands. If it does not then 
more complicated methods of survival analysis can be explored including 
Cox regression as there is no violation of proportionality. 
In addition, the rate of co-morbidity can be studied, e.g. those who 
develop polyarthritis (IP) following a diagnosis of PMR. Since PMR and 
GCA affect older people, it is likely that there will be associated expected 
mortality. For these reasons survival analysis will need to take account of 
deaths that occur in the cohort. Kaplan Meier is the most commonly used 
method, producing a survival curve often called the survivor function but 
is non-parametric and is unable to be used with more than one predictor 
variable. Cox regression, or more precisely Cox Proportional Hazards 
model, allows for multiple predictors in the model and produces a hazard 
function, its main assumption being that the proportional hazards stay 
constant over time (221). 
The analytical plan will therefore comprise: first studying the effect of age 
and sex, using Lexis expansion, if there are no statistical differences for 
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the effect of sex across the age bands then Cox regression will be used 
with finally competing risk of death due to the elderly nature of the 
cohort. 
As with any observed data there is also the potential for unobserved 
confounding for which no model can account.  
4.9.1 Approaches to confounding 
There is no statistical test for confounding, which occurs when a variable 
is associated both with the risk factor and the outcome but is not a causal 
factor. Confounding can be dealt with either by use of modelling or 
stratification. Stratification can be used if there are enough individuals or 
observations in each strata and it does not require the investigator to 
know assumptions about the distribution of the confounder within each 
stratum or the relationship between each confounder variable. When 
there are few observations to make strata cut-points feasible, modelling 
has the advantage over stratification. However to prevent spurious 
conclusions, the distribution and relationship of the confounder variable 
have to be considered in the model for example assessing the effect of 
age over age strata.  
4.9.2 Bias 
Bias can be introduced anywhere in the study process, from the design 
and set-up to case ascertainment and validation, to the way the results 
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are analysed. Studying associations between possible risk factors and 
disease outcomes are particularly difficult in older aged populations 
mainly due to confounding by indication.  
4.9.3 Summary of the analytical approaches 
Of the datasets presented in this thesis, each have their advantages and 
disadvantages in respect of the analysis possible. Chapter six details the 
risk of morbidity associated with PMR and GCA, with the EPIC dataset 
ideally suited to analyse such associations. DCVAS contains only cases of 
vasculitis or comparator conditions, where vasculitis was or could be 
suspected but ultimately was not confirmed by the treating physician and 
so cannot be used to make estimates of incidence or prevalence of PMR 
or GCA. For the risk of inflammatory polyarthritis following a diagnosis of 
PMR, the standard Cox-proportional hazard model was extended to 
include a competing risk for death using the Fine-Gray method (222). A 
summary of the different data sets and statistical approaches is displayed 
in the Table 4.2 below. 
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Table 4.2 Summary of statistical methods 
Estimate Data source Statistical method  
Prevalence of PMR and GCA GCANS Minimum cumulative prevalence (period prevalence) 
 EPIC-Norfolk Minimum cumulative prevalence (period prevalence) 
Incidence of PMR and GCA EPIC-Norfolk Incidence rate per 100,000 person years (incidence density) 
Visual impairment in cases with PMR and 
GCA  
EPIC-Norfolk Eye 
study 
Absolute risk and logistic regression 
Blindness in GCA DCVAS Absolute risk 
Risk factors for disease onset   
Age, sex genetic and traditional 
cardiovascular risk factors 
EPIC-Norfolk Lexis expansion for age with rate ratios  
  Logistic regression for smoking and other traditional cardiovascular factors 
  Logistic regression for previously identified genetic loci 
  Cox-proportional hazard ratios for traditional cardiovascular risk factors 
  Cox-proportional hazards with Fine-Gray extension for traditional cardiovascular risk factors 
  Logistic regression for common medication at baseline, including anti-hypertensives and lipid lowering medication 
Risk factors for progression   
Risk factors for blindness associated with 
GCA 
DCVAS Odds ratios for risk factors including previous medical conditions including cardiovascular disease 
Risk factors for inflammatory polyarthritis 
associated with PMR 
EPIC-Norfolk Cox-proportional hazards with Fine-Gray extension for baseline clinical features at time of PMR diagnosis 
Retinal morphology including 
vasculometric measures 
EPIC-Norfolk Eye 
study 
Linear regression modelling to compare differences in mean widths for retinal vessel venules and arterioles between controls and cases 
of PMR and GCA 
  Retinal morphology characteristics in case-control (matched 1:3) with test on counts using Chi2 or Fisher's exact tests when appropriate 
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CHAPTER 5   ESTIMATES OF PREVALENCE 
AND INCIDENCE 
5.0 SUMMARY 
The prevalence and incidence of PMR and GCA and their complications 
are described using information from the Norfolk population using GCANS 
and EPIC-Norfolk datasets.  
The GCANS study was designed to provide community-based prevalence 
estimates. Part of the study surveyed the practice population to estimate 
the frequency of symptoms commonly associated with PMR and GCA to 
provide an indication of the number in the community with undiagnosed 
disease. All confirmed diagnoses of GCA fulfilled the 1990 American 
College of Rheumatology (ACR) classification criteria. Of confirmed PMR 
diagnoses, 67-89% fulfilled classification criteria, depending on the 
criteria used. In summary, the GPs’ diagnosis of PMR/GCA was sensitive 
although not all diagnoses fulfilled classification criteria. In addition a 
minority of patients had their diagnoses switched subsequently to an 
alternative diagnosis, suggesting that GP diagnoses for PMR and GCA 
may lack specificity (this is discussed further in the subsequent sub-
headings on GCANS 5.1.0). 
For EPIC-Norfolk, amongst the 25,639 participants, aged 40-79 years, 
recruited between the years 1993-1997 there were 404 diagnoses of PMR 
and 123 diagnoses of GCA to the end of the follow-up (31st March 2015). 
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After accounting for those individuals who died the cumulative prevalence 
estimates were calculated for those aged over 50 years old. Similar to 
GCANS, not all diagnoses met the current classification sets, with 61.7% 
of GCA cases meeting the 1990 ACR criteria for GCA and 70.4% of PMR 
cases meeting the current EULAR/ACR criteria (this is discussed further in 
the following sub-headings on EPIC-Norfolk 5.2.0). 
5.1.0 PREVALENCE OF PMR AND GCA IN NORFOLK – GCANS 
The prevalence of PMR and GCA was calculated from a single GP practice 
in Norfolk by the GCANS study (Giant cell arteritis in Norfolk study). The 
calculated prevalence was based on a minimum cumulative estimate for 
all diagnoses of PMR and GCA. This study used review of GP practice 
records supplemented by a postal survey (Figure 4.1 shows a flowchart 
for the sampling method). The cumulative prevalence took account of all 
registered individuals on the GP register irrespective of whether they 
returned the postal questionnaire. As a result the cumulative prevalence 
estimate will represent a minimum estimate and not be upwardly biased.  
5.1.1 Database search 
A total of 6,159 patients registered with the practice were aged 50 years 
and older, of whom 117 had a diagnosis of PMR and 22 had a diagnosis 
of GCA in their care record.  
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5.1.2 Survey 
A total of 5,159 patients registered with the practice were aged ≥55 
years with a median age of 62.5 years, of whom 2,706 (52.5%) were 
female. After applying exclusion criteria, the postal survey was sent to all 
eligible individuals aged 55 years or older. The exclusion criteria 
comprised those with terminal illness, dementia, nursing home residents 
or those individuals who had previously informed the practice they did 
not wish to take part in research.  
Questionnaires were sent to 4,728 eligible patients registered with the 
practice to discover any missed diagnoses of PMR and GCA not recorded 
in the GP register. Of the 2,277 (48% response rate) returned 
questionnaires, 97.2% had complete data. The median age of 
respondents was 70 years and 52% were female. The age and sex 
distribution of the non-responders was similar to that of the responders 
(Table 5. 1). 
5.1.3 Clinical review of questionnaire respondents 
A total of 15 individuals reported a diagnosis of GCA, nine of whom were 
confirmed by the practice record and fulfilled the 1990 ACR classification 
criteria. In all nine cases the diagnoses were confirmed following referral 
to secondary care specialists including rheumatologists, ophthalmologists, 
geriatricians and neurologists.  These subjects were not invited for 
further clinical review. 
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Among the remaining 2,268 respondents who did not have a GP-recorded 
diagnosis of PMR or GCA, 31 reported the triad of visual disturbance, 
scalp tenderness and symptoms suggestive of jaw claudication.  All these 
were contacted and following clinical review, none were thought to have 
GCA.  At least one symptom was reported in 1,007 respondents.  Of 
these, a sample of 93 were reviewed and 25 had reported symptoms 
suggestive of PMR without key features of GCA: namely, lack of 
headache, jaw claudication, visual disturbance or scalp tenderness. After 
clinical review none were thought to have undiagnosed PMR nor GCA.  All 
those invited attended for assessment.  Table 5.1 lists the clinical 
characteristics of the survey responders. 
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Table 5.1.  Characteristics of survey responders 
Characteristics Total 
Population 
Survey 
Pool 
Survey 
Responders 
PMR Self-
reported 
PMR Confirmed by 
GP 
 GCA Self-
reported 
GCA Confirmed by 
GP 
Number ≥55 years 5,159 4,728 2,277 83 73  15 9 
Median age, years  62.5 68.0 70.0 75.6 75.8  72.1 73.9 
Female (%) 52.2 53.6 52.0   70.0 67.4  78.6 71.5 
Clinical features reported on questionnaire            
Headache (%)     4.7 8.4 9.5  31.3 55.6 
Jaw Pain (%)     7.5 20.5 19.2  31.3 44.4 
Visual Disturbance (%)     19.8 22.9 24.7  37.5 44.4 
Scalp Tenderness (%)     7.8 15.7 6.2  56.3 88.9 
Shoulder Pain (%)     24.9 67.5 67.1  50 77.8 
Myalgia (%)     18.8 68.7 67.1  43.8 55.6 
Unexplained Weight loss 
(%)     4.2 12.1 11.0 
 
31.3 55.6 
Migraine with aura (%)     15.0 14.6 16.7  18.8 11.1 
No Symptoms (%)     55.8 20.5 21.9  18.8 0.0 
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Of the 83 who reported a diagnosis of PMR on the questionnaire, 73 
cases were confirmed to have the condition by the practice.  Practice 
records confirmed the diagnoses of the two respondents with both PMR 
and GCA.   
All participants reporting diagnoses of either GCA (n=6) or PMR (n=10) 
but without confirmation on the GP record were contacted by telephone.  
The discrepancy was found to be either due to participants misreading 
arteritis for arthritis on the questionnaire, or to the diagnoses being 
refuted by the GP later and withdrawn. 
5.1.4 Case classification 
Based on the information included in the GP record, of the 21 cases 
identified with GCA, a total of 13 fulfilled the 1990 ACR classification 
criteria set, with a median age of 70 years at diagnosis and a mean ESR 
of 74 mm/hr.  The remaining eight failed to fulfil classification criteria 
based on their inflammatory marker results and the absence of typical 
histological findings on temporal artery biopsy; of these, six had changed 
GP practice and had insufficient diagnostic information on their records.   
The five most commonly-used classification criteria sets for PMR used in 
the previous published estimates all rely on the combination of typical 
clinical features, age and elevated inflammatory markers but the cut-
points for these vary (Table 2.2).  
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Of the 117 cases identified in the GP records with PMR, 73 (71%) were 
female and a median age was 70 years. Inflammatory marker results, 
prior to steroid initiation, were available for 100 patients (96 with ESR; 
mean 45 mm/hr; 33 with CRP, mean 50 mg/dL; and 29 had both).  Of 
these 100 individuals, the proportion of those satisfying the different 
criteria sets are: 47% (Bird), 62% (Chuang), 62% (Healey), 62% 
(Doran), and 79% (Jones and Hazleman). The majority of PMR cases 
(71%) were managed exclusively in primary care with no further 
information available for more detailed classification. 
5.1.5 Prevalence estimates for PMR and GCA 
Of those cases which could be identified reliably through GP record 
review (namely those who had treatment with glucocorticoids and in 
whom the diagnosis was not later refuted), the minimum cumulative 
prevalence estimate for GP-diagnosed cases of GCA was 0.41% (95% CI 
0.23%, 0.58%) and for PMR was 2.27% (95% CI 1.86%, 2.67%) Table 
5.2 shows age and sex specific cumulative prevalence for both conditions. 
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Table 5.2  Cumulative prevalence estimate by sex and age bands based on GP records 
Age, 
years 
N Female Male PMR Female Male  GCA Female Male 
    N Pr (95%CI) N Pr (95%CI) N Pr  (95%CI)  N Pr (95%CI) N Pr (95%CI) N Pr (95%CI) 
55-59 978 500 478 1 0.10 (0.00, 
0.30) 
1  0.20 (0.00, 
0.59) 
0   1  0.10 (0.00, 
0.30) 
0  1  0.21 (0.00, 
0.62) 
60-69 1902 989 913 20  1.05 (0.59, 
1.51) 
15  1.52 (0.76, 
2.28) 
5  0.55 (0.07, 
1.03) 
 3  0.16 (0.00, 
0.34) 
3  0.30 (0.00, 
0.65) 
0 
70-79 1412 700 712 49  3.47 (2.52, 
4.43) 
33  4.71 (3.14, 
6.28) 
16  2.25 (1.16, 
3.33) 
 6  0.43 (0.09, 
0.76) 
4 0.57 (0.01, 
1.13) 
2  0.28 (0.00, 
0.67) 
80-89 695 395 300 40  5.76 (4.02, 
7.49) 
20  5.06 (2.90, 
7.22) 
20  6.67 (3.84, 
9.49) 
 9  1.30 (0.45, 
2.14) 
5 1.27 (0.16, 
2.37) 
4  1.33 (0.04, 
2.63) 
90-100 166 116 50 7  4.22 (1.16, 
7.27) 
5 4.31 (0.62, 
8.01) 
2  4.00 (0.00, 
9.43) 
 2 1.72 (0.00, 
4.09) 
2 1.72 (0.00, 
4.09) 
0 
100+ 6 6 0 0 N/A N/A  0 N/A N/A 
           
Total 5159 2706 2453 117  2.27 (1.86, 
2.67) 
74  2.74 (2.12, 
3.35) 
43  1.75 (1.23, 
2.27) 
 21  0.41% (0.23, 
0.58) 
14 0.52 (0.25, 
0.79) 
7 0.29 (0.07, 
0.50) 
 
*N: total number of people registered with the practice. Pr (95% CI): cumulative prevalence with 95% confidence interval based 
on the Poisson distribution 
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For those to whom it was possible to apply the 1990 ACR classification 
criteria retrospectively, cumulative prevalence of GCA was 0.25% (95% 
CI 0.11 to 0.39).  Applying the various classification criteria 
retrospectively to GP-diagnosed cases of PMR (Table 5.3) gave the 
following cumulative prevalence estimates: Bird criteria 0.91% (95% CI 
0.65 to 1.17); Chuang, Healey and Doran criteria 1.20% (95% CI 0.90 to 
1.50); and Jones and Hazleman criteria 1.53% (95% CI 1.20 to 1.87). 
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Table 5.3  Cumulative prevalence estimates for cases which satisfy classification criteria applied to GP 
record data. 
Criteria set All  Female  Male  
 N Pr (95%CI) N Pr (95%CI) N Pr  (95%CI) 
       
GCA (21 cases reported in GP records)       
Hunder 13 0.25 (0.11, 0.39) 9 0.33 (0.12, 0.55) 4 0.16 (0.00, 0.32) 
       
PMR (117 cases reported in GP records)      
Bird 47 0.91 (0.65, 1.17) 28 1.04 (0.65, 1.42) 19 0.78 (0.43, 1.12) 
Healey; Chuang;  Doran 62 1.20 (0.90, 1.50) 39 1.44 (0.99, 1.89) 23 0.94 (0.56, 1.32) 
Jones and Hazleman 79 1.53 (1.20, 1.87) 49 1.81 (1.31, 2.31) 30 1.22 (0.79, 1.66) 
 
N: total number of people identified in the practice. Pr (95% CI): cumulative prevalence with 95% confidence interval calculated using the 
Poisson distribution based on a total population of 5,159 (2,706 female, 2,453 male). Inflammatory markers were available in 100 out of 117 
GP record cases (of which 96 had ESR and 33 CRP with overlap of 29 cases with both CRP and ESR results at time of diagnosis).  
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5.1.6 Comments 
These are the first community-based estimates for the prevalence of PMR 
and GCA in the UK for over 30 years and from these data, it appears 
unlikely that there are cases of PMR and GCA in the community unknown 
to their General Practitioner.  
There is no validated questionnaire for the purposes of classification or 
diagnosis of PMR or GCA. An instrument was required that was sensitive 
to the entire range of symptoms which can be associated with either PMR 
or GCA. Every effort was made to enrich the available clinical data using 
direct record, questionnaire sampling and clinical review. Of the 5,159 
potential participants selected based on age, after applying exclusion 
criteria 4,728 were contacted via the postal survey, a 48% response rate 
was received. It is encouraging that 55.8% of responders returned the 
questionnaire had no symptoms, perhaps indicating that the majority 
with symptoms returned the questionnaire. 
Around half of the cases diagnosed with PMR or GCA fulfil appropriate 
classification sets, which may be a problematic when comparing 
community-based and hospital-based cohorts due to selection bias. 
5.2.0 EPIC-NORFOLK 
The GCANS study discussed above indicated the need for more detailed 
verification of cases. The next phase required verification of the cases 
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having occurred within the EPIC-Norfolk cohort.  Electronic and paper 
records were reviewed to extract clinical information to confirm diagnoses 
of PMR and GCA and to allow retrospective application of the classification 
criteria sets for the two diseases.  
Having arranged the necessary collaboration agreements with EPIC-
Norfolk potential cases of PMR and GCA within the cohort were identified. 
5.2.1 Baseline characteristics of the EPIC-Norfolk 
cohort 
The baseline characteristics of the EPIC-Norfolk cohort are shown in Table 
5.4 and Table 5.5 shows the clinical features of the cases. The cases of 
PMR and GCA are first defined as those over the age of 50 as set-out 
above in section 4.3.3 and 4.3.4. Subsequently the cases were defined by 
those meeting the current classification criteria sets for PMR and GCA 
respectively. 
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Table 5.4  Baseline characteristics of the EPIC-Norfolk cohort 
Characteristics (Cases - age over 50) PMR50 (n = 395) GCA50 (n = 118) Control (n = 25,147) 
Age at baseline* 64.5 64.6 58.9 
Female, n (%) 294 (74.4) 88 (74.6) 13,670 (54.4) 
Never smoker, n (%) 197 (49.9) 47 (39.8) 11,443 (45.5) 
High Blood pressure†, n (%) 78 (19.8) 23 (19.5) 3,570 (14.2) 
Systolic BP (mm/Hg) (SD) 140 (20) 135 (16) 135 (18) 
Diastolic BP (mm/Hg) (SD) 84 (12) 82 (11) 83 (11) 
Diabetes†, n (%) 7 (1.8) 2 (1.7) 581 (2.3) 
BMI (kg/m2) (SD) 26.7 (3.9) 26.0 (3.7) 26.4 (3.9) 
Triglycerides (mmol/L)* 1.6 1.6 1.5 
HDL (mmol/L) (SD) 1.49 (0.42) 1.47 (0.42) 1.42 (0.43) 
LDL (mmol/L) (SD) 4.30 (1.16) 4.21 (1.09) 3.96 (1.03) 
Alcohol (units/week)* 2.5 2.5 3.5 
N-6 Polyunsaturated fatty acids (g)* 9.9 9.1 9.9 
N-3 Polyunsaturated fatty acids (g) 1.6 1.6 1.6 
Loss of adult teeth, n (%) 360 (91.1) 109 (92.4) 21,347 (84.9) 
Parity four or more children, n (%) 41 (14.0) 13 (14.8) 1,391 (10.2) 
Characteristic (Cases - meeting 
classification sets) 
PMR (n = 272) GCA (n = 76) Control (n = 25,312) 
Age at baseline* 64.6 64.6 60 
Female, n (%) 204 (75.0) 57 (75.0) 13,791 (54.5) 
Never smoker, n (%) 139 (51.7) 30 (41.1) 11,518 (45.9) 
High Blood pressure†, n (%) 52 (19.2) 19 (25.0) 3,600 (14.3) 
Systolic BP (mm/Hg) (SD) 140 (20) 136 (17) 135 (18) 
Diastolic BP (mm/Hg) (SD) 84 (12) 82 (11) 83 (11) 
Diabetes†, n (%) 5 (1.8%) 2 (2.6%) 583 (2.3%) 
BMI (kg/m2) (SD) 26.3 (3.6) 25.7 (3.5) 26.4 (3.9) 
Triglycerides (mmol/L)* 1.6 1.6 1.5 
HDL (mmol/L) (SD) 1.48 (0.40) 1.47 (0.38) 1.42 (0.43) 
LDL (mmol/L) (SD) 4.30 (1.13) 4.23 (0.96) 3.96 (1.04) 
Alcohol (units/week)* 2.5 3 3.5 
N-6 Polyunsaturated fatty acids (g)* 9.7 8.8 9.9 
N-3 Polyunsaturated fatty acids (g) 1.5 1.5 1.5 
Loss of adult teeth, n (%) 251 (93.7) 70 (93.3) 21,495 (88.0) 
Parity four or more children, n (%) 29 (14.2) 7 (12.3) 1,409 (10.2) 
*medians, otherwise arithmetic means and standard deviations are presented 
(SD), †Self-reported at baseline questionnaire. 
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Table 5.5  Clinical features of PMR and GCA cases 
Clinical Features PMR50 PMR EULAR/ACR GCA50 GCA ACR 
Age at Diagnosis* 73.6 (8.6) 73.5 (8.6) 74.1 (8.5) 74.9 (8.5) 
Female, n (%) 294 (74.4) 204 (75.0) 88 (74.6) 57 (75.0) 
Diagnosed exclusively by GP, n (%) 254 (65.0) 182 (67.4) 14 (12.1) 4 (5.4) 
ESR at Diagnosis (mm/hr) 56 (30) 57 (29) 73 (34) 89 (24) 
CRP at Diagnosis* (mg/L) 30 28 52 79 
*medians, otherwise arithmetic means and standard deviations are presented (SD) 
5.2.2 Prevalence of PMR and GCA from EPIC-Norfolk 
Prevalence estimates for PMR and GCA were calculated for the EPIC-
Norfolk participants. This included all cases which developed over the 
observation period and therefore is a point prevalence estimate. 
The cohort was monitored until the 31st March 2015.  During this time, 21 
individuals had not reached the age of 50. To account for deaths, those 
who had died were also excluded from the analysis for the purposes of 
generating cumulative point prevalence estimates.  
PMR 
There were 404 incident diagnoses of PMR and restricting to those older 
than 50 years resulted in 395 cases. Due to deaths in the cohort, 295 
cases who had a diagnosis of PMR were still alive at the end of the study 
period. This resulted in a point prevalence of 1.62% (95% CI 1.44%, 
1.80%) on the 31st March 2015. Restricting to cases which fulfilled the 
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EULAR/ACR criteria set resulted in 207 cases of PMR with a corresponding 
prevalence estimate for PMR of 1.14% (95% CI 0.98%, 1.29%). 
GCA 
There were 123 patients with a diagnosis of GCA of whom 118 were aged 
over 50 years at time of diagnosis. Due to the deaths in the cohort, 85 
cases with a diagnosis of GCA and were still alive at the end of the study 
period. This resulted in a point prevalence estimate for GCA of 0.47% 
(95% CI 0.37%, 0.57%) on the 31st March 2015. Restricting to cases 
which fulfilled the ACR criteria set resulted in 76 cases of GCA with a 
corresponding prevalence estimate of 0.29% (95% CI 0.21%, 0.36%). 
5.2.3 Incidence of PMR and GCA from EPIC-Norfolk 
Incidence for PMR and GCA were calculated for the EPIC-Norfolk 
participants. During the follow-up period to 31st March 2015 of the cohort 
of 25,660 recruited at baseline, there were 398 incident cases of PMR and 
123 cases of GCA diagnosed.  There were 24 participants who had 
missing date-of-entry at the baseline time point. Excluding cases 
diagnosed under the age of 50 years resulted in 395 cases of PMR and 
118 cases of GCA. 
The cohort of 25,636 participants had a total follow-up time of 440,236.9 
person years (pyrs) at risk. This was used as the denominator for the 
purposes of calculating incidence density. 
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PMR 
The incidence of PMR for those aged 50 or older was 89.7 (95% CI 81.3, 
99.0) per 100,000 pyrs. Restricting the analysis to those 272 cases of 
PMR fulfilling the EULAR/ACR classification criteria set resulted in an 
incidence rate of 61.8 (95% CI 54.9, 69.6) per 100,000 pyrs at risk. 
GCA 
The incidence of GCA for those aged 50 or older was 26.8 (95% CI 22.4, 
32.1) per 100,000 pyrs. Restricting the analysis to those 76 cases of GCA 
fulfilling the ACR classification criteria set resulted in an incidence rate of 
17.3 (95% CI 13.8, 21.6) per 100,000 pyrs at risk. 
5.2.4 Comments 
This large, extensively phenotyped cohort has been used to calculate 
incidence rates for PMR and GCA which apply current classification 
criteria. The EPIC-Norfolk cohort is representative of the wider 
community in Norfolk but being largely Caucasian, the wider 
generalisability of the findings to other parts of the UK and world is 
limited. It is encouraging that the median age of diagnosis and sex 
distribution is in line with previously published data. The estimated 
incidence rates are similar to other UK-based estimates, which in turn are 
comparable with estimates of disease incidence from the United States 
and Northern European countries and in turn the prevalence estimate 
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from the USA (see Tables 2.3 and 2.4). The wider significance of these 
findings is discussed in Section 5.4. 
5.3.0 ESTIMATES OF OCULAR MORBIDITY 
The EPIC-Norfolk and DCVAS studies are ideally suited to measuring 
ocular morbidity due to comprehensive visual assessment, and allowing 
for accurate contemporary estimates of ocular morbidity to be produced 
for the first time. Details of the assessments is described earlier in 
Sections 4.4.4 and 4.5.1. 
5.3.1 EPIC-Eye Study 
A total of 8,623 participants aged 48-92 years attending the Eye Study 
(nested within EPIC-Norfolk) underwent assessment of visual acuity, 
measured using a logarithm of the minimum angle of resolution chart 
(LogMAR chart), which replaces the older Snelling Chart for measuring 
visual acuity. A LogMAR value of 0.0 corresponds with a Snellen 
equivalent of 6/6. The World Health Organisation (WHO) used LogMAR 
values to standardised definitions for visual impairment, low vision and 
blindness with the higher the LogMar value the worse the vision (see 
Section 4.5.1).  
5.3.2 Visual acuity thresholds in EPIC-Eye 
Data on visual acuity were available for 8,052 participants, comprising 
4,464 women (55.4%) of the cohort. The mean age at the third health 
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check was 68.8 years (SD 8.1). See Table 5.6 for visual acuity thresholds 
by those with and without GCA and or PMR. 
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Table 5.6  Visual acuity thresholds in EPIC-Eye 
Visual 
thresholds 
PMR (n = 132) GCA (n = 42) Controls (n = 7,938) 
Eyes Participants Eyes Participants Eyes Participants 
Visual 
impairment 
Left 7 
(5.7%) 
Right 12 
(9.8%) 
2 (1.6%) Left 6 
(14.3%) 
Right 2 
(4.8%) 
0 Left 284 (3.6%) 
Right 272 (3.4%) 
46 (0.6%) 
Low vision Left 5 
(4.1%) 
Right 9 
(7.3%) 
1 (0.8%) Left 6 
(14.3%) 
Right 2 
(4.8%) 
0  Left 252 (3.2%) 
Right 236 (3.0%) 
40 (0.5%) 
Blindness Left 2 
(1.6%) 
Right 3 
(2.4%) 
1 (0.8%) Left 0 Right 
0 
0 Left 25 (0.3%) 
Right 27 (0.3%) 
2 (0.03%) 
The above counts include all those with a diagnosis of GCA or PMR irrespective of their health check three date. Number of eyes affected are reported and 
secondly, number of participants in line with WHO definitions for visual impairment, low vision and blindness. WHO definitions refer to vision in the better eye to 
define level of visual impairment – it is therefore possible to be blind in one eye and yet considered to have no visual impairment (See Section 4.5.1 for details).  
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Sensitivity analysis – visual acuity 
The resultant age- and sex-adjusted odds ratios (ORs) for the different 
grades of visual impairment affecting either eye were as followings: 
visual impairment: GCA OR = 4.10 (95% CI 1.44, 11.72 p = 0.008) and 
PMR OR = 1.43 (95% CI 0.74, 2.76 p = 0.290); low vision, GCA OR = 
4.75 (95% CI 1.67, 13.54 p = 0.004) and PMR OR = 1.17 (95% CI 0.55, 
2.48 p = 0.681); and blindness; no cases in the GCA group, PMR OR = 
3.85 (95% CI 1.14, 13.04 p = 0.03). This analysis included all 
participants irrespective of the timing of their diagnosis of PMR or GCA. 
Therefore, some participants had undergone their visual assessment prior 
to their diagnosis of PMR or GCA and will result in a downward bias in the 
estimate for visual impairment. 
Of the cases occurring before their third health check, ten met the 1990 
ACR criteria for GCA and 59 met the EULAR/ACR criteria for PMR. If only 
those cases meeting the classification sets are used to define GCA and 
PMR, the resultant odds ratios are as follows: visual impairment, GCA OR 
= 5.21 (95% CI 1.31, 20.77 p = 0.019) and PMR OR = 1.48 (95% CI 
0.69, 3.18 p = 0.312); low vision; GCA OR = 6.03 (95% CI 1.52, 23.91 p 
= 0.011) and PMR OR = 1.26 (95% CI 0.53, 2.98 p = 0.600); and 
blindness, no cases in the GCA group, PMR OR = 3.38 (95% CI 0.78, 
14.67 p = 0.105). 
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The results reveal that participants with GCA had worse vision than 
controls, and that participants’ vision does not seem to be affected by a 
diagnosis of PMR.  
5.3.3 DCVAS ocular morbidity 
DCVAS uses the vasculitis damage index (VDI) to record damage 
associated with a diagnosis of vasculitis. This item was completed 
retrospectively at the six month time point, following the diagnosis of 
vasculitis.  
5.3.4 Cases of GCA and blindness in DCVAS 
Of the 715 patients recruited into DCVAS by December 30th 2014 with 
complete data: 433 were considered to have GCA with ≥75% diagnostic 
certainty at six months; 404 fulfilled the 1990 ACR criteria for GCA; and 
235 had a positive temporal artery biopsy. The patients were mainly 
(95.6%) Caucasians from Europe or North America (baseline 
characteristics - Table 5.7). Six months after diagnosis, 34 (7.9%) 
patients had at least monocular blindness, of whom 3 (0.7%) had 
binocular blindness (with no statistical significant difference in the rate of 
blindness between men and women). 
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Table 5.7  Clinical Features at baseline of patients with giant cell 
arteritis in the DCVAS study 
Clinical Features Physician Diagnosis of GCA at 6 months (>75% 
certainty) n=433 
  Blind at six months 
(n=34) 
Not blind at six 
months (n=399) 
p-value* 
Age at diagnosis 
(median, years) 
74.9 73.0 0.073 
Male (%) 12 (35.3) 133 (33.3) 0.816 
New-onset headache 23 (67.7) 282 (70.7) 0.710 
Any visual symptom 
(%) 
32 (94.1) 154 (38.6) 0.000 
Jaw claudication (%) 13 (38.2) 163 (40.9) 0.766 
Tongue claudication 
(%) 
3 (8.8) 16 (4.0) 0.188 
Morning stiffness 
shoulders arms (%) 
7 (20.6) 87 (21.8) 0.869 
Morning stiffness 
hips/thighs (%) 
5 (14.7) 69 (17.3) 0.700 
Myalgia (%) 5 (14.7) 109 (27.3) 0.109 
Fever (%) 3 (8.8) 68 (17.0) 0.214 
Fatigue (%) 13 (38.2) 164 (41.1) 0.744 
Weight loss (%) 12 (35.3) 138 (34.6) 0.934 
*p-value of difference between those who were subsequently declared blind in at least 
one eye versus those who were not; all calculated using the chi squared test except for 
median age at diagnosis, ESR and CRP which was tested by the Mann-Whitney test. 
 
Of the patients who had blindness recorded at six months, 31 (22 women 
and 12 men) had presented with symptoms of sudden visual loss, with 
only two patients with no visual disturbance (including amaurosis fugax, 
visual loss, blurred vision or diplopia) at baseline being declared blind at 
six months. The visual manifestations of disease for all patients with GCA 
at presentation included: blurred vision in 98 (22.6%), sudden visual loss 
in 70 (16.2%), diplopia in 51 (11.8%), amaurosis fugax in 33 (7.6%), 
and red eyes in nine (2.1%). As expected, blindness at six months 
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occurred more frequently in those who presented with visual symptoms. 
Of those with sudden visual loss at presentation, 44.3% (31/70) were 
blind at six months as assessed using the VDI; of those with no recorded 
visual loss at presentation, 0.8% (3/363) were recorded as being blind at 
the six month review. 
5.3.5 Comments 
While the EPIC-Norfolk eye study sample of 8,623 participants is 
relatively small, it is strengthened by the detailed visual acuity 
assessment. To date, studies of sight-loss in GCA have been mainly of 
case-series design with lack of ability to estimate relative risks. In 
addition the author is unaware of any study which documents visual 
performance in individuals diagnosed with PMR. 
Although there was no formal ophthalmologic assessment of all 
participants, the strength of the DCVAS is its size and multi-site and 
multi-national setting, allowing for a robust and generalisable estimate of 
the occurrence of blindness in participants with GCA. Although blindness 
is a serious consequence of GCA and other individuals may have had loss 
of visual field or reduced visual acuity, this was not captured routinely as 
part of the study protocol and it is not possible to comment on the 
burden of less severe forms of sight loss.  
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5.4.0 CONCLUSIONS OF ESTIMATES OF PREVALENCE AND 
INCIDENCE 
The datasets of GCANS, EPIC-Norfolk and DCVAS have provided new up-
to-date incidence and prevalence estimates for PMR and GCA and 
absolute and relative risk for visual impairment amongst participants with 
GCA. 
5.4.1 Prevalence of PMR and GCA in Norfolk 
The GCANS study was not able to provide a prevalence estimate for PMR 
using the current EULAR/ACR criteria. However since the EULAR/ACR 
criteria require elevated inflammatory markers without stating a specific 
cut-point they are most similar to the criteria of Jones and Hazleman 
which require an ESR >30 mm/hr or CRP >6 mg/L. For GCANS the 
prevalence estimate for PMR fulfilling the Jones and Hazleman criteria 
was 1.53% (95% CI 1.20 to 1.87). For EPIC-Norfolk the prevalence 
estimate for cases fulfilling the EULAR/ACR criteria was 1.14% (95% CI 
0.98%, 1.29%), lower than the last estimate of prevalence published by 
Kyle et al but comparable to the estimates published from the Mayo clinic 
(See Table 2.3). 
The Norfolk-based datasets of GCANS and EPIC-Norfolk reveal a 
prevalence estimate for GCA fulfilling the 1990 ACR classification set of 
0.25% (95% CI 0.11 to 0.39) and 0.29% (95% CI 0.21 to 0.36) 
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respectively. Similarly, in PMR the estimates are lower than the last UK 
study but in line with those published from the USA (See Table 2.3). 
Current estimates of disease prevalence are important for public health 
planning. It is likely that the prevalence estimates for those studies, 
which have not defined disease by current classification criteria would be 
lower if they had. The estimates produced from the current work are 
comparable with estimates that have used similar methods and are from 
populations of Northern European heritage.  
5.4.2 Incidence of PMR and GCA in Norfolk 
Due to relatively small sample size GCANS was unable to provide an 
estimate for incidence rates. For EPIC-Norfolk the incidence rate per 
100,000 for those cases fulfilling their current classification sets for PMR 
and GCA was 40.1 (95% CI 35.6, 45.2) and 11.2 (95% CI 9.0, 14.0) 
respectively. Again these figures are lower than for the UK CPRD study 
but in keeping with the estimates from the USA (See Table 2.4). 
The estimates from EPIC-Norfolk have advantages in terms of being 
community-based and disease definitions using current classification 
criteria. They provide a greater certainty to the true rate of disease than 
the previously published estimates.  
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5.4.3 Prevalence of visual impairment in PMR and GCA 
From the EPIC-Norfolk eye study, PMR does not appear to be associated 
with visual impairment compared to controls. There were eight (19.1%) 
individuals who had at one eye affected by visual impairment but no 
individual suffered from blindness. From the EPIC-Norfolk eye study the 
odds of visual impairment and low vision associated with GCA were OR = 
4.10 (95% CI 1.44, 11.72 p = 0.008) and OR = 4.75 (95% CI 1.67, 
13.54 p = 0.004) respectively. This was despite only comprising 42 
cases, not separated by incident or prevalent disease. Restricting the 
estimate to only the 10 cases diagnosed with GCA prior to their eye 
assessment resulted in odds ratios for visual impairment and low vision 
of OR = 5.21 (95% CI 1.31, 20.77 p = 0.019) and OR = 6.03 (95% CI 
1.52, 23.91 p = 0.011) respectively. 
For the multi-national DCVAS, the rate of blindness in at least one eye 
was 7.9% amongst those participants with a diagnosis of GCA. 
The previously published estimates for ocular morbidity are limited due to 
problems of case selection, variations in definition and standardisation for 
visual loss making interpretation difficult. The current estimates have 
many advantages in applying appropriate and standardised definitions to 
adequately defined cases of disease. In addition, despite the relatively 
small numbers, odds ratios of visual morbidity associated with diagnosis 
of PMR and GCA have been produced relative to appropriately matched 
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controls. These figures should prove useful for health care providers and 
planners.  
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CHAPTER 6   RISK FACTORS FOR ONSET  
6.0 SUMMARY 
This chapter documents risk factors associated with PMR and GCA disease 
onset. Of the three datasets, the data within EPIC-Norfolk is the most 
appropriate source to answer these questions due to the prospective 
study design and ability to adjust for confounders. The methods used for 
analysis comprise, crude and adjusted rate ratios from the incidence 
density, with subsequent logistic, then Cox regression.  
Risk factors are assessed against those cases diagnosed in the cohort and 
subsequently, those fulfilling the current classification criteria sets. 
6.1.0 EPIC-NORFOLK: RISK FACTORS ASSOCIATED WITH PMR AND 
GCA 
The published aetiological factors for PMR and GCA have, in the main, 
been from studies using case-control design. Chapter 2.5.1 details the 
putative risk factors published to date, approaching these risk factors 
firstly by calculating incidence and rate ratios for age strata and for sex, 
with other risk factors recorded as part of the baseline health check. 
Logistic regression is used to assess the associations between baseline 
risk factors and incident diagnoses of PMR and or GCA.  
Between 25th February 1993 to 13th May 1998, 25,660 healthy volunteers 
were recruited from 35 GP practice sites across Norfolk. The participants 
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were aged between 39 and 79 years with 14,052 women (54.8% of the 
cohort).  
6.1.1 PMR diagnosis and association with age and sex 
Cases of PMR were defined firstly as those over the age of 50 years at 
time of diagnosis and, secondly, those cases which met the current 
EULAR/ACR classification set. The analysis for cases of PMR and GCA was 
carried out separately, with those cases diagnosed with GCA converted to 
missing data so as not to contribute data as controls. PMR diagnosis was 
associated with age and female sex.  
There were 395 cases of PMR diagnosed amongst a total baseline cohort 
of 25,542 participants at recruitment. Cases diagnosed with PMR who did 
not meeting the inclusion criteria were considered not be cases and 
contributed to the control pool, rather than being converted to missing 
data. Of these, 272 cases met the EULAR/ACR classification set amongst 
a total of 25,586 participants at baseline.  
The odds ratio for each increase in age category (age in five year 
increments) was 1.06 (95%CI 1.05, 1.07 p=<0.0001). The crude rate 
ratio derived by the Mantel-Haenszel method for female sex was 2.29 
(95% CI 1.83, 2.87 p=<0.0001). The Hazard Ratio (HR) derived using 
Cox regression was similar with a HR for the effect of females compared 
to males and PMR diagnosis of 2.29 (95% CI 1.83, 2.87, p=<0.0001). 
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Lexis expansion was used to analyse incidence rates for PMR cases across 
age bands and to compare rate ratios between men and women. 
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Table 6.1  Lexis expansion analysis for age at PMR diagnosis 
Age band (years) PMR cases (D) (n=395) Person years follow-up 
(100,000 pyrs) 
Rate per 100,000 pyrs 95% CI of rate 
55-59  1 0.57 1.77 0.25, 12.54 
60-64 5 0.71 7.04 2.93, 16.91 
65-69 14 0.77 18.25 10.81, 30.82 
70-74 41 0.70 58.80 43.30, 79.86 
75-79 76 0.58 131.43 104.97, 164.56 
80-89 186 0.50 370.74 321.12, 428.04 
90+ 72 0.03 2129.22 1690.07, 2682.47 
Age band (years) PMR cases fulfilling 
EULAR/ACR criteria set (D) 
(n=272) 
Person years follow-up 
(100,000 pyrs) 
Rate per 100,000 pyrs 95% CI of rate 
55-59  1 0.57 1.77 0.25,12.54  
60-64 3 0.71 4.22 1.36,13.10 
65-69 7 0.77 9.13 4.35, 19.15 
70-75 32 0.70 45.90 32.46, 64.90 
75-79 47 0.58 81.23 61.07, 108.18 
80-89 131 0.50 261.11 220.02, 309.89 
90+ 51 0.03 1508.20 1146.21, 1984.50 
The incidence density of PMR for those aged 50 years or older was 89.7 (95% CI 81.3, 99.0) per 100,000 pyrs. Restricting the analysis to those 272 cases of PMR 
which fulfil the EULAR/ACR classification criteria set resulted in an incidence rate of 61.8 (95% CI 54.9, 69.6) per 100,000 pyrs at risk. 
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The effect of age on sex was analysed across age bands. 
Table 6.2 comparing females to males by age band for PMR 
Age band (years) PMR Rate ratio 95% CI 
55-59 Reference N/A 
60-64 3.12 0.35, 27.92 
65-69 1.45 0.49, 4.33 
70-74 3.40 1.57, 7.36 
75-79 2.44 1.45, 4.11 
80-89 2.03 1.46, 2.82 
90+ 1.34 0.80, 2.25 
Overall effect of female sex 
controlling for age band 
2.04 1.63, 2.56* 
Age band (years) PMR 
EULAR/ACR criteria 
Rate ratio 95% CI 
55-59  Reference N/A 
60-64 1.56 0.14, 17.21 
65-69 2.01 0.39, 10.38 
70-74 2.47 1.11, 5.51 
75-79 2.13 1.12, 4.04 
80-89 2.28 1.52, 3.41 
90+ 1.51 0.80, 2.84 
Overall effect of female sex 
controlling for age band 
2.10 1.60, 2.77* 
*chi2 p=<0.0001  
The age-adjusted effect (RR=2.04, 95%CI 1.63, 2.56) of female sex on 
diagnosis of PMR is the average effect across all subjects with no 
evidence (p=0.93) that the effect of female sex varies across the age 
band strata. An assumption of constant hazards is therefore justified and 
Cox regression appropriate although the effect is likely to be confounded 
by age since the crude rate ratio was 2.27. 
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6.1.2 GCA diagnosis and association with age and sex 
Similar to the analysis of PMR cases, GCA cases were analysed separately 
from PMR. 
There were 118 cases of GCA diagnosed over 50 years of age amongst a 
total baseline cohort of 25,265 participants at recruitment. Cases 
diagnosed with GCA not meeting the inclusion criteria were considered 
not be cases and contributed to the control pool rather than being 
converted to missing data. Of these 76 cases fulfilled the classification set 
amongst a total of 25,388 participants at baseline. 
GCA diagnosis was associated with age and female sex. The odds ratio 
for each increase in age category (age in five year increments) was 1.05 
(95%CI 1.03, 1.07 p=<0.0001). The crude rate ratio for female sex was 
2.28 (95% CI 1.51, 3.45 p=0.0001) for all GCA cases over 50 years at 
diagnosis and 2.33 (95% CI 1.40, 3.92 p=0.001) for those fulfilling the 
ACR classification set. 
Lexis expansion was used to analyse rate ratios for GCA cases across age 
bands. 
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Table 6.3  Lexis expansion analysis for age at GCA diagnosis 
Age band (years) GCA cases (D) (n=118) Person years follow-up 
(100,000 pyrs) 
Rate per 100,000 pyrs 95% CI of rate 
55-59 1 0.57 1.77 0.25, 12.54 
60-64 1 0.71 1.41 0.20, 10.00 
65-69 10 0.77 13.04 7.02, 24.23 
70-74 10 0.70 14.34 7.72, 26.66 
75-79 17 0.58 29.40 18.28, 47.29 
80-89 64 0.50 127.57 99.85, 162.98 
90+ 15 0.03 443.59 267.42, 735.80 
Age band (years) GCA cases fulfilling ACR 
criteria set (D) (n=76) 
Person years follow-up 
(100,000 pyrs) 
Rate per 100,000 pyrs 95% CI of rate 
55-59  1 0.57 1.77 0.25,12.54  
60-64 0 0.71 0.00 n/a 
65-69 8 0.77 10.43 5.22, 20.86 
70-74 5 0.70 7.17 2.99, 17.23 
75-79 12 0.58 20.75 11.79, 36.54 
80-89 40 0.50 79.73 58.48, 110 
90+ 10 0.03 295.73 159.12, 549.62 
The incidence density of GCA for those aged 50 or older was 26.8 (95% CI 22.4, 32.1) per 100,000 pyrs. Restricting the analysis to those 76 cases of GCA which 
fulfil the ACR classification criteria set resulted in an incidence rate of 17.3 (95% CI 13.8, 21.6) per 100,000 pyrs at risk. 
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Assessing the effect of age on sex for a diagnosis of GCA, Table 6.4 
compares rate ratios between females and males by age band. 
Table 6.4  comparing females to males by age band for GCA 
Age band (years) GCA Rate ratio 95% CI 
55-59  Reference N/A 
60-64 n/a n/a 
65-69 1.88 0.49, 7.27 
70-74 7.42 0.94, 58.57 
75-79 2.65 0.86, 8.12 
80-89 1.81 1.16, 5.12 
90+ 1.42 0.45, 4.46 
Overall effect of female sex 
controlling for age band 
2.10 1.38, 3.15* 
Age band (years) ACR GCA Rate ratio 95% CI 
55-59 Reference N/A 
60-64 n/a n/a 
65-69 2.42 0.49, 11.98 
70-74 n/a n/a 
75-79 1.63 0.49, 5.41 
80-89 2.44 1.16, 5.12 
90+ 0.78 0.22, 2.75 
Overall effect of female sex 
controlling for age band 
2.13 1.27, 3.55** 
*chi2 p=0.0003 **Chi2 p=0.003 
The age-adjusted effect (RR=2.10, 95%CI 1.38, 3.15) of female sex on 
diagnosis of GCA is the average effect across all subjects with no 
evidence (p=0.77) that the effect of female sex varies across the age 
band strata. However the effect is likely to be confounded by age since 
the crude rate ratio was 2.28. 
6.1.3 PMR and GCA diagnoses and smoking status 
The analysis of age and sex shows an effect for both of these and a 
diagnosis of PMR or GCA. In the logistic regression model both these 
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factors would need to be adjusted for in any estimates produced. The 
previous published studies find a positive association between PMR or 
GCA and smoking. 
From the baseline data (see Table 5.5) 2,987 (11.7%) were current 
smokers, 10,766 (42.3%) former smokers and 11,687 (45.9%) never 
smokers. Data for smoking status was missing for 81 males and 139 
females (0.86% of the cohort). Participants with GCA were more likely to 
have missing data for smoking: GCA cases over the age of 50 years  
2.5% vs 0.86% overall and GCA cases meeting classification criteria set 
4% vs 0.86%.  
Due to the possibility that some current smokers may stop smoking a 
combined ever-smoker variable was created. Although it is possible that 
participants began smoking, the author believes this unlikely particularly 
given the age of the participants at baseline. 
6.1.4 Smoking and its association with diagnosis of 
PMR 
After adjusting for age at entry to the cohort and sex, ever-smoking was 
not associated with a diagnosis of PMR. For the PMR cases over the age 
of 50 years at diagnosis the OR = 0.95 (95% CI 0.77, 1.17, p=0.633) 
and for those PMR cases fulfilling the EULAR/ACR criteria OR = 1.16 
(95% CI 0.89, 1.50 p=0.269). 
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6.1.5 Smoking and its association with a diagnosis of 
GCA 
After adjusting for age at entry to the cohort and sex, ever-smoking was 
positively associated with a diagnosis of GCA. For the GCA cases over the 
age of 50 years at diagnosis the OR = 1.44 (95% CI 0.98, 2.11, 
p=0.060) and for those GCA cases fulfilling the 1990 ACR criteria OR = 
1.44 (95% CI 0.89, 2.32 p=0.138). Re-coding as ever-smokers all those 
with missing data for smoking status resulted in OR of 1.47 (1.01, 2.15) 
p=0.045 and 1.50 (0.94, 2.41) p=0.091. 
6.1.6 PMR and GCA diagnoses and vascular risk factors 
and modulators of endothelial dysregulation 
Chapter 2.5.1 lists the aetiological factors published to date. The analysis 
of age at diagnosis and sex confirmed these as important factors 
associated with diagnoses of PMR and GCA, therefore any subsequent 
model is adjusted for these factors. Table 6.5 lists the univariate analysis 
using logistic regression, adjusting for age and sex at baseline. 
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Table 6.5  Logistic regression analysis - Univariate analysis of traditional cardiovascular risk factors and 
their association to PMR and GCA diagnoses within the EPIC-Norfolk cohort 
Characteristic* PMR (n=395) PMR ACR/EULAR (n=272) GCA (n=118) GCA ACR (n=76) 
Ever smoking 0.95 (0.78, 1.17)  p=0.643 0.90 (0.70, 1.15)  p=0.407 1.44 (0.98, 2.11)  p=0.06 1.44 (0.89, 2.32)  p=0.138 
Self-reported high blood pressure 0.91 (0.70, 1.17)  p=0.451 0.95 (0.69, 1.29)  p=0.732 0.88 (0.55, 1.40)  p=0.593 0.63 (0.37, 1.07)  p=0.087 
Systolic BP >140 mm/Hg 1.00 (0.81, 1.24)  p=0.980 0.91 (0.70, 1.17)  p=0.463 0.65 (0.44, 0.97)  p=0.036 0.79 (0.48, 1.28)  p=0.336 
Diastolic BP >90 mm/Hg 1.24 (0.99, 1.55)  p=0.064 1.12 (0.89, 1.53)  p=0.272 0.80 (0.51, 1.26)  p=0.338 1.06 (0.62, 1.79)  p=0.839 
HDL <1.0 mmol/L 0.57 (0.35, 0.93)  p=0.024 0.59 (0.33, 1.04)  p=0.066 0.97 (0.48, 1.97)  p=0.938 0.83 (0.33, 2.11)  p=0.698 
LDL >4.1 mmol/L 1.34 (1.08, 1.66)  p=0.008 1.37 (1.07, 1.77)  p=0.014 1.20 (0.82, 1.77)  p=0.350 1.46 (0.90, 2.37)  p=0.124 
LDL/HDL ratio >2.5 1.20 (0.95, 1.50)  p=0.122 1.32 (1.01, 1.73)  p=0.045 1.18 (0.78, 1.79)  p=0.422 1.30 (0.77, 2.19)  p=0.321 
Triglycerides >2.2 mmol/L 0.86 (0.68, 1.10)  p=0.224 0.89 (0.67, 1.18)  p=0.423 1.06 (0.69, 1.61)  p=0.796 0.85 (0.49, 1.48)  p=0.563 
Self-reported diabetes 1.50 (0.70, 3.18)  p=0.297 1.43 (0.59, 3.49)  p=0.433 1.51 (0.37, 6.13)  p=0.569 0.95 (0.23, 3.88)  p=0.938 
BMI >30 kg/m2 0.83 (0.62, 1.10)  p=0.198 0.71 (0.50, 1.03)  p=0.067 0.63 (0.35, 1.12)  p=0.116 0.60 (0.29, 1.25)  p=0.174 
hs-CRP >2.6 mg/L 1.18 (0.93, 1.50)  p=0.184 1.18 (0.92, 1.52)  p=0.198 1.45 (0.95, 2.22)  p=0.082 2.11 (1.25, 3.58)  p=0.006 
Data presented are odds ratios with 95% CI and p values. *Adjusted for age and sex at baseline. Self-reported diagnoses are from baseline questionnaire at time 
of recruitment. BP – Blood pressure, LDL – Low-density lipoprotein, HDL – high-density lipoprotein, BMI – Body mass index, hs-CRP – high sensitivity CRP 
(measured from a range of 0 to 160 mg/L with values outside this range converted to missing data). 
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The logistic regression analysis revealed a positive association between 
serum levels of LDL cholesterol above 4.1 mmol/L and subsequent 
diagnoses of PMR. GCA was positively associated with a raised hs-CRP of 
greater than 2.6 mg/L. As the presence of raised inflammatory markers 
may be the result of the inflammatory process of GCA at time of disease 
development, all cases of GCA with a diagnosis made within a year of 
serum hs-CRP were excluded. This resulted in 11 cases of GCA being 
excluded of whom three were excluded from those defined by the ACR 
criteria set. This resulted in an adjusted odds ratio associated with hs-
CRP >2.6 mg/L of 1.44 (0.93, 2.22) p=0.102 for all cases of GCA over 50 
years of age and 2.13 (1.24, 3.65) p=0.006 for those meeting the ACR 
classification criteria set. 
A multivariate logistic model was used to estimate the odds ratios for 
PMR and GCA cases incorporating a number of variables and possible 
confounders (See table 6.6). 
Generally, raised systolic blood pressure and BMI of > 30 kg/m2 was 
associated with an odds ratio of below one for both PMR and GCA but 
failed to reach statistical significance apart from systolic BP >140 mm/Hg 
and GCA and BMI > 30 kg/m2 and PMR.  Logistic regression analyses 
revealed these factors to be associated with death. Competing risk 
analysis was used to explore this relationship further using the Fine-Gray 
method (222). 
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Table 6.6  Logistic Regression analysis multivariable modelling 
Logistic Regression model Variable  PMR50 OR (95% CI) p value 
(n=22,923) 
PMR EULAR/ACR OR (95% CI) p value  
(n=22,961) 
age, sex, LDL, diastolic BP age 1.06 (1.05, 1.07)  p <0.001 1.06 (1.04, 1.07)  p <0.001 
sex 2.44 (1.91, 3.10)  p <0.001 2.61 (1.96, 3.48)  p <0.001 
LDL >4.1 mmol/L 1.31 (1.05, 1.62)  p = 0.015 1.35 (1.05, 1.74)  p = 0.021 
diastolic BP >90 mm/Hg 1.18 (0.93, 1.51)  p = 0.169 1.12 (0.85, 1.49)  p = 0.420 
age, sex, LDL, diastolic BP  
with interaction term for LDL and sex 
age 1.06 (1.05, 1.07)  p <0.001 1.06 (1.04, 1.07)  p <0.0001 
sex 2.31 (1.65, 3.23)  p <0.001 2.75 (1.83, 4.14)  p<0.0001 
LDL >4.1 mmol/L 1.21 (0.80, 1.83)  p = 0.373 1.46 (0.89, 2.40)  p = 0.136 
diastolic BP >90 mm/Hg 1.18 (0.93, 1.50)  p = 0.171 1.13 (0.85, 1.50)  p = 0.417 
Logistic Regression model Variable  GCA50 OR (95% CI) p value 
(n=18,004) 
GCA ACR OR (95% CI) p value   
(n=18,022) 
age, sex, ever smoking, hs-crp age 1.06 (1.03, 1.08)  p<0.001 1.05 (1.02, 1.08)  p-0.002 
sex 2.72 (1.65, 4.48)  p<0.001 2.71 (1.45, 5.08)  p=0.002 
ever smoking 1.67 (1.06, 2.65)  p=0.028 1.52 (0.87, 2.68)  p=0.144 
hs-crp >2.6 mg/L 1.41 (0.91, 2.19)  p=0.127 2.13 (1.24, 3.68)  p=0.007 
age, sex, ever smoking, hs-crp 
with interaction term for ever smoking 
and sex 
age 1.06 (1.03, 1.08)  p<0.001 1.05 (1.02, 1.08)  p=0.002 
sex 2.31 (0.89, 6.04)  p=0.087 1.36 (0.50, 3.73)  p=0.550 
ever smoking 1.41 (0.52, 3.83)  p=0.506 0.70 (0.23, 2.10)  p=0.521 
hs-crp >2.6 mg/L 1.41 (0.91, 2.19)  p=0.124 2.17 (1.26, 3.75)  p=0.006 
PMR model: total cohort (n=25,542) missing data for LDL (n=2578) and diastolic bp (n=84). Likelihood ratio tests between models:  chi2 p value 0.6589 and 0.7173 
respectively no evidence of an interaction between LDL and sex. GCA model: total cohort (n=25,265) missing data for hs-crp (n=7,113) and ever smoking (n=217). 
Likelihood ratio tests between models: chi2  p=0.7093 and 0.1344 respectively no evidence for an interaction between ever smoking and sex.  
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6.1.7 Competing risk analysis for death and diagnoses 
of PMR and GCA 
Survival methods were used to test aetiological factors associated with 
disease outcome. Due to the longitudinal data within EPIC-Norfolk and 
the dynamic nature of the cohort due to the long enrolment period, and 
ability to test several covariates, Cox regression is an appropriate 
analytical model. A Cox proportional hazards model was created including 
age, sex and the dichotomised diastolic hypertension variable used to 
test the association to PMR. The resultant hazard ratios were 2.02 (95% 
CI 1.61, 2.53) for female sex after adjusting for age and after including 
the diastolic hypertension variable was 2.04 (95%CI 1.62, 2.56). The 
graphic outputs did not reveal a violation of the proportional hazard 
assumption and this was supported by a non-significant p value based on 
a Chi2 test of the Schoenfeld residuals, again supporting no violation of 
the proportionality assumption. 
Due to the strong association between age and diagnoses of PMR and 
GCA, it is possible that there is competing risk with death. As traditional 
cardiovascular risk factors are known to increase the risk of death, the 
risk factors used in the logistic regression analysis may therefore be 
confounded by death.  
Survival analysis techniques were used to assess risk factors for 
subsequent PMR and GCA diagnoses with a competing risk for death. Cox 
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regression with a Fine-Gray extension was used to produce the following 
cumulative incidence function diagrams for the putative risk factors and 
subsequent diagnoses of PMR and GCA. This was firstly carried out 
adjusting for duration of follow-up time and subsequently for age, with 
PMR defined as those with the condition diagnosed over 50 years of age 
with baseline diastolic blood pressure as a predictive variable. (See 
Figure 6.1). Figure 6.1 panel A, shows a separation between the lines of 
those at baseline with a diastolic blood pressure of greater than 90 
mm/Hg having an increased risk for PMR. The lines follow similar profiles 
by the dichotomised diastolic blood pressure variable, with no apparent 
violation of the proportional hazards assumption. However since the 
logistic regression analysis (Table 6.6) showed no association when 
adjusting for age, the Cox proportional model with competing risk for 
death was set using participants’ date of birth as the origin, rather than 
entry to the cohort at the time of recruitment. This analysis displayed in 
Panel B shows no association between the dichotomised diastolic blood 
pressure variable and subsequent risk of PMR. This analytical exercise 
reveals the importance of age as a confounder in the risk for both PMR 
and increased diastolic blood pressure. As a consequence all subsequent 
Cox-proportional models were set with date of birth as the origin, with 
competing risk for death. Figures 6.2 and 6.3 show the cumulative 
incidence plots for cases of PMR and GCA defined firstly by those older 
than 50 years at diagnosis and those meeting the current classification 
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criteria set. The risk factors identified from the logistic regression analysis 
are re-analysed using Cox regression with competing risk for death. 
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Figure 6.1  Cox regression with competing risk for death for PMR 
diagnosis 
 
The above figure are from Cox regression with competing risk for death showing cumulative incidence of PMR 
diagnosis within the EPIC-Norfolk cohort. Panel A is stratified from time at entry to the cohort and panel B 
accounting for age by using date of birth as the origin in the analysis.  
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Figure 6.2 Cox regression with competing risk for death, 
predictors of PMR 
The above panel diagram shows predictors of PMR from baseline assessment. Figures A1, B1 and C1 are by 
cases of PMR diagnosed over the age of 50, with A2, B2 and C2 defined by EULAR/ACR criteria. Panel A assess 
the effect of sex, B the effect of LDL and C the effect of raised diastolic blood pressure. 
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Figure 6.3  Cox regression with competing risk for death, 
predictors of GCA 
 
The above panel diagram shows predictors of GCA from baseline assessment. Figures A1, B1 and C1 are by cases 
of GCA diagnosed over the age of 50, with A2, B2 and C2 defined by ACR 1990 criteria. Panel A assess the effect 
of smoking, B the effect of sex and C the effect of high-sensitivity CRP.  
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The results from the Cox regression with competing risk for death reveal 
similar risk factors to the logistic regression modelling for PMR and GCA 
diagnosis. 
For PMR (See Figure 6.2), an increased risk was associated with an LDL 
of greater than 4.1 mmol/L at baseline, with those cases of PMR aged 
greater than 50 years having a sub-hazard ratio (SHR) of 1.25 (95% CI 
1.02, 1.54) p = 0.036 and those meeting the EULAR/ACR classification 
criteria a SHR of 1.29 (95% CI 1.01, 1.64) p = 0.043. Female sex 
resulted in a sub-hazard ratios of 2.56 (95% CI 2.04, 3.21) p < 0.0001 
and 2.64 (95% CI 2.00, 3.47) p <0.0001 respectively by those cases 
defined by age and those meeting classification criteria.  
For GCA (See Figure 6.3), despite a signal for ever-smoking in cases 
defined over the age of 50 years at diagnosis using logistic regression, no 
similar increased risk was not found using Cox regression and competing 
risk for death. The resultant SHRs for ever-smoking were 1.05 (95% CI 
0.72, 1.53) p = 0.25 and 1.04 (95% CI 0.65, 1.67) p = 0.16 by cases 
defined over the age of 50 years at diagnosis and those meeting the 
current classification criteria respectively. For high-sensitivity CRP, all 
cases diagnosed within a year of serum assessment were excluded from 
the analysis. This resulted in SHRs of 1.26 (95% CI 0.82, 1.93) p = 
0.298 and 1.85 (95% CI 1.09, 3.14) p = 0.022 respectively. Similarly as 
for PMR, female sex resulted in SHRs of 2.56 (95% CI 1.69, 3.87) p < 
0.0001 and 2.61 (1.56, 4.39) p < 0.0001 respectively. 
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6.1.8 PMR and GCA diagnoses and genetic risk factors 
Several GWAS studies have been published assessing the genetic 
contribution of SNPs to diagnoses of PMR and GCA. The strongest and 
most consistent associations have been found with HLA-DRB1*0401. SNP 
analysis was carried out on the EPIC-Norfolk cohort.  The SNP 
rs6910071, as a tag of HLA-DRB1, has been reported previously to be 
associated with both conditions, with greatest risk associated with the A 
allele (223, 224).  
The logistic regression analysis revealed an odd ratio of 1.57 (1.33, 1.85) 
p=<0.0001 for PMR cases defined by the age cut-off and 1.47 (1.21, 
1.79) p<0.001 for those meeting the PMR classification set. 
For GCA the logistic regression analysis revealed an odd ratio of 1.39 
(1.01, 1.91) p=0.044 for GCA cases defined by the age cut-off and 1.43 
(0.96, 2.12) p=0.075 for those meeting the GCA classification set. The 
results remained very similar with adjustment for age and sex at 
baseline. 
6.1.9 Comments 
The factors associated with greatest risk for PMR and GCA are increasing 
age and female sex, in keeping with the published literature. This is the 
first time that a prospective cohort study design has been used to explore 
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risk factors for PMR and GCA development and to apply current 
classification criteria. 
Analysis of traditional cardiovascular risk factors firstly with logistic 
regression then Cox proportional hazards with Fine Gray extension, 
resulted in associations between raised LDL (>4.1 mmol/L) and PMR and 
raised hs-crp (>2.6 mg/L) and GCA. Due to the possibility of raised 
inflammatory markers being a manifestation of undiagnosed GCA, all 
cases of GCA diagnosed within a year of hs-CRP assessment were 
excluded from the analysis. 
Analysis for diastolic blood pressure suggested a possible signal 
associated with PMR when using logistic regression, but this was nullified 
when using Cox proportional hazards and competing risk for death. It is 
possible that many more participants developed hypertension during 
follow-up, with analysis based only on baseline data resulting in a 
spurious non-significant association. However, it is impossible to 
speculate further without data for blood pressure at later time points. 
In agreement with previously published data, the greatest risk estimates 
for PMR and GCA are increasing age and female sex. It is still possible 
that the associations are chance findings, but others have found similar 
associations and the major strength of the prospective study design 
reduces the risk of Type I error through reductions of recall and selection 
biases. The EPIC-Norfolk cohort has allowed for robust phenotypic 
analysis and use of classification criteria in case definition.  
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CHAPTER 7   INFLUENCE OF MEDICATION 
PRIOR TO DIAGNOSIS OF PMR AND GCA 
7.0 SUMMARY 
Several studies have assessed the effect of statins and their influence in 
GCA development and outcome. The Cox regression analysis revealing an 
effect of LDL and subsequent PMR diagnosis. In keeping with a 
cardiovascular dysfunction aetiological mechanism further analysis was 
carried out using the EPIC-Norfolk cohort and baseline questionnaire data 
for several medications used to treat cardiovascular disease and its risk 
factors namely hypertension and hyperlipidaemia. The baseline 
questionnaire asked in question 12: “In the last week, have you taken 
any drugs or medicines either prescribed by your doctor or bought from 
the chemist? (Please include inhalers, pain killers etc.). See Table 7.1 for 
details of medication recorded for the various case definitions and 
controls.  
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Table 7.1  Medication at baseline by subsequent PMR and GCA diagnosis 
Medication from baseline 
questionnaire 
PMR50 
(n=395) 
PMR EULAR/ACR 
(n=275) 
GCA50 
(n=118) 
ACR GCA 
(n=76) 
Controls 
(n=25,147*) 
Anti-hypertensives  n,(%) 90 (22.8) 62 (22.8) 31 (26.3) 20 (26.3) 4,701 (18.7) 
ACE-inhibitors  n,(%) 8 (2.0) 6 (2.2) 4 (3.4) 3 (4.0) 804 (3.2) 
Calcium-channel blockers  n,(%) 27 (6.8) 19 (7.0) 8 (6.8) 4 (5.3) 1,407 (5.6) 
Beta-blockers  n,(%) 30 (7.6) 19 (7.0) 10 (8.5) 7 (9.2) 1,581 (6.3) 
Lipid-lowering medication  n,(%) 11 (2.8) 7 (2.6) 2 (1.7) 1 (1.3) 369 (1.5) 
Collected from baseline questionnaire at time of recruitment. *Controls are for the PMR and GCA cases defined by age greater than 50 years at time of diagnosis 
but the overall percentages by drug class do not vary amongst the controls by the various case definitions. 
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7.1.0 Hypertension and its definition 
Not everyone with hypertension will be prescribed treatment. To assess 
the differences in hypertension definition and subsequent disease 
outcome, the various questions relating to hypertension and its treatment 
are presented in the cross tabs below (Table 7.2). Of those prescribed 
anti-hypertensives, 51.5% had systolic blood pressure above 140 mm/Hg 
at their baseline health check attendance, and those who reported having 
high blood pressure, 78.0% stated they were on medication. Using all 
three definitions (i.e. if at least one definition was affirmative), 11,769 
(45.9%) participants within the cohort had high blood pressure: either 
self-declared hypertension; were on treatment or had a systolic BP of > 
140 mm/Hg (average of two readings). 
Table 7.2  Agreement in definitions of Hypertension amongst 
EPIC-Norfolk participants at baseline 
Systolic BP > 140mm/Hg  Self-reported high 
BP 
Anti-hypertensives 
Systolic BP 
>140mm/Hg  
(n = 9,166) 
 
25.1% 27.1% 
Self-reported 
high BP  
(n =3,671) 62.7% 
 
78.0% 
Anti-
hypertensives  
(n = 4,822) 51.5% 59.4% 
 
For example of those with a raised systolic blood pressure of > 140 mm/Hg, 25.1% self-reported having high 
blood pressure and 27.1% declared they were taking anti-hypertensive medication.  
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Table 7.2 shows the various definitions for hypertension. The greatest 
agreement was between those who reported hypertension and were on 
anti-hypertensives, however of those on treatment 51.5% were 
hypertensive when having their blood pressure measured. 
From Chapter 6.1.6 and Table 6.5 defining hypertension by self-declared 
diagnosis or baseline blood pressure measurement was associated with 
reduced odds for PMR and GCA although few estimates reached statistical 
significance. 
Recalculation using Cox proportional hazards with competing risk for 
death, adjusted for age and sex, resulted in the following estimates using 
the combined hypertension variable: PMR50 SHR = 0.83 (0.68, 1.01)  p 
= 0.06, PMR EULAR ACR classified cases SHR = 0.77 (0.60, 0.97)  p = 
0.03, GCA50 SHR = 0.59 (0.41, 0.85)  p = 0.005 and ACR classified 
cases of GCA SHR = 0.69 (0.44, 1.09)  p = 0.111. Most of the results 
reveal a reduced risk amongst individuals with the combined 
hypertension variable, which could be due to contribution from 
medication modifying the risk.  
7.1.1 Anti-hypertensives 
The baseline questionnaire recorded all anti-hypertensive agents, 
irrespective of class. From Table 7.1 not all participants could remember 
the class or precise name of their anti-hypertensive agent so there are a 
number of participants whose class of medication is unknown. At least 
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70% of those with PMR or GCA and 80% of controls did report their class 
of anti-hypertensive.  
Cox-proportional hazards with competing risk for death, adjusted for age 
and sex was calculated for anti-hypertensive medication with the results 
displayed in Table 7.3 
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Table 7.3  Anti-hypertensive medication and subsequent risk for PMR and GCA diagnosis 
Medication at baseline 
from questionnaire 
PMR50 (n=395) PMR EULAR/ACR (n=272) GCA50 (n=118) GCA ACR (n=76) 
Anti-hypertensives,  SHR 
(95% CI) 
0.72 (0.57, 0.91)  p = 0.006 0.72 (0.54, 0.95)  p = 0.020 0.90 (0.60, 1.36)  p = 
0.625 
0.91 (0.55, 1.51)  p = 
0.705 
ACE-inhibitors, SHR (95% 
CI) 
0.46 (0.23, 0.92)  p = 0.029 0.50 (0.22, 1.12)  p = 0.093 0.80 (0.30, 2.18)  p = 
0.665 
0.94 (0.30, 3.00)  p = 
0.919 
Calcium-channel 
blockers, SHR (95% CI) 
0.77 (0.52, 1.14)  p = 0.186 0.78 (0.49, 1.25)  p = 0.302 0.79 (0.39, 1.60)  p = 
0.504 
0.60 (0.22, 1.64)  p = 
0.319 
Beta-blockers, SHR (95% 
CI) 
0.80 (0.55, 1.16)  p = 0.239 0.73 (0.46, 1.16)  p = 0.177 0.92 (0.48, 1.76)  p = 
0.800 
1.01 (0.46, 2.21)  p = 
0.980 
 
 144 
 
7.1.2 Lipid lowering drugs 
The results for baseline serum LDL > 4.1 mmol/L revealed an increased 
sub-hazard ratio for subsequent PMR diagnosis (See chapter 6.1.7). 
Relatively few participants taking lipid lowering drugs were subsequently 
diagnosed with PMR or GCA. The results of the Cox-proportional hazard 
with competing risk for death and adjusting for age and sex revealed the 
following sub-hazard ratios: PMR50 SHR = 1.39 (0.76, 2.51)  p = 0.284, 
PMR EULAR ACR classified cases SHR = 1.27 (0.60, 2.69)  p = 0.531, 
GCA50 SHR = 0.85 (0.21, 3.39)  p = 0.812 and ACR classified cases of 
GCA SHR = 0.66 (0.09, 4.70)  p = 0.674. 
7.1.3 Comments 
The combined hypertension variable resulted in reduced risk for later 
diagnosis of PMR and GCA. It is important to note that this exposure was 
collected at baseline with PMR and GCA diagnosed during the following 20 
years. Not all those with hypertension measured at baseline were on 
treatment and this is likely to have changed over follow-up. In addition, 
changes in national guidance may have affected the choice of agent 
offered over the follow-up period with the joint NHS and British 
Hypertension Society guidelines being published in 2006. Subsequently 
ACE-I became the most commonly prescribed agent having previously 
been beta-blockers (225). Prescription of anti-hypertensives lowered the 
risk for PMR and although the estimate for GCA, was similarly protective, 
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this did not reach statistical significance. It is possible that those 
identified with hypertension started treatment resulting in their apparent 
reduction in risk but this cannot be ascertained from the data available. 
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CHAPTER 8   RISK FACTORS ASSOCIATED 
WITH PROGRESSION 
8.0 Summary  
The risk factors associated with blindness in GCA and inflammatory 
polyarthritis in PMR were investigated using DCVAS and EPIC-Norfolk 
datasets. DCVAS due to its set-up of recruiting cases and comparator 
conditions allowed to compare factors associated with blindness amongst 
cases of GCA using logistic regression to calculate odds ratios. EPIC-
Norfolk with its prospective study design enabled use of survival methods 
in this case Cox-proportional hazards with a Fine-Gray extension to 
assess baseline clinical features associated with subsequent diagnosis of 
inflammatory polyarthritis.  
8.1.0 RISK FACTORS ASSOCIATED WITH BLINDNESS IN DCVAS 
In those recruited to DCVAS, descriptive statistics were used to assess 
patient characteristics and their association to blindness, with standard 
nonparametric tests used to assess differences between groups. Previous 
studies have found an association between laboratory markers and 
subsequent blindness, including relatively lower inflammatory markers, 
anaemia and thrombocytosis (58, 198, 199). For these reasons 
inflammatory markers: Erythrocyte Sedimentation Rate (ESR), C-reactive 
protein (CRP), and haematological tests: anaemia – haemoglobin (Hb) 
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<100 g/L and platelets > 500 x 10⁹/L were assessed for their association 
with subsequent blindness  
8.1.1 Analytical approach 
Previous data have suggested a relationship between prior vascular 
disease and ischaemic complications in GCA. A logistic regression analysis 
was applied to examine the strength of the association between vascular 
risk factors with blindness at six months, recorded as odds rations (OR) 
with 95% confidence intervals (CI). In a sensitivity analysis, the models 
were recalculated, firstly using the 1990 ACR criteria set and secondly 
positive temporal artery biopsy (TAB) findings to define GCA diagnosis. 
8.1.2 Laboratory values at diagnosis and risk of 
blindness 
Patients who developed blindness had a lower CRP at presentation (Table 
6.7); however, no other clinical feature of GCA itself was significantly 
associated with blindness at six months. 
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Table 8.1  Baseline characteristics 
Clinical Features Physician Diagnosis of GCA at 6 months (>75% 
certainty) n=433 
  Blind at six months (n=34) 
Not blind at six 
months (n=399) p value* 
Age at diagnosis (median, years) 74.9 73.0 0.073 
Male (%) 12 (35.3) 133 (33.3) 0.816 
New-onset headache 23 (67.7) 282 (70.7) 0.710 
Any visual symptom (%) 32 (94.1) 154 (38.6) 0.000 
Jaw claudication (%) 13 (38.2) 163 (40.9) 0.766 
Tongue claudication (%) 3 (8.8) 16 (4.0) 0.188 
Morning stiffness shoulders arms 
(%) 
7 (20.6) 87 (21.8) 0.869 
Morning stiffness hips/thighs (%) 5 (14.7) 69 (17.3) 0.700 
Myalgia (%) 5 (14.7) 109 (27.3) 0.109 
Fever (%) 3 (8.8) 68 (17.0) 0.214 
Fatigue (%) 13 (38.2) 164 (41.1) 0.744 
Weight loss (%) 12 (35.3) 138 (34.6) 0.934 
Smoking Status    
Current (%) 4 (14.0) 56 (11.8) 0.741 
Former (%) 9(31.1) 124 (26.5) 0.741 
Never (%) 21 (54.9) 219 (61.8) 0.741 
Comorbidities    
Coronary heart disease (%) 2 (5.9) 27 (6.8) 0.843 
Heart failure (%) 0 (0.0) 9 (2.26) 0.376 
Peripheral vascular disease (%) 5 (14.7) 6 (1.5) 0.000 
Hypertension requiring therapy (%) 15 (44.1) 164 (41.1) 0.732 
Diabetes mellitus (%) 7 (20.6) 33 (8.3) 0.017 
Cerebrovascular accident (%) 4 (11.8) 10 (2.5) 0.003 
Dyslipidaemia (%) 10 (29.4) 87 (21.8) 0.307 
Chronic obstructive Pulmonary 
disease 
0 (0.0) 24 (6.0) 0.141 
Laboratory test results at 
presentation (%) 
   
Positive temporal artery biopsy 23 (67.7) 203 (50.9) 0.060 
Median ESR mm/hr 65 70 0.620 
Median CRP mg/L 46 64 0.025 
Anaemia (Haemoglobin <100g/L) (%) 4 (11.8) 62 (15.5) 0.803 
Thrombocytosis (platelets > 500 x 
10⁹/L) (%) 
3 (8.8) 75 (18.8) 0.330 
*p-value of difference between those who were subsequently declared blind in at least one eye versus those 
who were not; all calculated using the chi squared test except for median age at diagnosis, ESR and CRP which 
was tested by the Mann-Whitney test. GCA: giant cell arteritis; ESR: erythrocyte sedimentation rate; CRP: C - 
reactive protein. 
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8.1.3 Vascular disease and blindness 
Table 6.8 shows the results of logistic regression analysis, examining 
associations between potential vascular risk factors assessed at baseline 
and blindness (adjusted for age and sex). Factors positively associated 
with blindness at six months included i) a prior history of cerebrovascular 
accident (CVA) (OR = 4.47, 95% CI: 1.30 to 15.41), and ii) peripheral 
vascular disease (PVD) (OR = 10.44, CI: 2.94 to 37.03). There was no 
association between baseline laboratory findings and blindness. 
With the sensitivity analysis, the findings were largely unchanged: rates 
of blindness in those meeting the 1990 ACR criteria and those with a 
positive TAB were 7.4% and 9.8%, respectively. The associations 
between PVD and CVA remained statistically significant with positive 
associations for blindness at six months (for PVD, ACR cases OR = 9.40, 
(2.14 to 41.34), TAB positive cases OR = 9.22, (1.56 to 54.70), for CVA, 
ACR cases OR = 5.29, (95% CI 1.39 to 20.07), TAB positive cases OR = 
4.02, (0.89 to 18.16)). The association between prevalent diabetes 
mellitus and blindness reached statistical significance for those cases 
defined by positive TAB (4.28, CI: 1.42 to 12.92) although not the cases 
defined by 1990 ACR criteria (2.24, CI: 0.84 to 5.96). 
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Table 8.2  Association between vascular disease factors assessed at presentation and blindness at 6 
months 
Presenting features Physician Diagnosis of GCA at 6 months   (>75% certainty) n=433 1990 ACR Criteria cases 
n=404 
TAB positive cases 
n=235 
  Unadjusted OR, 95% CI Adjusted* OR, 95% CI Adjusted* OR, 95% CI Adjusted* OR, 95% CI 
BMI† 1.10, (1.01 to 1.19) 1.10, (1.02 to 1.20) 1.10, (1.00 to 1.21) 1.13, (1.00 to 1.28) 
Smoking (ever vs never) 0.75, (0.37 to 1.55) 0.78, (0.36 to 1.68) 0.65, (0.28 to 1.54) 0.70, (0.26 to 1.84) 
Cardiovascular disease at baseline 0.86, (0.20 to 3.79) 0.77, (0.17 to 3.45) 0.77, (0.16 to 3.58) 2.02, (0.38 to 10.78) 
Diabetes at baseline 2.88, (1.16 to 7.10) 2.48, (0.98 to 6.25) 2.26, (0.82 to 6.17) 4.19, (1.39 to 12.67) 
Stroke at baseline 5.19, (1.54 to 17.53) 4.47, (1.30 to 15.41) 5.29, (1.39 to 20.07) 4.02, (0.89 to 18.16) 
Peripheral vascular disease at baseline 11.29, (3.25 to 39.23) 10.44, (2.94 to 37.03) 9.40, (2.14 to 41.34) 9.22, (1.56 to 54.70) 
Hyperlipidaemia at baseline 1.49, (0.69 to 3.24) 1.45, (0.67 to 3.15) 1.43, (0.62 to 3.29) 2.20, (0.87 to 5.60) 
Hypertension on medication at baseline 1.13, (0.56 to 2.29) 0.99, (0.48 to 2.03) 1.11, (0.51 to 2.39) 0.73, (0.30 to 1.79) 
*Adjusted for age and sex. †Missing data for BMI (n = 131). GCA: giant cell arteriƟs; OR: odds raƟon; BMI: body mass index; ESR: erythrocyte sedimentation rate; 
CRP: C -reactive protein. 
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8.1.4 Comments 
The DCVAS data are international and therefore should be widely 
generalisable but potentially could be biased due to being sampled from 
secondary and tertiary care centres. In keeping with previous published 
data on GCA, the DCVAS participants were similar in terms of their age at 
diagnosis and in that 288 of the 433 (66.5%) were women. A formal 
recording of visual performance was not made for all individuals in 
DCVAS and therefore a hard, but relatively severe, definition of blindness 
was used, captured as part of the VDI assessment. Finally, the results 
from the analysis of BMI should be interpreted cautiously due to the 
relatively large proportion of missing data. 
8.2.0 RISK FACTORS ASSOCIATED WITH A SUBSEQUENT 
DIAGNOSIS OF INFLAMMATORY POLYARTHRITIS FOLLOWING 
PMR IN EPIC-NORFOLK 
The rate of occurrence of inflammatory polyarthritis (IP) amongst 
participants diagnosed with PMR was calculated using Cox-proportional 
modelling with competing risk for death. At baseline, clinical features of 
those diagnosed with PMR were examined to determine whether there 
were differences between early or late transformations to IP, and to 
assess whether clinical features at presentation might predict those at 
risk of subsequent IP diagnosis. To assess how robust the findings were 
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to disease definition we repeated the analysis using classification criteria 
to define cases of PMR (35) and RA (226).  
8.2.1 PMR cohort construction 
From the 24,068 men and women recruited into EPIC-Norfolk, a total of 
363 persons were diagnosed with PMR between 1st February 2002 and 
31st January 2015. 
There were 39 refuted diagnoses comprising osteoarthritis (n=13), 
rotator cuff tendinopathy (n=11), cervical spondylosis (n=6), malignancy 
(n=5), and one each of statin-related myalgia, greater trochanteric pain 
syndrome, systemic lupus erythematosus and primary 
hyperparathyroidism. 
The final sample comprised 324 incident diagnoses of PMR (73.2% 
female) with 65% of diagnoses made exclusively by general practitioners. 
The mean age at diagnosis was 75.6 years. The maximum follow-up was 
13 years (median 4.82 years). Baseline characteristics are shown in Table 
6.9.  
Within the PMR cohort there were 65 deaths during the follow-up period, 
four who had been diagnosed with IP of whom three met RA classification 
criteria. 
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8.2.2 Incidence of inflammatory polyarthritis following 
a diagnosis of PMR 
During 1,855 person years of follow-up, 32 (10.5%) participants (20, 
63% female) were diagnosed with IP by a rheumatologist (see Figure 
6.4), nine diagnoses of IP were made within six months of diagnosis of 
PMR. The cumulative incidence, accounting for censoring for losses to 
follow-up and competing risk for death, of IP occurrence at six months, 
one, two, five and ten years was: 2.2% (95% CI 1.0 to 4.3), 3.5% (95% 
CI 1.9 to 6.0), 6.5% (4.1 to 9.6), 8.4% (5.6 to 11.9), and 12.9% (8.8 to 
17.9) respectively. Using only those cases of PMR fulfilling the current 
ACR/EULAR resulted in a PMR cohort of 292 participants, of whom 26 
developed IP, 12 of whom met the current criteria for RA. The 
subsequent cumulative rate for RA occurrence at six months, one, two, 
five and ten years was 1.1% (95% CI 0.3 to 2.9), 1.1% (95% CI 0.3 to 
2.9),  1.8% (0.7 to 3.9), 4.0% (2.0 to 7.0), and 5.4% (2.9 to 9.1) 
respectively. 
Clinical features remained broadly similar between those participants 
diagnosed with IP within six months, and the remaining IP cases, with 
the only difference found being a higher CRP at baseline PMR diagnosis 
(see Table 6.9). 
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Table 8.3  Baseline characteristics of those diagnosed with polymyalgia rheumatica  
Population Age at PMR 
diagnosis a 
Female 
n (%) 
Never 
smokers n 
(%) 
ESR mm/hr 
(95% CI)a 
CRP mg/L 
(95% CI) a 
RhF 
positive 
ACPA 
positive 
Meeting EULAR/ACR 
PMR criteria 
Any small joint 
synovitis 
Total initial PMR 
diagnosis (n=363) 
75.3 266 
(73%) 
163 (45%) 54 (51, 58) 43 (36, 50) 14/224 
(6%) 
26/258 
(10%) 
N/A N/A 
PMR cohort (n=324) † 75.6 237 
(73%) 
146 (46%) 56 (52, 60) 47 (39, 55) 12/203 
(6%) 
25/233 
(11%) 
292/324 (90%) 15/324 (5%) 
 Men (n=87) 76.1 N/A 60/87 
(31%)*** 
52 (45, 59) 50 (37, 64) 5/50 
(10%) 
4/63 
(6%) 
79 6 (5%) 
 Women (n=237) 75.4 N/A 119/234 
(51%)*** 
58 (53, 62) 46 (36, 56) 7/153 
(5%) 
21/170 
(12%) 
213 9 (3%) 
Remaining as PMR 
(n=290) 
75.9** 216 
(75%) 
135 (47%) 56 (52, 60) 47 (38, 56) 8/180 
(4%)** 
20/205 
(10%) 
264/290 (91%) 10 (4%)*** 
Transforming to IP 
(n=34) 
72.8** 21 
(62%) 
11 (32%) 57 (43, 71) 51 (27, 75) 4/23 
(17%)** 
5/28 
(18%) 
28/34 (82%) 5 (15%)*** 
 Early 
transformers 
(n=9) 
76 4 (44%) 2 (22%) 71 (42, 101) 85 (31, 
138)** 
1/8 
(13%) 
1/7 
(14%) 
8/9 (89%) 2 (22%) 
 Late 
transformers 
(n=25) 
71.6 17 
(68%) 
9 (36%) 51 (34, 67) 34 (10, 
58)** 
3/15 
(20%) 
4/21 
(19%) 
20/25 (80%) 3 (12%) 
†For all PMR once the 39 whose diagnosis was refuted other than those considered to have IP.  Early transformer are those being diagnosed with IP with 6 
months of PMR diagnosis   astudents non-paired t-test, all other variables tested using chi2   ** p value <0.05  *** p value <0.01 
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Figure 8.1  Cumulative incidence for IP in the PMR cohort by 
clinical feature with competing risk of death using Cox modelling 
 
Cummulative incidence density using Cox-proportional hazard modelling with Fine-Gray extension 
for IP amongst participants diagnosed with PMR. Dashed lines refer to those participants with the 
risk factor present compare to the solid line – those without. 
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8.2.3 Clinical characteristics at baseline predictive of 
subsequent occurrence of IP 
In the first five years males were at greater risk of IP compared to 
females (cumulative incidence for males at 1 and 5 years: 7.1% (2.9 to 
13.8) and 13.1% (6.9 to 21.2); females: 2.2% (0.8 to 4.7) and 6.6% 
(3.8 to 10.5)), see Figure 6.1.  
Table 6.10 shows clinical features and characteristics at baseline and 
their risk for subsequent IP occurrence using competing risk Cox 
regression analysis. Risk estimates were calculated for all PMR diagnoses; 
those fulfilling the classification set and those who were subsequently 
considered to have IP following clinical diagnosis, and those meeting the 
classification set for RA. Associated with the greatest hazard for 
subsequent diagnosis of IP or RA, irrespective of whether the cases of 
PMR fulfilled the current classification set for PMR, was small joint 
synovitis at time of PMR diagnosis. Rheumatoid factor carried a greater 
risk for subsequent IP and or RA compared to ACPA.  
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Table 8.4  Sub-hazard ratios for IP/RA by clinical features at 
baseline diagnosis of PMR using Cox modelling with competing 
risk of death 
Clinical feature – all cases of PMR (n=324) PMR changing to IP (n=32) 
Sub-hazard ratio 
and 95% CI 
p value 
Age at time of PMR diagnosis >75.9 years 0.33 (0.15, 0.74) 0.007 
Male sex 1.72 (0.84, 3.53) 0.139 
Ever smoked 1.93 (0.92, 4.04) 0.083 
adjusted 1.77 (0.84, 3.72) 0.131 
RhF Positive 4.28 (1.48, 12.37) 0.007 
adjusted 3.46 (0.89, 13.51) 0.074 
ACPA Positive  2.51 (0.93, 6.72) 0.068 
adjusted 3.14 (1.16, 8.54) 0.025 
Wrist synovitis at time of PMR diagnosis 2.91 (0.40, 20.96) 0.290 
adjusted 3.41 (0.54, 21.50) 0.192 
Small joint synovitis at time of PMR diagnosis 3.45 (1.14, 10.42) 0.029 
adjusted 3.11 (1.08, 8.93) 0.035 
Cases of PMR meeting EULAR/ACR criteria* 
(n=292) 
PMR changing to RA (n=12) 
Sub-hazard ratio 
and 95% CI 
p value 
Age at time of PMR diagnosis >75.9 years 0.49 (0.15, 1.62) 0.244 
Male sex 1.47 (0.45, 4.84) 0.524 
Ever smoked 1.83 (0.56, 5.95) 0.317 
adjusted 1.72 (0.50, 5.93) 0.393 
Wrist synovitis at time of PMR diagnosis 7.66 (0.93, 62.93) 0.058 
adjusted 8.55 (1.05, 69.74) 0.045 
Small joint synovitis at time of PMR diagnosis 6.69 (1.44, 31.13) 0.015 
adjusted 6.17 (1.34, 28.43) 0.019 
Clinical features at baseline at time of PMR diagnosis and subsequent risk of IP or RA occurrence using Cox 
hazard modelling with competing risk for death.  *The EULAR/ACR criteria for PMR include a requirement for 
lack of rheumatoid factor and or anti-ccp antibodies.  
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In those younger at PMR onset there was a greater risk of IP. The 
majority of participants with IP were rheumatoid factor negative 
(81.8%), one of whom was positive for ACPA. During the follow-up period 
12/20 (60.0%) women and 4/12 (33.3%) men fulfilled the EULAR ACR 
criteria set for rheumatoid arthritis (see Table 2). Of the participants with 
IP, five developed erosions (15.6%) during the follow-up period, of whom 
three (18.8%) fulfilled the current RA classification set. The presence of 
peripheral synovitis at baseline diagnosis was noted in 13 (4.5%) of 
those considered subsequently to remain as PMR, three (9.4%) of those 
considered subsequently to have IP and two (12.5%) of those considered 
subsequently to have RA. The positive likelihood ratio for peripheral 
synovitis at baseline PMR diagnosis was 2.1 for IP and 2.7 for RA, this 
ratio increasing if only those who fulfilled the current classification criteria 
for PMR were used for the baseline cohort, resulting in positive likelihood 
ratios of 2.3 and 3.3 for IP and RA respectively.  
8.2.4 Comments 
Although the number of participants who developed IP was relatively 
small, the detailed characterisation of the PMR cohort and the ability to 
apply current classification criteria were major strengths of this analysis. 
From the data available from the EPIC-Norfolk cohort, males and those 
who smoked were at greatest risk of subsequent IP diagnosis.  
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8.3.0 CONCLUSIONS OF RISK FACTORS FOR PROGRESSION 
These are the first estimates for onset of PMR and GCA from a 
prospective cohort study. Whilst challenges exist in applying classification 
criteria retrospectively, the ability to define cases which meet 
classification criteria is a major strength of this work.  
8.3.1 Risk factors for blindness in GCA 
The DCVAS analysis indicates that blindness is still a major concern with 
a diagnosis of GCA and most individuals who had visual disturbance at 
presentation were declared blind at six months of follow-up. Whilst the 
definition of blindness is severe in terms of the spectrum of visual loss, it 
is a robust measure and compares similarly to results from the Mayo 
clinic, with 14.9% of patients in their series suffering monocular 
blindness (136). 
8.3.2 Risk factors for inflammatory arthritis following a 
diagnosis of PMR 
There is significant overlap in the clinical features of PMR, IP and RA, and 
due to lack of a single diagnostic test with which to separate them, 
makes studying these sub-populations difficult. However, every attempt 
was made to start with a pure PMR cohort. We excluded all diagnoses 
other than for IP which occurred in our PMR participants within six 
months from original PMR diagnosis. As a single clinical feature, the use 
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of peripheral joint synovitis to differentiate between PMR and IP is 
inappropriate, with many other authors concluding that such a finding is 
a feature of PMR. In addition, there are many cases of IP and indeed RA 
which lack serology from RhF and ACPA yet the lack of these markers 
does not prevent the individual from developing inflammatory arthritis. 
While, in keeping with many others on this subject, this study relied on a 
single rheumatology unit for its diagnoses of RA (227-229), this unit is 
the largest in the region and catchment area for the EPIC-Norfolk 
population with its patients contributing to the long-running inflammatory 
arthritis data for the Norfolk Arthritis Register (NOAR) (230). 
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CHAPTER 9   OCULAR MORPHOMETRY – 
RETINAL CHANGES AND CHARACTERISTICS 
9.0 SUMMARY 
Retinal images were acquired from participants who attended the third 
health check, known as the EPIC-Eye study, the dates of which were from 
2005 to 2011. Non-mydratic digital retinal images were captured using a 
Topcon fundus camera. Images were reviewed for retinal characteristics 
to ascertain whether any morphological features were associated with 
cases of PMR or GCA compared to controls. Digital retinal images were 
reviewed at Moorfield eye hospital with independent review by 
technicians. Features were recorded using the scoring sheet in Appendix 
2. The aim was to establish whether any morphological features were 
characteristic of either PMR or GCA compared to matched controls. 
9.1.0 Data Source EPIC-Eye 
In total there were 135 cases of PMR and / or GCA, these comprising 103 
cases of PMR, and 32 cases of GCA, of whom nine had co-existing PMR 
with GCA.  
The results of the inflammatory marker assessment at time of diagnosis 
were similar to all cases at diagnosis from the cohort – See Table 5.5. 
Previously published studies had found an association between lower 
inflammatory markers at baseline and increased risk for visual loss in 
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patients with GCA (see Section 2.6.7). The cases for the EPIC-Eye study 
had ESR measured at time of diagnosis: 
 PMR cases ESR (mm/hr): mean 51 (SD 27), median 46 (IQR 38);  
 GCA cases ESR (mm/hr): mean 82 (SD 36), median 91 (IQR 54);  
 Co-existing cases ESR (mm/hr): mean 62 (SD 33), median 52 
(IQR 61).  
The dates of diagnosis ranged from 1st Jan 1984 to 9th June 2015, with 
the date ranges for the third health check 17th August 2005 to 28th 
October 2011. This resulted in 56 (41.5%) individuals having their retinal 
fundus photograph taken before their diagnosis of PMR and / or GCA. The 
visual acuity of those participants who attended the third health check is 
described in Chapter 5.3.2. 
9.2.0 RETINAL FIELD CHARACTERISTICS 
The QUARTZ processed images have showed an increase in retinal venule 
width amongst participants with PMR. The images were reviewed to 
record other changes affecting the retinal field including a focal narrowing 
not captured by QUARTZ.  
Retinal characteristics were reviewed, from digital retinal images, 
independently by two researchers documenting features such as, focal 
vascular changes, disc morphology and retinal field characteristics. This 
comprised case-control analysis using the 17 incident cases of GCA and 
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39 cases of PMR, age and sex matched to three controls per case 
(n=168). A third senior researcher reviewed any discrepancies and made 
the final over-riding decision on the presence or absence of any 
characteristics (as described in methods chapter 4.3.6 and 4.3.7). In 
addition a selection of prevalent cases (those being diagnosed with PMR 
or GCA prior to health check three) were reviewed (PMR n = 64 and GCA 
n = 15) in order to ascertain whether the characteristics were present 
before or as a consequence of a diagnosis of PMR or GCA. Table 8.3 gives 
the disease status of all 303 participants reviewed for retinal field 
characteristics. 
Table 9.1 Cases of PMR and GCA by incident or prevalent disease 
status 
Diagnosis Number Incident cases n = 56 Prevalent cases n = 79 
    
PMR 103 39 64 
GCA 32 17 15 
Controls* 168 N/A N/A 
*controls matched on sex and age at time of retinal photograph to the incident 
cases (ratio 3:1). 
 
All retinal images were independently scored by two assessors. Any 
disagreements were highlighted with a third reader having final say on 
final scoring. Retinal field characteristics were recorded, including focal 
narrowing, arteriovenous nipping (AV nipping), pigment field loss, tigroid 
fundus and disc morphology. In total 38 cases were adjudicated by the 
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third reviewer. The retinal morphology characteristics presented are the 
final adjudicated set. 
9.2.1 Tigroid Fundus 
Potentially tigroid or tessellation of the fundus could have be as a 
consequence of disease or due to ageing. Table 8.4 details the prevalence 
of tigroid fundus by disease status.  
Table 9.2  Tigroid Fundus 
Diagnosis Number Strong  n (%) Mild  n (%) None  n (%) 
Prevalent PMR (n=64) 52 16 (30.8) 17 (32.7) 19 (36.5) 
Incident PMR (n=39) 32 11 (34.4) 13 (40.6) 8 (25.0) 
Prevalent GCA (n=15) 13 6 (46.2) 5 (38.5) 2 (15.4) 
Incident GCA (n=17) 14 4 (28.6) 7 (50.0) 3 (21.4) 
Control (n=168)  136 63 (46.3) 51 (37.5) 22 (16.2) 
Chi2 test p = 0.162 with Fisher’s exact p = 0.179. 
The analysis shows the presence of tessellation is not associated with 
cases of GCA and or PMR prior to or after their diagnosis. The cases were 
diagnosed between 28 days and 8.3 years from their third health check 
date. The median time period between the third health check and 
diagnosis was 2.9 years with 75% of cases having an interval of at least 
one year. 
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9.2.2 Focal vessel narrowing and arteriovenous nipping 
Review of the images revealed only focal narrowing of vessels in the 
superior nasal quadrant. In total only five participants were noted to have 
possible focal narrowing in the left eye, four with PMR (two with incident 
disease) and one control.  
AV nipping was noted in a number of participants. There was good 
agreement when no AV nipping was thought to be present (78 
participants vs 93 participants with agreement on 75 participants 
between first and second readers). However when changes were noted, 
there were discrepancies: the first reader noted possible changes of AV 
nipping in three participants with the second reader noting changes in 
one participant not observed by the other reader. The biggest difference 
was noted in those thought to have definite changes. A third reader 
reviewed the cases where there were discrepancies and the final 
adjudicated features were noted (See Table 8.5). 
There appeared to be no good statistical evidence to suggest there were 
any major differences between the cases and controls in respect of the 
presence of AV nipping. The total prevalence of AV nipping if present in 
any quadrant of either left or right eye was as follows: prevalent PMR 
18.8%, incident PMR 15.4%, prevalent GCA 20.0%, incident GCA 17.7% 
and controls 13.7%. Combining all the incident cases of PMR and GCA 
and comparing them with their age and sex controls resulted in a 
prevalence of AV nipping for the cases of 16.1% vs 13.7% for the 
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controls, but this difference was not statistically different with a chi2 of 
0.659. 
 
 167 
 
Table 9.3  Arteriovenous nipping by quadrant and left or right eye 
Cases Superior nasal quadrant Inferior nasal quadrant Superior temporal quadrant Inferior temporal quadrant 
Left eye Right eye Left eye Right eye Left eye Right eye Left eye Right eye 
Prevalent PMR (n=64) 6 (14.3) 7 (16.7) 3 (7.3) 4 (9.3) 1 (2.4) 0 1 (2.5) 2 (4.9) 
Incident PMR (n=39) 2 (6.7) 2 (6.9) 1 (3.5) 3 (10.3) 2 (6.9) 1 (3.5) 0 3 (10.3) 
Prevalent GCA (n=15) 1 (12.5) 0 2 (25.0) 1 (11.1) 0 0 0 1 (12.5) 
Incident GCA (n=17) 1 (10) 2 (15.4) 0 0 0 0 0 0 
Control (n=168)  9 (12.3) 6 (8.0) 3 (4.1) 6 (7.9) 2 (2.7) 0 0 1 (1.4) 
No statistical significant difference between disease status by each quadrant of each eye using Fisher’s exact test. 
Table 9.4  Retinal pigment epithelium loss 
Cases Superior nasal quadrant Inferior nasal quadrant Superior temporal quadrant Inferior temporal quadrant 
Left eye Right eye Left eye Right eye Left eye Right eye Left eye Right eye 
Prevalent PMR (n=64) 2 (4.4) 4 (9.0) 9 (19.6) 9 (19.6) 1 (2.3) 1 (2.2) 2 (4.7) 1 (2.5) 
Incident PMR (n=39) 1 (3.3) 0 6 (20.0) 6 (19.4) 0 0 1 (3.5) 1 (3.5) 
Prevalent GCA (n=15) 1 (14.3) 1 (10.0) 1 (14.3) 1 (10.0) 1 (16.7) 1 (12.5) 0 0 
Incident GCA (n=17) 0 0 2 (16.7) 4 (25.0) 0 0 0 1 (8.3) 
Control (n=168)  2 (2.7) 4 (5.4) 10 (13.5) 16 (21.9) 1 (1.4) 1 (1.4) 2 (2.7) 1 (1.4) 
No statistical significant difference between disease status by each quadrant of each eye using Fisher’s exact test. 
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For patches of loss of retinal epithelial pigment (REP) there was good 
agreement between the first and second readers particularly when no 
loss was thought to be present (80 vs 83 participants thought to have no 
loss of REP – agreement on 72 of the participants). Again a third reader 
was used to arbitrate on any discrepancies. There appeared to be no 
good statistical evidence to suggest there were any major differences 
between the cases and controls in respect of the presence of REP loss. 
9.2.3 Optic disc morphology 
GCA is known to cause anterior ischaemic optic neuropathy, typically in 
the hyper-acute phase of the illness and visual symptoms may be the 
first symptom of GCA at presentation. Unfortunately around one in 12 
people diagnosed with GCA will suffer blindness in the affected eye. 
Initially the disc can look swollen and / or pale but typically these 
changes resolve within a few weeks. Where ischaemia has been 
prolonged, the disc can atrophy and appear chalky white. Since other 
changes may be noted with the disc, discs from the EPIC-participants 
with retinal images were recorded. The results are below in Table 8.7. 
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Table 9.5  Optic disc morphology 
  Optic disc morphology 
  Normal Atroph
y 
Pale  Cupping Laminar 
dot sign 
Thick NNR Blurred 
nasal edge 
Blurred 
temporal edge  
Prevalent PMR 
(n=64) 
right eye (n=63) 18 (28.6) 0 4 (6.4) 2 (3.2) 5 (7.9) 26 (41.3) 2 (3.2) 6 (9.5) 
left eye (n=60) 19 (31.2) 1 (1.7) 5 (8.3) 2 (3.3) 4 (6.7) 20 (33.3) 0 9 (15.0) 
Incident PMR  
(n=39) 
right eye (n=38) 14 (36.8) 0 0 0 2 (5.3) 16 (42.1) 1 (2.6) 5 (13.2) 
left eye (n=38) 15 (39.5) 0 1 (2.6) 0 2 (5.3) 15 (39.5) 1 (2.6) 4 (10.5) 
Prevalent GCA 
(n=15) 
right eye (n=15) 8 (53.3) 0 0 0 0 6 (40.0) 0 1 (6.7) 
left eye (n=15) 11 (73.3) 0 1 0 0 3 (20.0) 0 0 
Incident GCA  
(n=17) 
right eye (n=17) 10 (58.8) 0 0 0 1 (5.9) 6 (35.3) 0 0 
left eye (n=17) 8 (47.1) 0 0 0 1 (5.9) 6 (35.3) 0 2 (11.8) 
Control  
(n=168)  
right eye (n=87) 55 (63.2) 0 0 4 (4.6) 13 (14.9) 9 (10.3) 0 3 (3.5) 
left eye (n=77) 43 (55.8) 0 0 2 (2.6) 12 (15.6) 17 (22.1) 0 3 (3.9) 
*thick neuroretinal rim (NRR) / small cup – disc to cup ratio of 0.25 or less. 
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9.2.4 Peripapillary atrophy (PPA) 
The digital retinal images were also reviewed for the presence of 
peripapillary atrophy. There was good agreement between the first and 
second readers with an agreement of 94.0% for the left eye and 92.5% 
for the right eye and 96.1% between eyes with a weighted kappa statistic 
of 0.75. The arbitrated features of PPA are shown in Table 8.8.  
Table 9.6  Peripapillary atrophy 
Participant group 
Peripapillary atrophy 
None temporal Nasal  Circumferential  
Prevalent PMR 
(n=64) 
right eye (n=58) 47 (81.0) 7 (12.1) 1 (1.7) 3 (5.2) 
left eye (n=53) 40 (75.5) 7 (13.2) 2 (3.8) 4 (7.6) 
Incident PMR 
(n=39) 
right eye (n=33) 25 (75.8) 8 (24.2) 0 0 
left eye (n=34) 25 (73.5) 8 (23.5) 0 1 (2.9) 
Prevalent GCA 
(n=15) 
right eye (n=14) 13 (92.9) 1 (7.1) 0 0 
left eye (n=15) 12 (80.0) 2 (13.3) 0 1 (6.7) 
Incident GCA 
(n=17) 
right eye (n=17) 17 (100.0) 0 0 0 
left eye (n=15) 15 (100.0) 0 0 0 
Control (n=168)  right eye (n=84) 61 (72.6) 8 (9.5) 5 (6.0) 10 (11.9) 
left eye (n=74) 59 (79.7) 9 (12.2) 4 (5.4) 2 (2.7) 
 
9.2.5 Other changes 
Other characteristics were also recorded, including: the presence of 
drusen, age related macular degeneration, epiretinal membrane (ERM), 
myopic atrophy and age-related macular degeneration (AMD), with 
descriptions recorded are shown in Table 8.9. None of the field changes 
were associated with cases of PMR and / or GCA more than for controls. 
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Table 9.7  Other characteristics of retina 
Characteristic PMR (n=103) GCA (n=32) Controls (n=168) 
No changes recorded 90 (87.3%) 28 (87.5%) 147 (87.5%) 
Drusen 5 (4.9%) 3 (9.4%) 8 (3.0%) 
ERM 1 (1%) 0 2 (1.2%) 
Myopic atrophy 1 (1%) 0 0 
AMD 0 1 (3.1%) 0 
ERM - Epiretinal membrane,  AMD – Age related macular degeneration. 
9.2.6 Comments 
Following careful and thorough review of 303 participants with digital 
retinal images, no characteristic features were displayed for either 
participants with PMR or GCA. The lack of any characteristic features 
amongst participants with GCA may due to the relatively small number 
reviewed. 
9.3.0 CONCLUSIONS OF RETINAL MORPHOMETRY IN PMR AND 
GCA 
This is the first time a thorough review of retinal morphology has been 
carried out amongst patients with PMR and GCA and compared to age 
and sex-matched controls. There were between 13.7% and 20.0% of 
participants showed AV nipping, compared with 18.7 to 20.3% on anti-
hypertensive therapy at baseline. Further analysis is required to ascertain 
the validity of the various definitions of hypertension and subsequent 
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development of AV nipping, but this work remains beyond the scope of 
this thesis  
The use of automated software enables reliable processing of the images 
in a relatively quick time-frame. However, in order to allow efficient 
processing, the QUARTZ program removes any areas where there is 
cross-over of retinal vessels and therefore information on arteriovenous 
nipping is not captured. The QUARTZ program produces vasculometric 
measures of retinal vessel width for arteriole and venules which may be 
important in disease development or risk, with changes in vessel calibre 
associated with cardiovascular risk factors. 
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CHAPTER 10   OCULAR SCREENING - QUARTZ 
10.0 SUMMARY 
The above chapter above describes the recording and cataloguing of 
retinal characteristics using automated software and manual review. The 
QUARTZ program produces measures of vessel width at the pixel level, 
with analysis of retinal width being carried out using a standardised 
measure of vessel width for the whole retina captured in the image. This 
process has been shown to be reliable and has been validated using both 
EPIC-Norfolk and UK Biobank images. 
10.1.0 RETINAL VASCULAR MORPHOLOGY – VESSEL WIDTHS 
Retinal fundal images were assessed in collaboration with researchers at 
St George’s Hospital, University of London. This group have developed 
QUARTZ (QUantitative Analysis of Retinal Vessel Topology and siZe), a 
software system providing automated quantification of retinal vessel 
morphology (Chapter 4.5.3 for detailed methods of the QUARTZ 
program).  
Retinal vessel tortuosity is associated with a number of established 
cardiovascular risk markers in the first decade of life (231). This suggests 
life-course patterning of vascular development and that retinal vessel 
morphology may be an important early marker of vascular health. Hence, 
accurate assessment of retinal vessel morphology (in both arterioles and 
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venules) may be an important biomarker of vascular health, which may 
predict those at high risk of disease in middle and later life. 
Using a case-control design retinal vascular morphology changes 
associated in patients with GCA or PMR are reported. 
10.1.1 Measures of retinal vessel width 
Retinal vessel width measures were calculated for all participants who 
attended the third health check and had digital retinal images which 
could be processed by the QUARTZ program (232). The retinal vessels 
are classified into venules and arterioles and a mean summary measure 
for venules and arterioles calculated for each participant. Average width 
measures for arterioles and venules for each eye is calculated. Data 
presented are based on Gaussian modelling for vessel widths and an 
ensemble classifier of bagged decision trees using colour information for 
the vessel type (arteriolar vs venular retinal vessel – not choroid 
vessels). Only vessels with a high degree of certainty (probability >75%) 
of the correct vessel type being awarded by the classifier were used. 
10.1.2. Retinal vascular widths 
In total, 10,494 images of adequate quality were obtained and analysed 
from 5,959 participants. Of these participants, 5,125 had images of 
adequate quality from both right and left eyes. Mean arteriolar and 
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venular widths were 64.8 µm (SD 8.4), and 93.6 µm (SD 10.1) 
respectively.  
Of those who attended the third health check with retinal images which 
could be processed by the QUARTZ program, there were 132 participants 
with PMR and 42 with GCA. Of these cases, 49 of the participants with 
PMR and 23 of those with GCA were diagnosed after attending their third 
health check. The mean age of those with PMR at health check three was 
75.3 years (SD 7.6) and for those with GCA the mean age was 72.8 
years (SD 7.9). The mean ESR at diagnosis was 56 mm/hr for those with 
PMR and 74 mm/hr for those with GCA (See Table 9.1 for baseline 
characteristics).  
Table 10.1 Baseline Characteristics of all participants attending the 
third health check  
 PMR (n = 132) GCA (n = 42) Control (n = 7,938) 
mean (SD) age at hc3, years  75.3 (7.6) 72.8 (7.9) 68.7 (8.1) 
Female sex (%) 93 (70.4%) 30 (71.4%) 4,373 (55.1%) 
Never smokers (%) 49.60% 46.30% 52.40% 
mean (SD) arteriolar width, m  65.0 (9.6) 65 (7.5) 64.8 (8.4) 
mean (SD) venular width, m 97.6 (10.9) 92.8 (8.4) 93.6 (10.1) 
 
The above calculations include all those with a diagnosis of GCA or PMR 
irrespective of the date of their third health check.  
Of the 72 cases with QUARTZ analysed images prior to their diagnosis of 
PMR and / or GCA, 56 (77.8%) participants had retinal fundal images 
 176 
 
available for manual review to assess for retinal morphology 
characteristics.  For the retinal morphology work, these cases (n=56) 
were age and sex matched to three controls (n=168). Features 
associated with subsequent diagnosis of PMR and / or GCA were 
analysed.  
Participants with PMR had wider venular widths compared to those 
without (mean difference 4.0 µm, 95% CI 1.7, 6.3 µm); there were 
negligible differences in arteriolar diameter (mean difference -0.2 µm, 
95% CI -1.8, 2.3 µm). There were no appreciable associations between 
vessel width and GCA. The difference in retinal venular widths was 
present in cases prior to their diagnosis of PMR. Adjusting for age and sex 
using multi-linear regression did not nullify the results (See Table 8.2).  
10.1.3 Sensitivity analysis and retinal vessel widths 
The linear regression model was recalculated using only those cases 
meeting the ACR criteria set for GCA and only those meeting the EULAR-
ACR criteria set for PMR. This resulted in no overall changes in the 
estimates (data not shown). 
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Table 10.2 Vessel width for incident and prevalent cases of PMR and GCA 
 Total Incident cases Prevalent case  
Control n=7,938 
PMR (n) 132 49 83 
Venular width (m) and SDb 97.6 SD 10.9 98.9 SD 13.3 96.5 SD 8.6  93.6 (SD) 10.1 from 5,033 controls 
 Venular width (m) 75% 
probability* 
4.0 (1.7, 6.3)     p=0.001 5.4 (0.7, 10.1)   p=0.003 3.0 (0.5, 5.5)        p=0.06 Reference 
Regression co-efficient for venular 
width† 
3.96 (1.57, 6.35) p=0.001 5.43 (1.79, 9.06) p=0.003 2.86 (-0.29, 6.0) p=0.075 N/A 
Arteriolar width (m) and SDb 65.0 SD 9.6 65.5 SD 11.3 64.7 SD 8.2 64.8 (SD) 8.4 from 5,034 controls 
 Arteriolar width (m) 75% 
probability* 
-0.2 (-1.8, 2.3) p=0.8231 0.7 (-3.3, 4.7)    p=0.648 -0.1 (-2.5, 2.7)   p=0.924 Reference 
Regression co-efficient for 
arteriolar width† 
0.69 (-1.29, 2.68) p=0.495 1.09 (-1.94, 4.13) p=0.479 0.42 (-2.18, 3.01) p=0.754 N/A 
GCA (n) 42 23 19  
Venular width (m) and SDb 92.8 SD 8.4 93.7 SD 8.9 90.4 SD 6.9  93.6 (SD) 10.1 from 5,033 controls 
 Venular width (m) 75% 
probability* 
-0.8 (-4.2, 2.7) p=0.730 0.2 (-4.3, 4.6) p=0.951 -3.2 (-10.1, 3.8) p=0.446 Reference  
Regression co-efficient for venular 
width † 
-0.59 (-4.82, 3.6) p=0.785 0.33 (-4.63, 5.28) p=0.897 -3.02 (-11.10, 5.06) p=0.464 N/A 
Arteriolar width (m) and SDb 65.0 SD 7.5 66.0 SD 8.1 62.2 SD 64.8 (SD) 8.4 from 5,034 controls 
 Arteriolar width (m) 75% 
probability* 
-0.2 (-2.9, 3.3)   p=0.918 1.2 (-2.9, 5.3)    p=0.565 -2.6 (-7.9, 2.7)   p=0.457 Reference  
Regression co-efficient for 
arteriolar width † 
0.58 (-2.94, 4.11) p=0.745 1.56 (-2.57, 5.70) p=0.458 -2.03 (-8.77, 4.71) p=0.554 N/A 
 mean difference between cases and controls. Controls comprise 7,938 participants unless otherwise stated.  btwo-sample non-paired t-test between incident and prevalent cases 
as respect of third health check and venular width and arteriolar width respectively for PMR and GCA cases revealed p=>0.1.  * two-sample non-paired t-test between cases and 
controls for all cases, incident cases and prevalent cases respecƟvely  † Linear regression on venular width with presentaƟon of regression co-efficient and adjusting for age at the 
time of retinal photograph and sex of the participant.   
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10.1.4 Comments 
The self-selected participants, with PMR or GCA attending the third health 
check did not differ in their gender or age at diagnosis compared to the 
rest of the cohort who had been diagnosed with PMR and GCA. The 
inflammatory markers at time of diagnosis were also similar. 
Nonetheless, the participants who attended the third health check could 
potentially result in a biased sample towards those with good vision as 
those with poor vision may have found travelling for assessment more 
burdensome.  
The presence of increased retinal venular width in cases with PMR is of 
interest and is plausibly related to vascular dysfunction. It is noteworthy 
that the increase in venular width was present prior to their diagnosis of 
PMR. The lack of any association between retinal vessel measures and 
GCA could be due to small numbers, or there may be no difference in 
retinal vessel widths between cases and controls.  
10.2.0 EXPLORATORY ANALYSIS 
However, each image processed by QUARTZ provides thousands of data 
points recorded within a large data and this additional data might be 
useful in further research.  
The approach to the data file could take two broad approaches 
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 Data driven - looking at the output how many clusters explain the 
variance in the data? 
 Goal driven - are there specific features we would hope to find 
based on the data of width, length and tortuosity? 
The data can look at the width, the length, the branching pattern, and 
how these are linked together in what is known as the “network”. 
The data file for one eye was obtained and the corresponding digital 
retinal image is shown in Figure 9.1. and Figure 9.2 shows the labelled 
segments once the image has been processed by QUARTZ. 
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Figure 10.1 Digital retinal image 
 
Digital retinal fundus image of a left eye from an EPIC-Norfolk participant. The venules in this image 
have been coloured in blue to facilitate discrimination between venules and arterioles. 
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Figure 10.2 QUARTZ labelled retinal image 
 
Segmented vessels after processing by QUARTZ. Segment 44 is an artifact. 
10.2.1 Cluster analysis 
Cluster analysis was taken of a processed QUARTZ image to see if the 
vessel segments grouped together. The variables used in the model were 
vessel width, local angle and location of the measures on the image. The 
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QUARTZ program records the orientation of the centre line (based in the 
central reflex of the vessel – see chapter 4.3.4 for details). 
Cluster analysis was performed, creating a location variable based on the 
x and y coordinates. This was carried out firstly with an origin in the top 
left corner and secondly with the origin set as the optic disc. Cluster 
analysis was undertaken including segment vessel width, local angle and 
location origin with subsequent dendrograms produced labelled by 
segmentation number (see Figure 9.3). The diagram shows the results of 
three cluster analysis models: A is a dendrogram based on a cluster 
model comprising an origin in the top left corner, vessel segment width, 
and local angle, B is a dendrogram based on a cluster model comprising 
an origin of the optic disc, vessel segment width and local angle and C is 
a dendrogram based on a cluster model comprising an origin of the optic 
disc and vessel segment width.  
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Figure 10.3 Dendrograms following Cluster analysis 
 
Dendrograms for the various cluster analysis models. Key for coloured boxes: yellow 1st, green 2nd, 
and purple 3rd order vessels, red arterioles, blue venules. Segments 35, 36 and 45 comprise small 
vessels on or arising from the disc which are impossible to categorise, segment 44 is an artefact.  
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10.2.2 Comments 
The results of the cluster analysis and subsequent dendrograms are 
shown in Figure 9.3. The models using the optic disc as the origin appear 
to group venules and arteriole segments better than the model with the 
origin set as the top left corner. There were many leaves in the cluster 
analysis and so an arbitrary cut of 25 levels was chosen. The results don’t 
show a strong separation by vessel segment, type, and location from the 
optic disc. Further work is needed to ascertain if more information can be 
used from the QUARTZ output but remains beyond the scope of this 
thesis.  
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CHAPTER 11   DISCUSSION 
11.0 SUMMARY 
This chapter concludes by considering how far the work presented in this 
thesis has been able to address its stated aims. Limitations in the study 
design and set-up of the three main dataset are given including which 
inherent biases could influence the results and subsequent conclusions. 
The chapter finishes by considering how the questions and problems 
highlighted could be addressed by intended further work. 
11.1.0 GCANS - strengths 
Previous studies of PMR and GCA have been criticised as they often 
recruit participants from secondary care populations and therefore are 
unrepresentative of the underlying larger community population. The 
studies which have made use of community-based registries have often 
failed to apply classification criteria, making comparisons difficult. The 
GCANS study therefore aimed to address these criticisms by surveying a 
community population. However, there are limitations to this study. 
Although the estimates from GCANS only apply to those individuals aged 
≥55 years, within the sample only 5% of GP-recorded cases of PMR and 
no cases of GCA were diagnosed before this age. Although a large 
population, (in excess of 5000 people) were screened, the community is 
typical of rural Norfolk comprising a largely Caucasian population and an 
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older age demographic compared with the rest of the UK. Those aged > 
55 years make up 36% of the Norfolk population compared with 29% for 
England and Wales so the older age of the Norfolk population it is likely 
to result in greater disease burden for PMR and GCA, since both 
conditions are strongly correlated to age with incidence density rising 
with each increase in age band. However, this region has provided 
epidemiological data on inflammatory arthritis and systemic vasculitis 
from the Norfolk Arthritis Register (NOAR) and Norfolk Vasculitis 
(NORVASC) cohorts (233, 234).  
Through direct record review and questionnaire sampling supplemented 
by clinical assessment, considerable effort was made to enrich the 
available clinical data. While laboratory data were available in all cases of 
GP-recorded GCA, the results of tests of inflammatory makers were 
missing in the clinical records of 15% of those assigned a GP diagnosis of 
PMR. Incomplete GP records and where blood test results prior to the 
year 2000 could not be retrieved electronically prevented confirming a 
diagnosis of PMR.  Confining the analysis to those individuals who 
responded to the questionnaire, the resulting prevalence estimates for 
GCA would be 0.19% (95% CI 0.07% to 0.32%) and 1.54% (95% 1.19% 
to 1.90%) for PMR.  
No validated questionnaire exists for diagnosis or classification of either 
PMR or GCA.  A concern was that cases might exist in the community 
which had not been identified by their GP. In the 1985 study by Kyle et 
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al., identified one case of GCA unknown to their GP. Historical diagnoses 
are difficult to capture through questionnaires, particularly in diseases 
that remit with treatment. It may have been difficult in this study to 
detect cases which had entered remission before 2000 who were also not 
captured on the GP records. However, by use of the combined 
approaches for case ascertainment, it is unlikely that undiagnosed or 
remitted disease were missed in this study. The results suggest that GP-
recorded diagnoses are likely to encompass all cases within a population, 
although not all will fulfil classification criteria sets. 
11.1.1 EPIC-Norfolk - strengths 
The major strengths of the EPIC-Norfolk cohort are its large size, long 
duration of follow-up and depth of clinical data available. These allow the 
description of a rich phenotype of the diseases of interest and for 
application of classification criteria. In addition the prospective nature of 
its design negates the problems of recall bias inherent in case-control 
studies.  In addition, reverse causality is minimised in prospective study 
designs because eventual cases are disease free at the start of follow-up 
and drawn from the same population as controls (235).  
The estimates for disease incidence of both PMR, GCA, and their 
complications from this large community-based cohort provide 
advantages over other published estimates, namely the 
representativeness of the controls and the ability to apply classification 
sets of disease. The estimates of disease incidence are similar to other 
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published data suggesting these findings are valid. In keeping with the 
results for GCANS not all cases of PMR and GCA meet their intended 
classification criteria set. 
The data on morbidity associated with PMR and GCA should also be 
interpreted with the knowledge that a full comprehensive visual 
assessment was made of those participants who attend the third health 
check. This is the first study of its kind to include detailed documentation 
of visual performance in such a large population and the use of digital 
retinal fundal images provides further insights into the disease aetiology 
of these important conditions.  
Cardiovascular and other risk factors for onset were assessed using the 
EPIC-Norfolk cohort, again due to the careful review of potential cases 
and enriching the dataset with detailed phenotypic information is a major 
strength of this work. Whilst data on risk factors was collected at the 
baseline assessment, this data was recorded at nurse-led clinics and any 
associations found are unlikely to be biased upwards since participants 
within the cohort are likely to have developed hypertension subsequently 
and prescribed lipid lowering medication or anti-hypertensive agents.  
Another major strength of the work is from the EPIC-Eye study in which 
over 8000 individuals had measurement of visual acuity and retinal 
fundal images were captured. This has allowed for estimates of the effect 
of a diagnosis of PMR and GCA has on visual performance and for 
calculation of both relative and absolute risks of visual impairment. 
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The other major part of the work on risk factors for progression was the 
development of IP in participants initially diagnosed with PMR. The shared 
clinical features between PMR and inflammatory polyarthritis are a 
diagnostic challenge for clinicians. Tracking the onset of PMR in the 
community setting is difficult, requiring adequate methods of disease 
classification and prolonged follow-up. Previous secondary care-based 
studies assessing the development of IP in patients with PMR have been 
published. In one, 21 (11.1%) patients with PMR developed arthritis 
during follow-up but it is unclear how many of these subsequently had 
their diagnosis changed to inflammatory polyarthritis and which of these 
fulfilled classification sets for RA (205). Other studies have reported that 
as many as 20% patients initially diagnosed with PMR go on to develop 
RA after twelve months of follow-up (17). No studies have found any 
clinical features consistently which would be of strong positive predictive 
value in identifying those who may be at increased risk of subsequent 
inflammatory polyarthritis (17).  
Finally this is the first time a thorough review of retinal morphology has 
been carried out amongst patients with PMR and GCA and compared to 
age and sex-matched controls. Although no characteristics particular to 
PMR and GCA were found on manual review, the retinal vasculometric 
measures from the QUARTZ analysis are interesting and support a role 
for vascular dysfunction in the aetiology of PMR. 
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11.1.2 DCVAS - strengths 
A strength of this study is its size: 433 new cases of GCA were included, 
each of which having a systematic structured assessment that included 
presenting features, comorbidities, and outcome at six months. 
Outcomes were assessed by the VDI, a validated means of recording 
permanent damage arising from vasculitis or its treatment. 
This large observational study demonstrates that blindness remains a 
major problem in GCA: by six months after diagnosis, around one in 
twelve patients is blind in one eye. Although most patients who develop 
blindness do so by the time of their first assessment, two patients 
without symptoms of visual disturbance suffered blindness at six months. 
These results re-emphasise the need for urgent referral and rapid 
treatment with glucocorticoids (236). The analysis shows an association 
between blindness and peripheral vascular disease. Recently published 
data from the Swedish registry may be supportive of this evidence to 
suggest a possible aetiological role of vascular dysfunction as risk of 
blindness was greatest in individuals treated with beta-blockers (200). 
The present study identified a lower rate of blindness than the majority of 
published estimates, possibly reflecting our narrower and more stringent 
definition of blindness. It could be that more patients in DCVAS suffered 
visual loss since 70 patients were noted to have this complication at their 
baseline visit. However, the Mayo clinic published data on 204 cases of 
GCA from Rochester, Minnesota, USA over a 55-year period revealing  47 
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patients (23.0%) had visual symptoms, with seven (3.4%) suffering 
blindness in one eye (of whom two had bilateral blindness), which is 
lower than our estimate (136). Subsequently this same research group 
reported that 8.2% of patients with GCA had permanent visual loss 
attributed to their vasculitis which newer data are more consistent with 
our current estimate (237). Our estimate is higher than the 2.9% 
reported in the register-based study by Mollan et al.(238), although 
interpretation of this is limited both by the fact that the cases were 
identified though hospital episodes, and classification criteria were not 
applied, which potentially could lead to an underestimate of the rate of 
blindness in those with GCA. In addition using care episodes, rather than 
individual patient records, could lead to the potential for double or 
multiple counting. 
A lower mean inflammatory marker result was noted in those with 
blindness, which reached statistical significance for CRP but not for ESR, 
in keeping with other studies. It is possible that patients with lower 
inflammatory markers at baseline assessment are at greater risk of 
blindness due to prior inadequate treatment with glucocorticoids; equally 
this factor may contribute to diagnostic delay, or reflect a propensity for 
inflammation in smaller vessels. Prior peripheral vascular disease was 
also identified as a risk factor for blindness in patients with GCA. Previous 
studies have implicated hypertension, a past history of ischaemic heart 
disease, thrombocytosis, constitutional symptoms, and low inflammatory 
response as potential risks for blindness (188, 198, 199). Reports have 
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been inconsistent and while many of these factors were not confirmed in 
the present study, taken together these findings suggest a potential role 
of endothelial dysfunction in both the development of GCA and its 
ischaemic complications. The increased risk of CVD following a diagnosis 
of GCA is also consistent with this hypothesis (239). 
11.2.0 SOURCES OF BIAS 
In observational data, the main sources of bias relate to sampling bias, 
information bias and confounding, the latter of which is dealt with a 
subsequent section in this chapter. Selection bias relates to the way 
participants were recruited and how representative they are of the 
population from which they derive. However in the context of this thesis 
information bias relates to the measurement error contributed through 
misclassification of either cases or covariates. 
11.2.1 Selection bias 
All the datasets used in this thesis are at risk of selection bias. The 
GCANS study had a single eligibility criteria for participants with an age 
over 55 years. However, those who had previously stated a wish not to 
be involved in research, those who were resident in a nursing home or 
considered too unwell to take part were excluded from the postal 
questionnaire, although all GP recorded diagnoses of PMR and GCA 
registered in the GP database were reviewed. In addition the resultant 
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cumulative prevalence estimates were minimum estimates preventing an 
upward bias of the estimate. 
EPIC-Norfolk is a large cohort study within the wider EPIC initiative which 
was set-up in 1989 (240), and in terms of anthropometry, serum lipids 
and blood pressure the cohort is similar to the national population 
samples studied in the Health Survey of England (211). Although the 
third health checks ran over seven years when the participants were aged 
between 48 and 92 years, staff followed a tight protocol minimising 
variation, differences in interpretation and reducing subjectivity (241). 
However, it is possible that patients with worse vision would face 
challenges in attending the third health check follow-up and therefore the 
results of visual assessment could be biased towards those with better 
vision. 
With DCVAS recruiting from 129 sites from 26 countries worldwide, the 
sampling bias arises from referral bias due to the fact that it was clinic-
based, rather than population-based. However, the sample was not 
selected from one individual specialty or specialist centre, providing 
potentially greater generalisability than earlier single-centre studies. 
11.2.2 Information bias 
Observational epidemiological analyses are particularly prone to 
information bias through misclassification. However, the contribution to 
measurement error is likely due to be non-differential misclassification as 
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covariates were not recorded differently between cases and controls. This 
is most likely for the EPIC-Norfolk cohort as eventual disease status was 
not known at the time of baseline assessment. 
With respect to misclassification, in all three datasets cases have been 
assessed using similar definitions of disease status and importantly, 
those cases fulfilling current classification criteria which is a major 
strength of this work. 
11.3.0 INTERPRETATION OF THE FINDINGS 
The data available within EPIC-Norfolk contributed greatly to the 
descriptive epidemiology and assessment of aetiological hypotheses in 
this thesis. Interpretation of these findings warrants further discussion. 
Inferences drawn rely on the analytical methods used and model 
assumptions and their implications are discussed in the following section. 
11.3.1 Model assumptions 
The use of logistic regression was appropriate for the data when using 
case-control study design. Confounding by age is likely given the 
difference in the crude and adjusted odds ratios. The subsequent models 
used appropriate analytical methods taking account of the confounders.  
The association of PMR and GCA with age and traditional cardiovascular 
risk factors highlighted the potential contribution of mortality in 
modifying results of any analytical modelling. The use of Cox-proportional 
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hazards with Fine-Gray extension was appropriate for the analyses since 
the assumption of proportionality was not violated. The data for PMR and 
GCA occurrence may suggest that a continuous hazard assumption also 
applies, particularly through the effect of age and female sex (see section 
6.1.0) and therefore appropriate to also be analysed using Poisson 
regression.  
11.3.2 Confounding 
There is no statistical test for confounding. Although in modelling, 
attempts were made to negate the effects of confounding, there could 
still be unknown or residual confounders.  
However, as these results are broadly in keeping with other published 
estimates, they appear unlikely due to chance.  
11.3.3 Limitations 
The limitations of each of the analyses are discussed below. Particular 
challenges were faced in applying classification criteria retrospectively, 
particularly for the GCANS study. In addition, GCANS was a relatively 
small study despite the effort required in setting up and carrying out 
postal survey to 4,728 people, there were only 23 cases of GCA on the 
GP electronic record.  
Over the course of 20 years of follow-up, the baseline variables assessed 
as part of the EPIC-Norfolk study are likely to have changed with many 
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more participants developing hypertension, for example. Therefore 
resultant estimates for the contribution for LDL and PMR should be 
viewed as a potential underestimate, compared to the true effect. The 
analysis of medication and subsequent diagnosis of PMR and or GCA is 
limited due to the single time point at which data was collected and the 
grouping of medication together. In addition doses and individual agents 
were unknown preventing a more comprehensive analysis.  
For DCVAS, blindness was recorded as part of the VDI assessment but 
formal systematic ophthalmic evaluation was not undertaken for all 
participants. It is difficult to comment fully on the detailed causal 
pathways involved in patients whose symptoms evolved over the six 
months of follow-up, although only two patients without any visual 
disturbance at baseline were declared blind in one eye at six months. Our 
analysis of obesity and blindness needs to be treated with caution due to 
the relatively high proportion of missing values for BMI in this dataset. 
There is no information regarding the initial dose, route or timing of 
glucocorticoid therapy or anti-platelets such as aspirin. However, recent 
registry-based studies of GCA (239, 242) have not included glucocorticoid 
treatment as a separate covariate, as its use is advised as standard 
management for GCA (93), and therefore it was not considered possible 
to separate the effect of treatment and disease. To date this is the 
largest study of visual loss in cases of clinically-confirmed GCA and 
provides a robust estimate of blindness associated with a diagnosis of 
GCA. Blindness, both monocular and binocular, remains a major problem 
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in GCA and this study emphasises the need to be especially vigilant of 
this outcome in patients with a higher conventional vascular risk. 
11.4.0 GENERALISABILITY AND APPLICATION OF THE FINDINGS 
These findings need to be interpreted in light of the fact that most of the 
participants were Caucasian and of European descent, although this is 
not unique amongst studies of PMR and GCA with higher estimates of 
disease incidence and prevalence from Northern European latitudes and 
North America.  
Major strengths of the analyses are that classification criteria have been 
applied to cases of PMR and GCA for all the datasets, which allows 
comparison to other studies which have similarly applied classification 
criteria.  
The results of the analyses, should be representative to the UK 
population more generally.  
11.4.1 The Public health implications 
These are the first estimates for the UK for PMR and GCA incidence and 
prevalence and to apply classification criteria in over 30 years. They 
reveal the strong association with age which, due to the changing 
demographic of the UK, will likely have increasing importance with regard 
to healthcare delivery. The association of traditional cardiovascular risk 
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factors for both disease onset and progression is a worry and adds 
further importance to tackling these. 
The results from DCVAS show that sight loss remains a major concern 
with GCA with around one in twelve patients blind in one eye by six 
months after diagnosis. Most patients who developed blindness did so by 
the time of their first assessment, with only two patients without 
symptoms of visual disturbance suffering blindness at six months. These 
results re-emphasise the need for urgent referral and rapid use of 
glucocorticoid therapy (236). The DCVAS analysis shows an association 
between blindness and peripheral vascular disease and these individuals 
may warrant closer follow-up. 
For the other main consequence of disease progression of this thesis, 
namely IP in PMR, the current EULAR/ACR recommendations for PMR 
conditionally recommend methotrexate to patients at high risk of relapse 
(44). The expert panel list these risks as: female sex, ESR >40 mm/hr 
and peripheral inflammatory arthritis at baseline diagnosis but then add 
that a number of studies failed to demonstrate an association between 
these factors and relapse (44). The results from the EPIC-Norfolk data 
suggest that males, ever-smokers, those with synovitis and positive 
serology are at increased risk of IP and it is these patients who would 
most likely benefit from early introduction of DMARDs. 
The shared clinical features between PMR and IP are a diagnostic 
challenge for clinicians. Serological testing for rheumatoid factor (RhF) 
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appears to be of limited clinical utility, with a relatively high proportion of 
PMR (21.8%) and IP (27.3%) cases having positive serology. Selecting a 
higher cut-off of >50 U/ml improves the specificity for RhF (18.2% IP 
cases being positive and only 4.5% of PMR cases being positive) resulting 
in a hazard ratio of 3.93 (95% CI 1.33, 11.65). Although improvement in 
specificity has been reported previously (243), relying on the presence of 
RhF or ACPA serology as the sole diagnostic feature would result in many 
undiagnosed cases of both IP and RA. Conversely, requiring an absence 
of rheumatoid factor or anti-ccp antibodies for a diagnosis of PMR would 
be unhelpful in view of the recognised increased prevalence of auto-
antibodies in older people, particularly in women. Indeed a longitudinal 
study of 79 patients thought to have PMR showed that by 12 months, 72 
were thought to have likely or definite PMR and anti-ccp antibodies were 
positive in up to 20 (28%) depending on the isotype of the antibody; IgM 
(n=20), IgA (n=3), IgG (n=1) (244). Ultimately clinicians must remain 
vigilant for diagnostic transformation when managing patients with PMR.  
11.5.0 FUTURE DIRECTIONS 
The major novelty of this thesis is the use of digital retinal imaging to 
record vascular morphology. The results show widened venules in 
participants with PMR which is in keeping with an effect of cardiovascular 
disease. Validation of such findings is needed in other large studies and 
work is currently underway to perform similar analyses within UK 
Biobank. In addition, as the data from the third health-check are from a 
 200 
 
single time-point investigation of the longitudinal relationship of retinal 
vascular change is a potential avenue of further scientific discovery. 
11.5.1 Improving the clinical measurement of disease 
in PMR and GCA 
Further extensions of the variation in phenotype of cases of PMR and GCA 
are possible but require collaborative effort from large consortia. The 
assessment of disease activity of PMR and GCA also requires urgent 
attention. These latter problems are being addressed by the Outcome 
Measures in Rheumatology (OMERACT) group in which the author is 
involved. Key domains of Core, Mandatory, Research and contextual have 
been identified for the development of a new outcome measure set in for 
use in study of patients with PMR. Identification and evaluation of 
instruments which map onto these domains is the next step of the 
process.  
11.5.2 Pharmocoepidmiology approaches 
The analyses of the contribution of medications to the diagnosis of PMR 
and GCA is limited in this thesis due to the single time-point at which 
participants were recruited. The intended aims to investigate how 
medications might modify the disease course and morbidity profile of 
participants with GCA, were not possible due to small numbers. In 
addition the precise time-point at which participants started their 
medication contributed to left censoring. The data available from EPIC-
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Norfolk precluded any more detailed or complicated analysis. Despite 
these problems, use of anti-hypertensives was associated with a reduced 
risk for PMR and when a combined hypertension variable was used, was 
associated with a reduced risk for both PMR and GCA. These findings 
would seem to go against the hypothesis that traditional cardiovascular 
risk factors are risk factors for PMR and GCA and it is possible that they 
are due to chance. However, in a recent analysis of traditional 
cardiovascular risk factors and length of stay amongst those patients 
admitted with acute coronary syndromes revealed hypertension and 
hyperlipidaemia were associated with a reduced length of stay (245). The 
authors speculate that this was because patients with these risk factors 
may be treated more aggressively leading to better outcome, but due to 
incomplete data are unable to certain of this conclusion (245). Similarly, 
although current BSR guidelines recommend the use of low-dose aspirin 
to prevent ischaemic complication in the condition, a study from eight UK 
secondary care centres revealed those taking aspirin prior to diagnosis 
had increased odds for ischaemic manifestations with an OR of 2.81 
(95% CI 1.06, 7.45) (190) although this could represent confounding by 
indication and identify those with increased risk for peripheral vascular 
disease and those with previous myocardial infarction.  
However the author is currently undertaking further work using a large 
community-based register to explore the effect of medication and 
outcomes in PMR and GCA using the CPRD to investigate the effect of 
medications and ocular outcomes in patients with PMR and GCA. 
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11.6.0 CONCLUSIONS 
This thesis has addressed the evidence gaps in the epidemiology of PMR 
and GCA using large datasets with detailed clinical phenotype necessary 
to apply classification criteria. Classification criteria are not intended for 
the purpose of diagnosis and therefore it is not intended that all 
diagnosed cases will met their intended classification set. However, by 
defining cases both pragmatically and subsequently by those which meet 
their intended classification set the estimates can be compared to other 
contemporary studies.  
This is an important area to study because of the lack of clarity of disease 
definition, the fact it is manged in the community, and the lifelong 
disease course. At time this work was started it was one of the most 
poorly characterised rheumatic diseases epidemiologically, despite PMR 
being as least as common as rheumatoid arthritis. Management was 
rooted in the past, and the risk of complications not known. 
This work has provided up to date data on occurrence, and for the first 
time looked at risk factors for occurrence prior to the onset of disease, 
and the risk factors for progression. Traditional cardiovascular risk factors 
have emerged as a risk factors and a potential route for prevention. The 
work has started to lay the foundations for ocular screening using 
automated processing, and identified promising avenues in retinal 
vasculometric measures that will be taken forward in future projects. 
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The results from this work confirm the strong positive association with 
age and as the proportion of the population over 50 years old rises the 
importance of these not uncommon conditions will intensify particularly 
given the type and nature of associated morbidity. Traditional 
cardiovascular risk factors appear to be important as both risk factors for 
disease onset and progression and may point towards more careful 
monitoring for complications amongst those with peripheral vascular 
disease and GCA.  
The analysis from the contribution of medications to modify the outcome 
of patients with PMR and GCA is limited due to lack of information on 
prescriptions and dosage variation over time. This problem is currently 
being addressed by the author using more definitive data sources, 
including the Clinical Practice Research Data Link (CPRD) which is a 
governmental, not-for-profit research service, jointly funded by the NHS 
National Institute for Health Research (NIHR) and the Medicines and 
Healthcare products Regulatory Agency (MHRA), a part of the 
Department of Health. 
The use of automated processing for analysing data on retinal 
morphology is a novel and important development in assessing 
aetiological hypotheses of disease, particularly those with an underlying 
vascular dysregulation mechanisms. Although the results for this work 
require replication in other datasets before firm conclusions can be drawn 
and this will form part of the intended post-doctoral work by the author 
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including large international datasets of retinal images and may be 
applicable to other rheumatic diseases. 
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APPENDICES 
Appendix 1 – Questionnaire for GCANS 
Giant Cell Arteritis in Norfolk and Suffolk 
 (GCANS) 
Dr Max Yates, Dr Richard Watts, Prof Alex MacGregor and Karly 
Graham are independent researchers working at the University of 
East Anglia in the United Kingdom and are carrying out a research 
project.  This is called ‘Giant Cell Arteritis In Norfolk and Suffolk 
(GCANS)’.  The purpose of the study is to explore the occurrence 
of Giant Cell Arteritis in Norfolk and Suffolk. 
 
Please take time to help by filling in this questionnaire.  You do 
not need to give your name and your answers are strictly 
confidential.  It may take approximately  5 -10 minutes of your 
time to complete. 
 
 What is your date of birth?   Day       Month       Year 
 
 Are you..?     Male  Female 
 
  
Questions.                                                             Please 
 
Yes 
 
No 
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circle Y or N: 
 
1 
 
 
 
 
Have you had pain in your jaw or tongue when chewing 
food (not toothache)? 
 
 If yes to 1, did you also have a headache at the same time? 
 
 If yes to 1, was this… (please circle) 
 
Within the last 6 mths    6 mths to 5 yrs    More than 5 yrs ago 
 
 
Y 
 
 
Y 
 
N 
 
 
Y 
 
2 
 
Have you ever had double vision and/or a sudden loss or 
reduction in eye sight, even if temporary? 
 
 
 If yes to 2, did you also have a headache at the same time? 
 
 If yes to 2, was this… (please circle) 
 
Within the last 6 mths    6 mths to 5 yrs    More than 5 
 
Y 
 
 
 
Y 
 
N 
 
 
 
N 
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yrs ago  
 
 
 
3 
 
 
 
 
Do you suffer of have you suffered with severe 
headaches lasting longer than 7 days at a time? 
 
 If yes to 3, was this… (please circle) 
 
Within the last 6 mths    6 mths to 5 yrs    More than 5 
yrs ago  
 
Y 
 
 
 
 
N 
 
 
 
 
4 
 
Has your scalp over your temples been sore (eg was it 
painful to brush your hair)? 
 
 If yes to 4, did you also have a headache at the same time? 
 
 If yes to 4, was this… (please circle) 
 
Within the last 6 mths    6 mths to 5 yrs    More than 5 
yrs ago  
 
 
Y 
 
 
Y 
 
N 
 
 
N 
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5 
 
 
 
Have you woken up with stiffness or aching in your 
shoulders which lasted longer than 1 hour? 
 
 If yes to 5, did you also have a headache at the same time? 
 
 If yes to 5, was this… (please circle) 
 
Within the last 6 mths    6 mths to 5 yrs    More than 5 
yrs ago  
 
Y 
 
 
Y 
N 
 
 
N 
 
6 
 
Have you ever had unexplained weight loss (not through 
dieting or exercise)? 
 
 If yes to 6, did you also have a headache at the same time? 
 
 If yes to 6, was this… (please circle) 
 
Within the last 6 mths    6 mths to 5 yrs    More than 5 
yrs ago  
 
Y 
 
 
Y 
 
N 
 
 
N 
 
7 
 
Have you ever had a feeling of being general unwell with 
 
Y 
 
N 
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achy muscles lasting longer than 2 weeks? 
 
 If yes to 7, did you also have a headache at the same time? 
 
 If yes to 7, was this… (please circle) 
 
Within the last 6 mths    6 mths to 5 yrs    More than 5 
yrs ago  
 
 
Y 
 
 
N 
    
 
8 
 
 
 
 
Have you ever been given a diagnosis of Giant Cell 
Arteritis or Temporal Arteritis? 
 
 If yes to 8, which year was this?        ____________ 
 
 
Y 
 
 
 
 
N 
 
 
 
 
9 
 
 
 
 
Have you ever been given a diagnosis of Polymyalgia 
Rheumatica (PMR)? 
 
 If yes to 9, which year was this?        ____________ 
 
 
Y 
 
N 
 
10 
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Do you get migraines? 
 
 If yes to 10, do you get visual disturbance? 
 
 If yes to 10, do you feel sick or vomit? 
 
Y 
 
Y 
 
Y 
N 
 
N 
 
Y 
 
 
 
Thank you for taking the time to complete this questionnaire.   
 
Please return it with 2 copies of the consent form in the postage 
paid envelope provided. 
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Appendix 2 - Proposed Retinal Grading 
A retinal grading system was carried out based on the National Health 
and Nutrition Examination Survey (NHANES) programme used for 
national ocular screening. 
Photo Quality 
QUARTZ is fully automated in its assessment of retinal images. However 
around 6% of images are wrongly graded as being unreadable by the 
software.  
Focus 
If retinal vessels are sharply defined or slightly fuzzy and small lesions 
such as retinal microaneurysms and small drusen are visible, the grade is 
"Good/Fair", code=0. If clarity is decreased so that small retinal lesions 
might be missed but larger lesions such as geographic atrophy, can be 
seen, the grade is "Borderline", code=1. If there is a pronounced 
decrease in sharpness where detail of larger lesions cannot be 
recognized, the grade is "Poor", code=2. 
Illumination 
If an image is poorly illuminated or overexposed, or there are pockets of 
uneven illumination (a dark macula) then Illumination should be graded 
“Yes”, code=2. 
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Field Definition 
EPIC-Norfolk images are foveal focused – a traditional Field 2 image in 
the diabetic retinopathy screening programme. If the field deviates more 
than one disc diameter from the optimum location then Field Definition 
should be graded “Yes”, code=2. 
Haze 
When a green/white halo or partial halo; or a green/white cast 
throughout the entire photograph is noted, Haze should be graded “Yes”, 
code=2. 
Dust 
White dots or spots that may be varying size but are in the same location 
of the image no matter what field of the retina is imaged are usually 
caused by one or more dirty lenses on the camera. When dust or dirt 
spots are prominent or located in just the wrong place and cause 
difficulty in grading, Dust should be graded “Yes”, code=2. 
Lashes 
Lashes or a partial blink often appear on the bottom of the image as 
either light or dark linear “shadows”. These “shadows” can easily obscure 
the lower half of the image. Occasionally lashes will appear in the upper 
half of the image as a bright reflectance but do not affect the ability to 
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grade as much. When lashes (or a blink) are present Lashes should be 
coded “Yes”, code =2. 
Arc 
A small pupil or incorrect patient-to-camera distance can cause a 
crescent shaped arc to appear on the image, which can range in colour 
from yellow orange to blue, and in size from a small slice to an arc that 
obscures more than half of the field. Normally arcs are found along the 
nasal or temporal margin rather than the superior or inferior margins 
although they can occur anywhere. When an arc is present the grade 
should be “Yes”, code = 2. 
Asteroid Hyalosis 
Multiple spherical and stellate opacities in the vitreous may be difficult to 
differentiate in non-stereoscopic photographs and should appear in front 
of vessels and disc. Care must be taken to differentiate from retinal 
drusen. If asteroid hyalosis is dense, this may prevent grading drusen. 
Gradeability 
The grader will judge the overall quality of both images to determine the 
gradeability. If the field are focused clearly enough to image the retina, 
optic nerve and blood vessels without any portion missing or obscured, 
the image is considered completely gradable. If more than 75% of optic 
nerve cannot be graded, but it is possible to grade the blood vessels, the 
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grade is "Disc ungradable", code=1. If a portion of blood vessels, 
between 25% and 75 % cannot be graded, but the optic nerve is 
gradable, the grade is "Portion blood vessels ungradable", code=2. 
If more than 75% of the blood vessels are in poor focus, missing, or 
obscured by a retinal haemorrhage, vitreous haemorrhage, asteroid 
hyalosis or some other condition and no lesion of any type is seen but it 
is possible to grade the disc, the grade is " blood vessels ungradable", 
code=3.  
If a portion of the disc and the blood vessels are ungradable (between 
25-75% or each), the grade is code=4. If neither the disc nor the blood 
vessels can be graded (more than 75% of each), but other portions of 
the retina are visible, the grade is code=5. If no part of the fields can be 
graded, the grade is code=6. 
Vascular Lesions  
Each quadrant, superior temporal (ST), superior nasal (SN), inferior 
temporal (IT) and inferior nasal (IN) is evaluated for the absence or 
presence of vascular lesions or changes (see Figure S.2).  
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Figure S.2  Quadrants of a retinal fundus image 
 
The following codes are used:  
 Focal narrowing  
Code Definition  
0 No focal narrowing.  
1 Questionable focal narrowing.  
2 Definite focal narrowing  
8 Cannot grade. 
 Arterio-venous crossing abnormalities BVO/CVO (branch vein 
occlusion/central vein occlusion)  
Each quadrant, superior temporal (ST), superior nasal (SN), inferior 
temporal (IT) and inferior nasal (IN) is evaluated for the absence of 
presence of AV nicking. The following codes are used:  
Code Definition  
0 No AV nipping.  
IN 
SN 
IT 
ST 
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1 Questionable AV nipping.  
2 Definite AV nipping.  
8 Cannot grade. 
 BAO/CAO (branch artery occlusion/central artery occlusion)  
 
Branch Vein Occlusion: Obstruction of a branch retinal venule. An older 
occlusion may demonstrate sheathed venules and retinal collateral 
vessels. Localised haemorrhages and/or IRMAs are commonly present. 
The occluded vessel may not always be obvious.  
Central Vein Occlusion: Obstruction of a central retinal venule. A fresh 
occlusion is distinguished by dilated retinal venules and diffuse retinal 
haemorrhages.  
Branch/Central Artery Occlusion: Obstruction of a branch or central 
retinal arteriole. If "fresh", may be associated with large greyish-white 
area of retinal infarction. Either generalised or localised ischaemia may 
be noted. 
 Hollenhorst Plaque 
Cholesterol emboli: These highly-refractile to smudgy-white lesions lie 
within arterioles and may be seen at artery bifurcations. Care must be 
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taken to distinguish from old retinal macroaneurysms or underlying 
drusen. 
Retinal pigment atrophy  
This lesion appears as a sharply defined area of drop-out of retinal 
pigment epithelium and choriocapillaries, exposing choroidal vessels 
as a result of degeneration of the deep layers of the retina. When 
atrophic lesions are definitely not a result of ARM, any other “Other” 
should be marked and a comment included. Similar to the other 
vascular lesions, each quadrant (ST, SN, IT, IN) was graded on the 
presence of retinal epithelial loss.  
Tigroid or Tessellated Fundus 
Graded as three indices of fundus tessellation: non, weakly and strongly 
tessellated. 
Disc 
Assessment of discs is coded as follows: 
“0” – normal 
“1” – atrophy 
“2” – large disc 
“3” – pale 
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“4” – cupping 
“5” – laminar dot sign present 
“6” – thick neuroretinal rim (NRR) / small cup 
“7” – blurred nasal edge 
“8” – blurred temporal edge 
Peripheral Atrophy 
PPA coded as none “0”, presenting on temporal sided “1”, present on 
nasal side “2”, circumferential “3”, and inferior “4”.  
Description 
There is a description variable. This is field is completed when there is a 
relevant comment required, for example: the presence of drusen, cotton 
wool spots, tortuous vessels, thick venules, thin arterioles, or myopic 
atrophy.  
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Appendix 3 – Published Papers 
Two original articles and two editorials published as a result from the 
work in this thesis appear in the following pages.  
